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Summary
1. It is postulated that dynorphin inhibits the cocaine-induced increase in striatal 
dopamine levels, that may contribute to dynorphin’s ability to prevent cocaine- 
induced conditioned place preference and to attenuate an increase in locomotor 
activity. In this thesis interactions between dynorphin and the dopaminergic 
system in cocaine addiction have been addressed using preprodynorphin gene 
knockout mice treated with a chronic “binge” cocaine protocol. Dopamine D l, D2 
receptor and dopamine transporter binding have been mapped by quantitative 
autoradiography in the brains of knockout mice treated with a chronic “binge” 
cocaine protocol. A significant decrease in D2 receptor binding was observed in 
the mediolateral part of the caudate putamen of chronic “binge” cocaine-treated 
knockout mice compared to knockout saline controls. Moreover, a significant 
decrease in overall D2 receptor binding was observed in the brains of chronic 
cocaine-treated preprodynorphin knockout mice compared to knockout controls 
and to cocaine treated wild-type animals. However, no significant difference in 
D2 receptor binding was observed in any of the regions of chronic cocaine-treated 
wild-type mice compared with saline controls. In contrast to D2 receptor binding, 
no significant differences in Dl receptor and dopamine transporter binding were 
observed between any of the groups in any of the regions analysed. These results 
suggest that dynorphin-derived endogenous opioid peptides can modulate chronic 
cocaine-induced alteration of D2 receptors but not Dl receptors or dopamine 
transporters.
2. A large body of evidence suggests that the endogenous opioid system directly or 
indirectly regulates dopaminergic tone in the central nervous system. Triple
Vlll
opioid receptor knockout and wild-type mice brains from congenic C57BL/6 and 
coisogenic 129S6 backround have been used to address whether the dopaminergic 
system could be influenced not only by the deletion of all classical opioid 
receptors but also by genetic background. The absence of all three classical opioid 
genes does not affect D l, D2 or dopamine transporter binding in either the 
C57BL/6 or 129S6 background strain suggesting that the endogenous opioid 
system may not modulate the dopaminergic system and this may not be dependent 
on the background strain of the knockout mice.
3. In order to investigate the prime receptor target of oxycodone in the brain, 
quantitative autoradiographic binding of [^H] oxycodone was carried out in the 
brains of mice lacking either p-, k - or ô-opioid receptor as well as in mice lacking 
all three classical opioid receptors (triple opioid receptor knockout mice). The 
distribution of [^H]oxycodone labelling was similar to the known distribution of p- 
opioid receptor binding sites. Moreover p-opioid receptor knockout mice had 
significantly lower [^HJoxycodone binding than wild-type mice across regions 
suggesting that oxycodone mainly binds to p-opioid receptors in the brains of 
mice. In contrast, the binding levels of [^H]oxycodone were significantly 
increased in the brains of K-opioid receptor and ô-opioid receptor knockout mice 
compared to wild-type mice suggesting [^H]oxycodone may also exert its effect on 
different opioid receptor sites such as p/6 and/or p/x-opioid heterodimers. No 
[^H]oxycodone binding was detected in brains of triple opioid receptor knockout 
mice indicating that the ligand can only bind to all three classical opioid receptors.
IX
4. Despite the development of several methods including biochemical, biophysical 
and pharmacological methods which have been used to investigate the existence of 
heterodimer/hetero-oligomer forms of the ô-opioid and K-opioid receptor in vitro 
and in vivo there has not been direct evidence showing whether heterodimerisation 
occurs in physiological systems. A novel method combining knockout mice with 
radioligand binding which is called KS A (knockout Subtraction Autoradiography) 
has been developed and is proposed to provide further evidence for the existence 
of heterodimer/hetero-oligomer forms of the ô- and K-opioid receptors in mouse 
brain tissue. Quantitative autoradiography of [^H]bremazocine and [^HJnor- 
binaltorphimine binding was carried out in single (p) and double (p and ô or p and 
k )  opioid receptor knockout mice. The principle of the method relies on 
quantification of receptor binding in knockout brain tissue where dimers can 
(single knockout’s) or cannot (double knockout’s) be formed. Both 
[^HJbremazocine and [nor-BNI binding fitted the heterodimer/hetero-oligomer 
model (p-opioid receptor knockout -  p-opioid receptor/K-opioid receptor 
knockout ^  p-opioid receptor/ô-opioid receptor knockout) in some regions and the 
monomer/homo-oligomer model (p-opioid receptor knockout -  p-opioid 
receptor/K-opioid receptor knockout = p-opioid receptor/ô-opioid receptor 
knockout) in other regions suggesting that the presence of heterodimer/hetero­
oligomer forms of the ô- and K-opioid receptors is region-specific. The KSA 
could prove a useful tool to identify heterodimers in vitro and test binding 
properties of pharmacological ligands to heterodimers.
X
Contents
Acknowledgements..................................................................................................................ii
Publications............................................................................................................................. iü
List of Abbreviations................................................................................................................
List of Neuroanatomical Abbreviations.............................................................................vii
Summary................................................................................................................................ viii
Contents....................................................................................................................................xi
List of Figures.......................................................................................................................xvii
List of Tables......................................................................................................................... xix
Chapter 1. General introduction...........................................................................................1
1.1. Historical background..........................  2
1.2. Endogeous opioid peptides..............................................................................................3
1.2.1. Proenkephalin..............................................................................................................3
1.2.2. Proopiomelanocorcotin............................................................................................. 11
1.2.3. Prodynorphin..............................................................................................................15
1.2.4. Atypical endogenous opioid-related peptides......................................................... 17
1.2.5. Gene targeting for generating conventional knockout mice.................................. 18
1.2.6. Opioid-peptide knockout mice................................................................................. 21
1.2.6.1. Preproopiomelanocortin................................................................................... 22
1.2.6.2. Preprodynorphin...............................................................................................22
1.2.6.3. Preproenkephalin..............................................................................................23
1.2.6.4. Prepronociceptin...............................................................................................23
1.3. Opioid receptors..............................................................................................................23
1.3.1. Background................................................................................................................24
1.3.2. Opioid receptor subtypes..........................................................................................25
1.3.3. Gene cloning of opioid receptors............................................................................. 29
1.3.4. Structure of the opioid receptors.............................................................................. 30
1.3.5. Opioid receptor knockout mice................................................................................ 31
1.3.5.1. MOPr knockout mice........................................................................................31
1.3.5.2. KOPr knockout mice.........................................................................................32
1.3.5.3. DOPr knockout mice.........................................................................................32
1.3.5.4. NOPr knockout mice.........................................................................................33
XI
1.4. Behavioural phenotypes in response to drugs of abuse in opioid peptide 
knockout mice......................................................................................................................... 34
1.4.1. Psychostimulants....................................................................................................... 34
1.4.1.1. Preprodynorphin knockout mice......................................................................34
1.4.1.2. Preproenkephalin knockout mice.................................................................... 43
1.4.2. Opioids.......................................................................................................................43
1.4.2.1. Preprodynorphin knockout mice..................................................................... 43
1.4.2.2. Preproenkephalin knockout mice.................................................................... 44
1.4.2.3. P-endorphin knockout m ice.............................................................................44
1.4.2.4. Nociceptin knockout m ice............................................................................... 45
1.4.3. Other addictive substances....................................................................................... 46
1.4.3.1. Preprodynorphin knockout mice..................................................................... 46
1.4.3.2. Preproenkephalin knockout mice.................................................................... 47
1.4.3.3. P-endorphin knockout m ice.............................................................................48
1.4.3.4. p-endorphin/enkephalin knockout m ice.........................................................48
1.5. Behavioural phenotypes in response to drugs of abuse in opioid receptor 
knockout mice......................................................................................................................... 49
1.5.1. Psychostimulants....................................................................................................... 49
1.5.1.1. DOPr knockout mice.........................................................................................49
1.5.1.2. KOPr knockout mice.........................................................................................50
1.5.1.3. MOPr knockout mice........................................................................................71
1.5.2. Opioids....................................................................................................................... 73
1.5.2.1. DOPr knockout mice.........................................................................................73
1.5.2.2. KOPr knockout mice.........................................................................................74
1.5.2.3. MOPr knockout mice........................................................................................75
1.5.2.4. NOPr knockout mice.........................................................................................77
1.5.3. Other addictive substances........................................................................................77
1.5.3.1. DOPr knockout mice.........................................................................................78
1.5.3.2. KOPr knockout mice.........................................................................................78
1.5.3.3. MOPr knockout mice...................................................................   80
1.5.3.4. MOPr/DOPr double knockout mice.................................................................82
1.6. Neurochemical effects of drugs of abuse in opioid peptide and receptor 
knockout mice......................................................................................................................... 83
1.6.1. Psychostimulants..................................................................................................... 83
1.6.1.1. Preprodynorphin knockout mice......................................................................83
1.6.1.2. Preproenkephalin knockout mice.....................................................................84
Xll
1.6.1.3. DOPr knockout mice........................................................................................ 85
1.6.1.4. KOPr knockout mice........................................................................................ 85
1.6.1.5. MOPr knockout mice....................................................................................... 87
1.6.2. Opioids.......................................................................................................................90
1.6.2.1. DOPr knockout mice........................................................................................ 90
1.6.2.2. MOPr knockout mice....................................................................................... 90
1.6.2.3. NOPr knockout mice........................................................................................ 91
1.6.3. Other addictive substances....................................................................................... 92
1.6.3.1. P-endorphin knockout mice.............................................................................92
1.6.3.2. Preproenkephalin knockout mice.....................................................................93
1.6.3.3. p-endorphin/enkephalin double knockout mice............................................. 93
1.6.3.4. DOPr knockout mice........................................................................................ 94
1.6.3.5. KOPr knockout mice........................................................................................ 94
1.6.3.6. MOPr knockout mice....................................................................................... 95
1.7. Dopaminergic pathways................................................................................................96
1.8. Dopaminergic system in drug addiction...................................................................102
1.9. Dopamine receptors..................................................................................................... 103
1.10. Interaction between the opioid and the dopaminergic system............................104
1.11. Aims of the Thesis...................................................................................................... 106
Chapter 2. Quantitative D l, D2 receptor and dopamine transporter
autoradiography in chronic “binge” cocaine treated preprodynorphin knockout and
wild-type mice....................................................................................................................... 107
2.1. Introduction  ........................................................................................................108
2.2. Materials and Methods................................................................................................ 110
2.2.1. Animals.................................................................................................................... 110
2.2.2. Drug treatment.........................................................................................................110
2.2.3. Materials.................................................................................................................. I l l
2.2.4. Autoradiography......................................................................................................I l l
2.2.4.1. Preparation of knockout mice tissue for sectioning..................................... I l l
2.2.4.2. Subbing microscope slides............................................................................. I l l
2.2.4.3. Tissue sectioning............................................................................................. 112
2.2.4.4. Dopamine D l, D2 receptor and dopamine transporter autoradiography... 112
2.2.5. Autoradiographic film preparation........................................................................ 114
2.2.6. Autoradiographic film development.....................................................................114
2.2.7. Autoradiographic image analysis........................................................................... 115
Xlll
2.2.8. Data analysis..........................................................................................................115
2.3. Results.............................................................................................................................116
2.3.1. The effects of chronic “binge” cocaine treatment on Dl receptor binding in the 
brain of ppDYN knockout and wild-type mice................................................................116
2.3.2. The effects of chronic “binge” cocaine treatment on D2 receptor binding in the 
brain of ppDYN knockout and wild-type mice................................................................121
2.3.3. The effects of chronic “binge” cocaine treatment on dopamine transporter 
binding in the brain of ppDYN knockout and wild-type m ice...................................... 121
2.4. Discussion....................................................................................................................... 131
Chapter 3. Effect of genetic background on dopamine D l, D2 receptors or 
dopamine transporters in triple opioid receptor knockout mice................................. 134
3.1. Introduction................................................................................................................... 135
3.2. Materials and Methods................................................................................................ 137
3.2.1. Animals.................................................................................................................... 138
3.2.2. Materials.................................................................................................................. 138
3.2.3. Autoradiography......................................................................................................141
3.2.4. Autoradiographic film preparation and development...........................................141
3.2.5. Autoradiographic image analysis........................................................................... 141
3.2.6. Data analysis............................................................................................................141
3.3. Results.............................................................................................................................142
3.3.1. Dl binding in the brains of wild-type and triple opioid receptor knockout mice 
of B6 and 129S6 genetic backgrounds............................................................................. 142
3.3.2. D2 binding in the brains of wild-type and triple opioid receptor knockout mice 
of B6 and 129S6 genetic backgrounds............................................................................. 142
3.3.3. DAT binding in the brains of wild-type and triple opioid receptor knockout 
mice of B6 and 129S6 genetic backgrounds.................................................................... 143
3.4. Discussion....................................................................................................................... 156
CHAPTER 4. Quantitative receptor autoradiography of [^H]oxycodone binding in 
the brains of single and triple opioid receptor knockout mice.................................... 161
4.1. Introduction................................................................................................................... 162
4.2. Materials and Methods..........................................................................   168
4.2.1. Animals.................................................................................................................... 168
4.2.1.1. Single MOPr, DOPr and KOPr knockout m ice............................................168
4.2.1.2. Triple opioid receptor knockout mice............................................................168
4.2.2. Materials.................................................................................................................. 169
4.2.3. Autoradiography......................................................................................................169
4.2.3.1. Preparation of knockout tissue for sectioning.............................................169
XIV
4.2.3.2. Subbing microscope slides and tissue sectioning........................................ 169
4.2.3.3. [^H]Oxycodone autoradiography...................................................................170
4.2.4. Autoradiographic film preparation........................................................................171
4.2.5. Autoradiographic film development and image analysis..................................... 171
4.2.6. Data analysis............................................................................................................171
4.3. Results.....................................................................   171
4.3.1. 2 nM oxycodone binding in MOPr knockout and wild-type m ice.............. 172
4.3.2. 50 nM oxycodone binding in wild-type, MOPr, KOPr and DOPr knockout
mice.....................................................................................................................................172
4.3.3. 100 nM oxycodone binding in MOPr knockout and wild-type m ice .177
4.3.4. 50 nM oxycodone binding in triple opioid receptor knockout mice 177
4.4. Discussion....................................................................................................................... 184
Chapter 5. Knockout Subtraction Autoradiography: A novel method to identify 
KOPr/DOPr heterodimers in mouse brain tissue.......................................................... 188
5.1. Introduction................................................................................................................... 189
5.2. Materials and Methods................................................................................................201
5.2.1. Animals....................................................................................................................201
5.2.1.1. Single MOPr, double MOPr/DOPr and MOPr/KOPr knockout m ice 201
5.2.1.2. Triple opioid receptor knockout mice........................................................... 201
5.2.2. Materials..................................................................................................................202
5.2.3. Autoradiography..................................................................................................... 202
5.2.3.1. Preparation of knockout tissue for sectioning.............................................. 202
5.2.3.2. Subbing microscope slides and tissue sectioning........................................ 202
5.2.3.3. [^HJBremazocine autoradiography............................................................... 203
5.2.3.4. [^H]nor-BNI autoradiography........................................................................203
5.2.4. Autoradiographic film preparation........................................................................203
5.2.5. Autoradiographic film development and image analysis.....................................203
5.2.6. Data analysis........................................................................................................... 204
5.3. Results............................................................................................................................ 205
5.3.1. [^H]Bremazocine binding in wild-type, MOPr, MOPr/DOPr and MOPr/KOPr 
knockout mice....................................................................................................................205
5.3.2. Absolute and corrected values of [^HJbremazocine binding in single and 
double opioid receptor knockout mice............................................................................. 210
5.3.3. [^H]nor-BNI binding in wild-type, single and double opioid receptor knockout 
mice.....................................................................................................................................213
XV
5.3.4. Absolute and corrected values of [^H]nor-BNI binding in single and double 
opioid receptor knockout mice..........................................................................................218
5.3.5. [^H]Bremazocine and [^H]nor-BNI binding in triple opioid receptor knockout 
mice.....................................................................................................................................221
5.4. Discussion.....................................................................................................................224
Chapter 6. General discussion...........................................................................................232
6.1. General discussion..................................................................................................... 233
6.1.1. Role of preprodynorphin in cocaine-induced changes in dopamine D2 
receptors...............................................................................................................  233
6.1.2. Genetic background does not influence the interactions between the 
dopaminergic system and opioid receptors......................................................................234
6.1.3. The binding profile of oxycodone is similar to p-opioid receptor.......................235
6.1.4. Knockout Subtraction Autoradiography as a useful tool to identify of 
heterodimer/hetero-oligomer in physiological system....................................................236
6.1.5. Future work........................................................................................ :....................238
7. References......................................................................................................................... 239
XVI
List of Figures
Figure 1.1. The four opioid peptide precursors and their possible products........................12
Figure 1.2. Strategy for generating conventional knockout mice........................................ 19
Figure 1.3. Cycling of dopamine in dopaminergic neurons..................................................97
Figure 1.4. Dopaminergic pathways.....................................................................................100
Figure 2.1. [^H]SCH23390 binding in wild-type and ppDYN knockout mice treated with 
chronic “binge” cocaine.........................................................................................................1 1 7
Figure 2.2. Quantification of [^H]SCH23390 in wild-type and ppDYN knockout mice 
treated with chronic “binge” cocaine....................................................................................1 1 9
Figure 2.3. [^HJRaclopride binding in wild-type and ppDYN knockout mice treated with 
chronic “binge” cocaine.........................................................................................................123
Figure 2.4. Quantification of [^H]raclopride in wild-type and ppDYN knockout mice 
treated with chronic “binge” cocaine....................................................................................125
Figure 2.5. [^H]Mazindol binding in wild-type and ppDYN knockout mice treated with 
chronic “binge” cocaine.........................................................................................................127
Figure 2.6. Quantification of [^H]mazindol in wild-type and ppDYN knockout mice 
treated with chronic “binge” cocaine....................................................................................129
Figure 3.1. Generation of a congenic C57BL/6 triple opioid receptor knockout strain.. 139
Figure 3.2. [^H]SCH23390 binding in the brains of wild-type and triple opioid receptor 
knockout mice from different genetic background..............................................................144
Figure 3.3. Quantitative autoradiography of [^H]SCH23390 binding in the brains of wild- 
type and triple opioid receptor knockout mice from different genetic background 146
Figure 3.4. [^H]Raclopride binding in the brains of wild-type and triple opioid receptor 
knockout mice from different genetic background............................. .............................. 148
Figure 3.5. Quantitative autoradiography of [^HJraclopride binding in the brains of wild- 
type and triple opioid receptor knockout mice from different genetic background.........150
Figure 3.6. [^HJMazindol binding in the brains of wild-type and triple opioid receptor 
knockout mice from different genetic background..............................................................152
Figure 3.7. Quantitative autoradiography of [^HJmazindol binding in the brains of wild- 
type and triple opioid receptor knockout mice from different genetic background 154
Figure 4.1. Relationship of selected natural and synthetic opiate drugs.......................... 163
xvii
Figure 4.2. 50 nM [^H]oxycodone binding in MOPr, KOPr and DOPr knockout mice.. 173
Figure 4.3. 100 nM oxycodone binding in MOPr knockout m ice..............................178
Figure 4.4. 50 nM oxycodone binding in triple opioid receptor knockout m ice 182
Figure 5.1. Diversity through oligomerization....................................................................190
Figure 5.2. Three possible scenarios for the assembly and maturation of a GPCR 
dimer/oligomer....................................................................................................................... 191
Figure 5.3. Knockout Subtraction Autoradiography: A model to demonstrate 
heterodimerisation in brain tissue.........................................................................................197
Figure 5.4. Correcting for compensatory receptor changes....................... 199
Figure 5.5. [^HJBremazocine binding in wild-type, single and double knockout brain.. 206
Figure 5.6. Quantification of [^HJbremazocine in wild-type, single and double knockout 
brain........................................................................................................................................208
Figure 5.7. Absolute and corrected values of [^H]bremazocine binding.......................... 211
Figure 5.8. [^H]nor-BNI binding in wild-type, single and double knockout brain...........214
Figure 5.9. Quantification of [^H]nor-BNI in wild-type, single and double knockout brain 
 216
Figure 5.10. Absolute and corrected values of [^H]nor-BNI binding................................219
Figure 5.11. [^HJBremazocine and [^H]nor-BNI binding in sagittal brain sections of wild- 
type and triple opioid receptor knockout m ice................................................................... 222
XVlll
List of Tables
Table 1.1. Endogenous opioid peptides and receptor affinity............................................... 5
Table 1.2. Behavioural and neurochemical effect of drugs of abuse in opioid peptide 
knockout mice.......................................................................................................................... 36
Table 1.3. Behavioural and neurochemical effects of drugs of abuse in opioid receptor 
knockout mice..........................................................   51
Table 4.1. 50 nM [^H]oxycodone binding in MOPr, KOPr and DOPr knockout mice... 175
Table 4.2. 100 nM oxycodone binding in MOPr knockout m ice............................... 180
Table 5.1. Ligand-binding properties of KOPr-DOPr heterodimer in cell systems..........196
XIX
Chapter 1. General introduction
1.1. Historical background
Opium is a crude mixture of many different chemical substances derived from the 
immature seed capsule of the opium poppy Papaver somniferum. It has been used for 
thousands of years for medical and recreational purposes because of its analgesic and 
euphoric properties. The use of opium dates to the Sumerian (5000 B.C) who called the 
opium poppy “plants of the happiness”. Ancient Egyptians (Tebas 1550 B.C.) discovered 
its usefulness in calming children and for the treatment of intestinal pain caused by worms 
(for review, see Aragon-Poce et al., 2002). One of the first references to the medical use 
of opium, as an anticonvulsant, was by the Greek philosopher Theophrastus (300 B.C.) 
who referred to it as meconium and Hippocrates who previously referred to it as “mecon” 
(for review, see Macht, 1915; Aragon-Poce et al., 2002). In Roman culture, “opium” also 
appears in the texts of the poets, Ovid and Virgilio (for review, see Dickson, 1968).
The opium poppy is the source of the narcotic analgesics morphine and codeine. The 
major constituents of opium are morphine (10%), noscapine (6%), papaverine (1%), 
codeine (0.5%), and thebaine (0.2%) (see Levine, 2003). Morphine and codeine are 
prototypical opioids and have been used medicinally for centuries. Noscapine and 
papaverine have antitussive and vasodilator properties, respectively, and thebaine is an 
important reactive starting material for the synthesis of other drugs such as oxycodone 
and etorphine (see Levine, 2003). Morphine was named after Morpheus (the Greek god 
of dreams) and was first isolated from opium by the German chemist, Friedrich Sertüner, 
in 1805 (for review, see Macht, 1915). Codeine was first isolated from opium in 1832 by
Robiquet and shown to be synthesized from morphine via 0-methylation (for review, see 
Macht, 1915). Both morphine and codeine are widely used for the treatment of pain. 
However, there are several side effects with the use of these drugs such as abuse potential 
and the incidence of side effects such as respiratory depression, nausea, vomiting and 
constipation. The abuse potential property of morphine and codeine was recognised when 
it was used for non-medical purposes. Moreover, prolonged use of the drugs also induces 
physical dependence and tolerance to the drug. Heroin (diacetylmorphine) was 
synthesised from morphine by Bayer in 1898 as a cough suppressant to assist breathing in 
patients with severe lung disease (for review, see Sneader, 1998). Although heroin was 
initially thought to be a non-addictive substitute for morphine, it has become the major 
drug of abuse (for review, see Lasagna, 1964; Substance Abuse and Mental Health 
Services Administration, 2003).
1.2. Endogeous opioid peptides
1.2.1. Proenkephalin
In 1975, endogenous morphine-like ligands were isolated by three independent groups 
using pharmacological (Hughes 1975) and receptor binding assays (Pasternak et al. 1975; 
Terenius and Wahlstrom 1975). The endogenous opioid peptides extracted and termed 
methionine ([Met])- and leucine ([Leu])-enkephalin differed in the carboxyl terminal 
amino acid (Hughes et al. 1975). This later contributed to the finding that classical 
endogenous opioid peptides share common sequence homology known as the opioid 
motif (Tyr-Gly-Gly-Phe-Leu or -Met) (Table 1.1.). The term endorphin also began
appearing in the literature in 1975. The name was from endo signifying endogenous and 
orphine (a common suffix in the names of opioids) and the final e was dropped in 
conformity with convention on nomenclature of natural peptides and biogenic amines (for 
review, see Goldstein et al., 1975 ; Kitchen, 1984).
Huang et al. (1979) isolated an opioid hexapeptide from porcine hypothalamus whose first 
five residues were identical to [Metjenkephin, however, the sixth residue 
([Met^Arg^Jenkephain) differed from that present in the known endorphins, and the entire 
sequence was not common to that of (3-LPH. This hexapeptide was named pro- 
methionine-enkephalin. Another peptide was purified to homogeneity and its sequence 
was shown to be [Met^Arg^,Phe^]enkephalin (Stem et al. 1979). It was shown to have 
opioid activity similar to [Met]enkephalin and [Leu]enkephalin (Rossier et al. 1980). On a 
molar basis, [Met^,Arg^,Phe^]enkephain has shown to have approximately 9 times more 
analgesic activity than [Met]enkephalin but was 1/63'^ as potent as morphine and 1/1156* 
as potent as fyendorphin when injected intracerebroventricularly (Inturrisi et al. 1980).
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10
[Met^,Arg^,Arg^]enkephalin and [Met^,Lys^]enkephalin were also isolated from brain and 
adrenal medulla (Lewis et al. 1980; Stem et al. 1980). In 1981, an octapeptide 
[Met ,Arg ,Gly ,Leu ] enkephalin was purified from bovine adrenal chromaffin granules 
and shown to have approximately 35 % the opiate receptor binding activity (IC50 = 17.0 
nM) of [Metjenkephalin (IC50 = 6 .2  nM) as determined in cultured NG-108 cells using 
[^H] [Leu]enkephalin (Kilpatrick et al. 1981a).
In 1982, the nucleotide sequence of cloned cDNA encoding bovine adrenal medulla 
preproenkephalin (ppENK) precursor mRNA was reported demonstrating that the 
precursor protein contains [Metjenkephalin, [Leu] enkephalin,
[Met^,Arg^,Gly^,Leu^]enkephalin and [Met^,Arg^,Phe^]enkephalin (Figure 1 .1 .) (Gubler et 
al. 1982; Noda et al. 1982). Weber et al. (1983) reported the presence of an amidated 
opioid octapeptide, named metorphamide (meaning [Metjenkephalin containing 
Qn&orphin with carboxyl-terminal amide) in bovine brain that appeared to be derived by 
proteolytic cleavage of ppENK and was shown to have a high p-opioid receptor (MOPr) 
binding activity. This peptide, named adrenorphin, was also isolated from human 
phaechromocytoma tumour and corresponded to the sequence of the first eight amino 
acids of peptide E which was derived from ppENK (Matsuo et al. 1983).
1.2.2. Proopiomelanocorcotin
Li and Chung (1976) isolated an untriakontapeptide from camel pituitary glands that has 
an amino-acid sequence identical to the COOH-terminal 31 residues of ovine p-lipotropin 
(P-LPH), a peptide of unknown function first isolated from sheep pituitary glands in 1965
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(Li et al. 1965). The 31 amino acid peptide, derived from the C fragment (61-91) of a 
larger peptide P-LPH was also found in human pituitary glands and was termed p- 
endorphini.31 (Li et al. 1976). P-endorphini.31 is a potent opioid analgesic, being 18 to 33 
times more potent than morphine on a molar basis, with long lasting effects (Loh et al. 
1976). Moreover, chronic infusion of P-endorphin into the periaqueductal gray of rat 
brain induced morphine-like physical dependence (Loh et al. 1976). Although synthetic 
P-endorphini-27 analogs produced by acétylation of a-NHi group in several opioid 
peptides markedly increased immunoreactivity for P-endorphin, analgesic and receptor 
binding activities were decreased in these analogs (Li et al. 1980). a- and y-Endorphin 
also isolated from porcine hypothalamus-neurohypophysis was shown to have a primary 
structure, identical to amino acid sequence as P-LPH61.76 und P-LPH61-77, respectively 
(Ling et al. 1976).
Mains et al. (1977) suggested that adrenocorticotropic hormone (ACTH) and endorphins 
can be derived from a single common precursor molecule based on a finding of the 
existence of a protein with a molecular weight of about 31,000 that crossreacts with 
antibodies to both ACTH and p-endorphin in mouse pituitary tumor cells. Rubinstein et 
al. (1977) showed, during studies on the opioid peptides in the rat pituitary, the presence 
of a protein, with molecular weight over 30 K dalton from which opioid activity could be 
generated by trypsin digestion. Soon after, the protein was given the name pro-opiocortin 
because this protein is the common precursor for the opioid peptides and corticotrophin 
(Rubinstein et al. 1978). Pro-opiocortin was also purified from camel pituitaries (Kimura 
et al. 1979). The nucleotide sequence of bovine ACTH-P-LPH precursor was reported by 
Nakanishi et al. (1979). Pro-opiocortin was later appropriately named 
proopiomelanocortin as the sequence coded for not only ACTH and opioid products of p-
14
LPH but also for the a- and P-melanocyte-stimulating hormones (MSH) (Figure 1.1.) 
(Chretien et al. 1979).
1.2.3. Prodynorphin
The search for a precursor to [Leu] enkephalin or a “big” [Leujenkephain resulted in the 
isolation of a novel tridecapeptide from pituitary which contains [Leujenkephain 
(Goldstein 1978). The identified tridecapeptide was named “dynorphin” {dyn- fiom 
Greek dynamis = power and orphine fiom a common suffix in the names of opioids) 
(Figure 1.1.) (Goldstein et al. 1979). Dynorphini.13 was shown to have typical opioid 
activity in two bioassays (Goldstein et al. 1979). In the guinea pig ileum preparation, the 
potency of dynorphini.13 was 730 times that of [Leu]enkephalin, 190 times that of 
normorphine, and 54 times that of pc-endorphin (camel p-endorphin) (Goldstein et al. 
1979). In the mouse vas deferens, dynorphini.13 was about three times more potent than 
that of [Leu] enkephalin.
A new opioid octapeptide (PH-8 P) was isolated from porcine hypothalamus (Minamino et 
al. 1980) and shown to be structurally identical to the subsequence (1-8) of dynorphini.13, 
purified from porcine pituitary (Goldstein et al. 1979). a-Neoendorphin, one form of 
“big” [Leujenkephalin, was isolated from porcine hypothalami (Kangawa et al. 1979) and 
was shown to have opioid activity in guinea pig ileum assay (Kangawa et al. 1981). The 
full sequence of the a-neoendorphin was not established until 1981 (Kangawa et al. 1981). 
Minamino et al. (1981) isolated another new opioid nonapeptide, named P-neoendorphin, 
and determined its complete amino acid sequence which was shown to differ from a-
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neoendorphin only by the absence of the C-terminal lysyl group. g-Neoendorphin was 3 
times less potent than a-neoendorphin in guinea pig ileum assay (Kangawa et al. 1981). 
The structure of dynorphin was further clarified by Goldstein (1981) who identified 
dynorphin as a heptadecapeptide (termed dynorphim.i?) which was different from the 
original description of dynorphini.13, though only the first 13 residues were needed for its 
biological activity. Dynorphini.13 was also isolated from porcine duodenum (Tachibana et 
al. 1982).
The primary structure of a precursor protein, preprodynorphin (ppDYN), that contains g- 
neoendorphin, dynorphin and a carboxyl extension of [Leujenkephalin flanked between 
paired basic amino acids was deduced fiom the nucleotide sequence of cloned DNA 
complementary to the porcine hypothalamic mRNA (Figure 1.1.) (Kakidani et al. 1982; 
Rossier 1982). A tridecapeptide termed rimorphin (dynorphin Bi.o) was purified from 
extracts of bovine posterior pituitary glands that is distinct fiom the sequence of 
dynorphin or a-neoendorphin except for the initial hexapeptide sequence and thus 
represents a third unique [Leu]enkephalin-containing peptide in the posterior pituitary 
gland that possesses high opiate activity (Kilpatrick et al. 1982). A novel dynorphin 
peptide which has 32 amino acids termed dynorphini.32 (dynorphin AB) was isolated fiom 
porcine pituitary (Fischli et al. 1982). The peptide was composed of an amino-terminal 
dynorphin A (dynorphim.i? or dynorphin Am?) (Goldstein et al. 1981) and a carboxyl- 
terminal dynorphin B (rimorphin or dynorphin B1.13) (Fischli et al. 1982) and was 
separated by the processing signal Lys-Arg (Fischli et al. 1982). ppDYN, contains a 
previously unknown peptide with 29 amino acids, which corresponds to amino acid 
residues 228-256 of ppDYN and has [Leu]enkephalin and rimorphin at the amino- 
terminal 1-5 and 1-13 portions, respectively. This peptide, named leumorphin (dynorphin
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Bi-29), is flanked by paired basic amino acid residues, Lys-Arg, known to be a typical 
prohormone processing signal (Steiner et al. 1980) and has been reported to be present in 
porcine neuro-intermediate pituitaries (Nakao et al. 1983).
1.2.4. Atypical endogenous opioid-related peptides
In 1981, a heptapeptide named dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) was 
isolated from methanol extracts of the skin of the South American frog (Broccardo et al. 
1981) and was found to bind preferentially to the MOPr (Rossi et al. 1986). In 1989, two 
deltorphins (deltorphins I and II) with the sequence Tyr-Ala-Phe-Asp(or Glu)-Val-Val- 
Gly-NH2, which have high-affmity for 8 -opioid receptor (DOPr) and differ by the 
presence of an aspartic or glutamic residue in position 4, were isolated from skin extracts 
of Phyllomedusa bicolour (Erspamer et al. 1989; Kreil et al. 1989).
In 1995, two independent groups identified a novel endogeneous opioid peptide for the 
“orphan” opioid receptor (Meunier et al. 1995; Reinscheid et al. 1995). The new peptide 
was named nociceptin as the physiological action of the peptide appeared to increase 
sensitivity to pain in animals (Meunier et al. 1995). It was also named orphanin FQ as it 
is a peptide with affinity for the “orphan” opioid receptor (FQ is a reference to the first 
and last amino acids, phenylalanine (F) and glutamine (Q)) (Reinscheid et al. 1995). 
Much of the literature uses both terminologies for the peptide but the most widely used is 
nociceptin/orphanin FQ (N/OFQ) or orphanin FQ/nociceptin (OFQ/N). For convenience, 
the term “nociceptin” will be used throughout the rest of this thesis to refer to both 
N/OFQ and OFQ/N. Like all neuropeptides, nociceptin is synthesized as part of a larger
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polypeptide (176 amino acids in human). The cDNAs encoding the nociceptin precursor 
have been cloned from mice (Saito et al. 1995), rat and human (Mollereau et al. 1996; 
Nothacker et al. 1996). The nociceptin precursor contains another biological active 
peptide (termed nocistatin; Glu-Gln-Lys-Gln-Leu-Gln) which was isolated from bovine 
brain (Okuda-Ashitaka et al. 1998). The two endogenous peptides, nociceptin and 
nocistatin, are generated from the same precursor and play opposite roles in pain 
transmission (Figure 1.1.) (Okuda-Ashitaka et al. 1998).
In 1997, two novel endogenous opioid peptides (Table 1.1.) from bovine frontal cortex 
were isolated by Zadina et al. (1997). The two new peptides, endomorphin-1 and 
endomorphin-2, have a high affinity and a clear specificity for MOPr (Zadina et al. 1997). 
To date no precursors have been identified for these peptides.
1.2.5. Gene targeting for generating conventional knockout mice
To generate conventional knockout (KO) mice, the homologous recombination method 
has been widely used by replacing the specific gene of interest with a cloning vector 
without affecting other loci in the genome (Capecchi 1989). Figure 1.2. shows the 
general gene targeting strategy for generating conventional opioid peptide and receptor 
KO mice.
A targeting vector, consisting of a neomycin resistance (Neo’^) gene as a positive selection 
marker in place of exons essential for the normal function of the target gene and 
thymidine kinase (tK) as a negative selection marker, is constructed and introduced into
18
Figure 1.2. Strategy for generating conventional 
knockout mice
Vector leo
Genome
Random gene 
insertionTargeted gene insertion No insertion
Targeted
genome a Veo'
Neomycin
Cell killed by neomycin
Gancyclovir
Cell résistent to neomycin killed 
by gancyclovir (nonhomolgous recombination)
Cell resistant to both neomycin
and gancyclovir (homologous recombiniation)
Microinjection 
Inner cell mass
Targeted ES cells from 129 strain 
-Blastocyst from C 57B L /6^_^jp ||^
Transfer early embryos into pseudopregnant 
mouse
Surrogate mother gives birth to chimeric pup
Mating between chimeric mouse and C57BL/6 mouse 
to produce Fl progeny carrying the mutant allele
Fl
+/-
^  Mating between heterozygous mutant to produce
 homozygous mutant
+/-
F2
+/+ +/- +/- -/-
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Legend to Figure 1.2.
General steps involved in the generation of opioid peptide and opioid receptor knockout 
mice by homologous recombination method. A targeting vector consisting of a positive 
[neomycin resistance (Neo )^ gene] and a negative [(thiymidine kinase (tK)] marker 
inserted into embryonic stem (ES) cells derived from 129 strains (agouti coat colour) via 
electroportation or microinjection. Inactivation of the gene of interest (exon 2) can be 
replaced with the Neo^ by homologous recombination. Ramdom gene insertion may take 
place in any places that can be selected by screening in gancyclovir containing medium. 
Rare cells from homologous recombination which survived in media containing both 
neomycin and gancyclovir are used for microinjection. The targeted ES cells are 
transferred into a blastocyst derived from a host of different genetic backgrounds 
(C57BL/6, black coat colour) and transplanted into a pseudopregnant female. This foster 
mother gives birth to chimeric pups from the modified ES cells (mixed coat colour; black 
and agouti). Breeding male chimeras to female C57BL/6 strain results in producing Fl 
heterozygous mutant mice (agouti). This can be identified by performing southern blot 
analysis or PCR. Mating of those heterozygous animals with each other produces wild- 
type, heterozygous and homozygous knockout mice. Adapted from Walinski, (2004)
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embryonic stem (ES) cells, from the 129 strain (agouti coat colour), by electroporation or 
microinjection (Figure 1.2.). The targeting vector finds the targeted gene and 
recombination takes place within the homologous sequences (homologous recombination). 
However, random gene insertion or no insertion may take place within the flanking DNA 
sequences. The cells containing the targeted mutation can be indentified by screening 
with the antibiotics neomycin and gancyclovir to kill any cells that contain the tK gene.
The selected cells containg the targeted mutation are injected into a blastocyst, from 
C57BL/6 (black coat colour), then transferred into a pseudopregnant mouse. The 
surrogate mother will give birth to a range of mice. Chimeric mouse derived from the 
targeted ES cells can be identified easily with a visible marker trait (agouti coat colour). 
These are then mated with C57BL/6 mice (homozygous for another allele of the marker 
trait) to determine whether the KO mutation is incorporated into the germ line 
transmission. This leads to a generation of heterozygous offspring carrying the mutant 
allele (agouti coat colour). Mating mice between heterozygous mutants will produce a 
generation of wild-type (WT), heterozygous and homozygous mice.
1.2.6. Opioid-peptide knockout mice
Classical endogenous opioid peptides (dynorphins, enkephalins, and endorphins) are 
derived from three precursors, ppDYN, ppENK, and preproopiomelanocortin (POMC), 
respectively (Figure 1.1.). Moreover, an atypical endogenous opioid peptide nociceptin 
has been identified which is processed from a larger polypeptide precursor by proteolytic
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cleavage. With the help of the development of gene targeting strategies, several opioid- 
peptide KO mice have been generated from various mice strains by different groups.
I.2.6.I. Preproopiomelanocortin
The POMC precursor contains an opioid peptide P-endorphin, the non-opioid peptides 
ACTH, P-, y-MSH as well as P-, y-LPH (Figure 1.1.) (Nakanishi et al. 1979). The 
generation of mice deficient in P-endorphin was reported by Rubinstein et al. (1996 ). To 
produce mice lacking P-endorphin, a point mutation of exon 3 in POMC gene was used 
that prevented the synthesis of the opioid peptide without affecting MSH content and 
ACTH immunoreactivity. A mutant mouse lacking all POMC-derived peptides has also 
been generated by deleting the entire third exon of POMC which contains coding regions 
for all POMC peptides (Yaswen et al. 1999).
1.2.6.2. Preprodynorphin
Dynorphins (dynorphin A and B), a- and P-neoendorphin are all derived from the 
ppDYN gene (Figure 1.1.) (Kakidani et al. 1982). All of these peptides begin with [Leuj­
enkephalin sequence (Tyr-Gly-Gly-Phe-Leu) (Table 1 .1 .). Mice lacking the ppDYN gene 
were generated by two laboratories (Sharifi et al. 2001; Zimmer et al. 2001). Deletion of 
whole coding regions spanning exons 3 and 4 (Sharifi et al. 2001) or exon 3 and part of 
exon 4 from ppDYN gene (Zimmer et al. 2001) successfully produced dynorphin- 
deficient mice.
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1.2.6.3. Preproenkephalin
The proenkephalin precursor contains four different copies of [Metjenkephain, one copy 
of [Met^Arg^,Phe^] enkephalin, one copy of [Met^Arg^,Gly^,Leu^] enkephalin and a single 
copy of [Leujenkephain (Figure LL) (Noda et al. 1982). Mice lacking ppENK gene have 
been generated by two independent groups. Konig et al. (1996) replaced the 5’ part of 
exon 3 in the ppENK gene, which contains all enkephalin-coding sequences in order to 
block enkephalin peptide production with phosphoglycerine kinase-neo. Another group 
also produced ppENK KO mice by targeting a recombinant locus lacking the 5’ part of 
exon 3 (Ragnauth et al. 2001).
I.2.6.4. Prepronociceptin
Pronociceptin precursor contains an atypical novel endogenous opioid peptide nociceptin 
(Saito et al. 1995; Mollereau et al. 1996; Nothacker et al. 1996) and nocistatin (Okuda- 
Ashitaka et al. 1998). The primary structure of the pronociceptin contains the typical 
structural elements of a neuropeptide precursor, in particular an amino terminal signal 
peptide necessary for its secretion. Nociceptin-deficient mice are generated by targeted 
disruption of exon 2 of the nociceptin gene (Koster et al. 1999). Another group produced 
nociceptin-deficient mice by deleting the majority of the exon 3 coding sequences (Chen 
etal. 1999).
1.3. Opioid receptors
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1.3.1. Background
Although progress had been made to identify and isolate some receptors that drugs act on, 
opioid binding sites had not been identified until the standard radioligand binding method 
was developed (Goldstein et al. 1971). The first evidence for the existence of opioid 
binding sites in the brain were demonstrated by three different laboratories in 1973 (Pert 
and Snyder 1973; Simon et al. 1973; Terenius 1973). This work lead to a search for 
opioid receptor subtypes. In 1976, Martin et al. (1976 ) postulated the existence of three 
opioid receptors interacting with three different drugs based on producing distinct 
pharmacological effects in chronically spinalized dogs; the MOPr for morphine, the k - 
opioid receptor (KOPr) for ketocyclazocine and the o receptor for N-allylnormetazocine 
(SKF-10,047). Morphine produced miosis, bradycardia, hypothermia, depression of 
nociceptive responses whereas the nalorphine-like compound ketocyclazocine produced 
pupilliary constriction, flexor reflex depression, sedation without marked effects on pulse 
rate or the skin twitch reflex (Martin et al. 1976). SKF-10,047, in contrast to morphine 
and ketocyclazocine, produced a third behavioural effect - tachycardia, mydriasis, 
tachypnea and mania (Martin et al. 1976). Although for the latter case, the existence of a 
receptors was postulated, the o receptor is no longer classified as an opioid site as it does 
not mediate naloxone-reversible effects (Quirion et al. 1987). Soon after. Lord et al. 
(1977) provided further evidence for multiple opioid receptors in different isolated tissues 
based on differences in the rank order of potency of opioid drugs in mouse vas deferens 
(termed DOPr or enkephalin-like) versus guinea pig ileum (termed MOPr or morphine­
like). In 1979, Chang and Cuatrecasas (1979) proposed the existence of DOPr binding 
sites by using [I^^^]-labeled enkephalin analogs. Young and Kuhar (1979) proposed a 
new method to examine the distribution of opioid receptors at the light microscopic level
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that had many advantages over earlier studies where receptors are labelled by in vivo 
injection. This technique has become a standard method for receptor autoradiography 
(Goodman et al. 1980; Herkenham and Pert 1980). Shortly thereafter, three major opioid 
receptors were studied with the use of highly selective ligands in the early 1980s; [d- 
Ala^,N-Me-Phe"^,Gly^-ol]enkephalin (DAMGO) for MOPr (Handa et al. 1981), trans-3,4- 
dichloro-N-methyl-N-[2-( 1 -pyrrolidinyl)cyclohexyl]-benzeneacetamide (U-50,488H) for 
KOPr (Vonvoigtlander et al. 1983) and [D-Pen^,o-Pen^]enkephalin (DPDPE) for DOPr 
(Mosberg et al. 1983a). Mansour et al. (1987) showed the anatomical distribution of the 
three major opioid receptors using in vitro autoradiography in rat brain demonstrating all 
three opioid receptors were differentially distributed in the rat brain although they could 
be localized within the same brain areas.
1.3.2. Opioid receptor subtypes
The development of selective agonists and antagonists enabled the study of 
pharmacological and biological functions of the three classical opioid receptors. Evidence 
from behavioural and pharmacological studies suggested multiple subtypes for the DOPr 
(8 i, Ô2, 5cx, ôncx), MOPr (pi, P2) and KOPr (ki, K2, Ks) although the existence of the 
subtypes is still a matter of debate.
The existence of DOPr subtypes has been suggested by behavioural and binding studies 
(Jiang et al. 1991; Sofuoglu et al. 1991a; Portoghese et al. 1992; Rothman et al. 1992a; 
Xu et al. 1992). The agonist ligands such as DPDPE and [D-Ala^,D-Leu^]enkephalin 
(DADLE) are known as putative 8 rpreferring peptides (Mosberg et al. 1983b), whereas
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[D-Ser^Leu^Thr^]enkephalin (DSLET) and [o-Ala^Jdeltorphin II are selective for putative 
Ô2 (Gacel et al. 1980; Erspamer et al. 1989). With respect to antagonist ligands, [d- 
Ala^,Leu^Cys^]enkephalin (DALCE) is selective for putative 81, while naltriben and 
naltrindole 5 '-isothiocyanate (5’NTH) are selective for putative 82 (Bowen et al. 1987; 
Portoghese et al. 1990; Portoghese et al. 1991). Two sub-populations of DOPr binding 
sites (81 and 82) are thought to exist in rat brain membranes from studies using 
competitive binding (Negri et al. 1991). DPDPE was shown to produce a biphasic 
inhibition of specific [^H][D-Ala^]deltorphin I binding, whereas [o-Ala^]deltorphin I 
produced an apparent monophasic inhibition of specific [^HJDPDPE binding suggesting 
the existence of DOPr heterogeneity (Negri et al. 1991). Behavioural studies further 
support the heterogeneity of DOPr subtypes which was based on the findings that 81 and 
82 can be distinguished by several DOPr agonists or antagonists in antinociception studies 
(Jiang et al. 1991; Sofuoglu et al. 1991a, b). Jiang et al. (1991) showed that the 
antinociceptive actions of [o-Ala^Jdeltorphin II and of DSLET were sensitive to 5’-NTII 
but not to DALCE whereas the antinociception of DPDPE was sensitive to DALCE but 
not to 5’-NTH suggesting the existence of subtypes of DOPr which was classified as 
either 5’-NTII-sensitive (i.e., acted upon by [o-Ala^Jdeltorphin II and DSLET) or 
DALCE-sensitive (i.e., acted upon by DPDPE). Deltorphin II, which is a highly selective 
peptide for the 82 subtype, played an important role in identifying the functional 
distinction between DOPr subtypes. Other studies demonstrated that naltriben was more 
effective in antagonizing the antinociceptive action of DSLET than those of DPDPE or 
DADLE and this antagonist selectivity profile was more apprarent at spinal sites 
compared to supraspinal sites suggesting the DOPr agonists DADLE, DSLET and 
DPDPE may interact with different sites in mediating antinociception upon spinal or 
supraspinal administration and may possibly represent DOPr subtypes (Sofuoglu et al.
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1991a). In addition to the 8 i and Ô2 receptors, a putative ô site thought to be associated 
with a MOPr complex, termed the ôcx (Scompiexed) binding site and a putative ô site that has 
not been associated with the MOPr complex, termed the 6 ncx (ônoncompiexed) binding site, 
have been proposed (Rothman et al. 1992a; Xu et al. 1992). Nevertheless, these 
behaviourally and pharmacologically defined subtypes of DOPr have not been identified 
at a molecular level although the cloned DOPr has been reported to exhibit higher affinity 
for putative 82-selective ligands than for ôi-selective compounds (Raynor et al. 1994). 
However, in saturation binding studies using DOPr KO mice, 81- ([^HJDPDPE), 82- 
([^H]deltorphin II) or both 81- and 82- ([^Hjnaltrindole) preferring radioligand binding 
were absent from DOPr KO mice indicating that the DOPr gene (Oprdl) may encode both 
“81” and “82” receptor subtypes (Zhu et al. 1999; Filliol et al. 2000).
Early evidence from pharmacological and biochemical studies support the presence of 
two subtypes of the MOPr referred to a pi- and p2-subtypes (Pasternak and Wood 1986). 
The two different subtypes were characterized by their high (pi) and low (p2) affinity for 
naloxazone and naloxonazine which are selective and long-lasting pi-receptor antagonists 
(Pasternak and Wood 1986; Pasternak 2001). The naloxonazine-sensitive binding sites 
(pi) were proposed to be involved in a number of opioid actions, including supraspinal 
analgesia, prolactin release, acetylcholine turnover, catalepsy and hypothermia (Pasternak 
and Wood 1986). The naloxonazine-insensitive binding sites (P2) were proposed to be 
involved in respiratory depression, bradycardia, and dopamine (DA) turnover (Pasternak 
and Wood 1986). Subtracting p2 binding ([^H]dihydromorphine plus a low concentration 
of DADLE) from total MOPr (pi, P2) binding ([^H]Dihydromorphine alone) was used in 
order to determine the distribution of pi and p2 binding sites in mouse brain (Moskowitz 
and Goodman 1985). High densities of pi binding sites were detected in laminae I and II
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of the spinal cord and in the periaqueductal gray known to be involved in the processing 
of nociceptive information whereas either low (dorsal nucleus of the vagus nerve) or no 
(nucleus of the solitary tract) pi binding sites were dectected in the areas that may mediate 
the respiratory depressant effects of opioids in mouse brain suggesting opioids-induced 
analgesia is mediated primarily by pi sites. A cDNA from rat brain corresponding to the 
P2-subtype was identified according to its relatively low affinity for morphine and 
DADLE (Thompson et al. 1993). On the other hand, other cloned MOPr from rat brain 
were identified which corresponded to the pi-subtypes because of their high affinity for 
naloxonazine (Chen et al. 1993b; Wang et al. 1993; Raynor et al. 1994). In addition to the 
pi- and p2-subtypes, behavioural and binding studies suggested a novel p analgesic 
system which is activated by morphine-6|3-glucuronide (Rossi et al. 1995; Rossi et al. 
1996; Brown et al. 1997; Schuller et al. 1999). For example, morphine-6 p-glucuronide 
retained its analgesic activity in MOPr KO (Schuller et al. 1999) and CXBK mice, which 
are insensitive to morphine (Rossi et al. 1996). Moreover, low levels of [^HJmorphine- 
6 P-glucuronide were detected in MOPr KO mice (Schuller et al. 1999). These results 
suggested that the major morphine metabolite morphine-6 p-glucuronide might have a 
unique binding site that may act through an opioid receptor distinct from that mediating 
morphine’s actions (Rossi et al. 1995; Rossi et al. 1996; Brown et al. 1997; Schuller et al. 
1999).
The possible existence of at least two subtypes of the KOPr in the brain has been 
suggested (Zukin et al. 1988; Clark et al. 1989). Zukin et al. (1988) provided evidence for 
the presence of two KOPr subtypes; the (5a,7a,8P)-N-methyl-N-[7-(l-pyrrolidinyl)-l- 
oxaspiro[4,5]dec-8-yl]benzeneacetamide (U-69,593)-sensitive site (k i)  site which 
predominates in guinea pig brain, and the U-69,593-insensitive site (K2) site which
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predominates in the rat brain. In addition, the existence of K3 receptor binding sites, 
which have a high affinity for naloxone benzoylhydrazone but no affinity for U-69,593, 
has been proposed by Clark et al. (1989). The binding sites corresponding to k i receptors 
are distinct from K2 binding sites in rat and guinea pig brain (Unterwald et al. 1991). In 
rat brain, k i receptors labeled by [^H]U-69,593 are of low density and confined to a small 
number of structures whereas K2 receptors labeled by [^HJethylketocyclazocine or 
[^HJbremazocine, under conditions in which MOPr, DOPr, and k i binding was suppressed, 
are of high density and widely distributed throughout all regions of the brain (Unterwald 
et al. 1991). In guinea pig brain, K2 sites are more uniformly and widely distributed 
throughout the brain than arexi sites (Unterwald et al. 1991). The relative proportion of 
Ki sites labeled with [^H]CI-977 is far greater in the mouse than the rat and indeed is 
substantially higher than in the guinea pig brain whereas K2 sites are higher in rat brain 
compared with guinea pig and mouse (Unterwald et al. 1991; Kitchen et al. 1997). These 
results demonstrate the important interspecies differences in the distribution of k i and K2 
opioid receptors. [^H](5R)-(5a,7a,8P)-N-methyl-N-[7-(l-pyrrolidinyl) 1 -oxaspiro[4,5]dec- 
8-yl]-4-benzofuranacetamide (CI-977) is used for labelling k i receptors, while the non- 
selective ligand [^HJbremazocine in the presence of excess cold DAMGO (MOPr), 
DPDPE (DOPr) and CI-977 (k i)  is used for labelling K2 receptors as no selective 
compound for K2 sites has been identified (Tiberi and Magnan 1990). A cDNA 
corresponding to the k i rather than K2 (Meng et al. 1993; Yasuda et al. 1993; Raynor et al. 
1994) has been cloned. A Kg-related protein has been obtained although it is not clear 
whether it represents the K3 receptor itself or a splice variant (Pan et al. 1995).
1.3.3. Gene cloning of opioid receptors
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A complementary DNA clone encoding a functional DOPr was obtained from NG108-15 
cell line (Evans et al. 1992; Kieffer et al. 1992) and mouse brain (Yasuda et al. 1993). In 
1993, soon after the cloning of the DOPr, the MOPr was cloned from rat brain (Chen et al. 
1993b; Thompson et al. 1993; Wang et al. 1993). In the same year the KOPr was cloned 
from rat (Meng et al. 1993; Minami et al. 1993) and mouse brain (Yasuda et al. 1993). A 
fourth family of opioid receptors which was called the opioid receptor-like 1 (ORLl) or 
nociceptin opioid receptor (NOPr) is a major target for the atypical ligand nociceptin 
(Meunier et al. 1995; Reinscheid et al. 1995). This new member of the opioid receptor 
gene family was cloned from several species by a number of groups between 1994 and 
1995. The nomenclature of this novel receptor named according to the initial findings 
from different laboratories; KOR-3 (Pan et al. 1994; Pan et al. 1995) or MOR-C (Nishi et 
al. 1994) in mouse, XORl (Wang et al. 1994; Wick et al. 1994), LC132 (Bunzow et al. 
1994), Ratxorl (Chen et al. 1994), C3 (Lachowicz et al. 1995) or ROR-C (Fukuda et al. 
1994; Keith et al. 1994) in rat and hORLl in human (Mollereau et al. 1994). The 
isolation of a cDNA clone showed seven transmembrane domains and a similar structure 
to the other classical opioid receptors although the novel seven-helix receptor exhibited a 
lack of affinity for classical opioid receptor ligands (Chen et al. 1994; Nishi et al. 1994).
1.3.4. Structure of the opioid receptors
Opioid receptors belong to the superfamily of seven putative membrane-spanning G 
protein-coupled receptors, and share extensive sequence homologies (for review, see 
Waldhoer, 2004). The amino sequences of the three classical opioid receptors are about 
60% identical to each other (Chen et al. 1993a). The most conserved regions are the
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transmembrane domain 2, 3 and 7, the first extracellular loop, and the second, third and 
‘fourth’ cytoplasmic loops (Chen et al. 1993a). The third intracellular loop has been 
implicated in the binding of G proteins and also has consensus sequences for 
phosphorylation, which might be involved in regulatory processes such as G protein 
docking (Zaki et al. 1996). The less conserved regions are the transmembrane domain 1, 
4 to 6 , and the second and third extracellular loops. The greatest divergence among the 
opioid receptors lies at the N- and C-terminal ends (Chen et al. 1993a). In addition, all 
four opioid receptors possess two conserved cysteine residues which are believed to be 
involved in disulfide bonding occuring in the first and second extracellular loops (for 
review, see Waldhoer, 2004).
1.3.5. Opioid receptor knockout mice
There are three different types of classical opioid receptors and a new family of opioid 
receptor in the central nervous system; MOPr, KOPr, DOPr and NOPr, respectively 
(Mogil and Pasternak 2001; Kieffer and Gaveriaux-Ruff 2002). Recent success in 
developing MOPr (Matthes et al. 1996; Sora et al. 1997; Tian et al. 1997; Loh et al. 1998; 
Schuller et al. 1999), KOPr (Simonin et al. 1998; Ansonoff et al. 2006), DOPr (Zhu et al. 
1999; Filliol et al. 2000), NOPr (Nishi et al. 1997) KO and combinatorial opioid receptor 
KO mice (Simonin et al. 2001) enable us to examine further the role of each receptor 
and/or the combination of two or all three classical opioid receptor functions in the central 
nervous system.
I.3.5.I. MOPr knockout mice
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MOPr-defîcient mice have been generated from five laboratories with different gene 
targeting strategies; deletion of exon 1 (Sora et al. 1997; Tian et al. 1997; Schuller et al. 
1999), exon 2 (Matthes et al. 1996) or both exons 2 and 3 (Loh et al. 1998). The binding 
of the radiolabelled MOPr agonist [^HJDAMGO was abolished in all the MOPr-deficient 
mice confirming the absence of MOPr regardless of the different gene targeting strategy 
(Matthes et al. 1996; Sora et al. 1997; Loh et al. 1998; Schuller et al. 1999). In addition, 
the expression profile of several KOPr and DOPr ligands was maintained intact in MOPr- 
deficient mice suggesting a lack of major compensatory changes of KOPr and DOPr in 
mice lacking MOPr (Matthes et al. 1996; Kitchen et al. 1997; Loh et al. 1998; Schuller et 
al. 1999; Chen et al. 2000).
1.3.5.2. KOPr knockout mice
The generation of mice deficient in KOPr was reported by two groups (Simonin et al. 
1998; Ansonoff et al. 2006). Homologous recombination led to deletion of the first 
(Simonin et al. 1998) or third coding exon (Ansonoff et al. 2006). The binding of KOPr 
([^H]CI-977 and [^H]U-69,593) was undetectable in KOPr KO mice indicating that both 
gene targeting strategies led to a complete loss of KOPr binding sites (Simonin et al. 
1998; Ansonoff et al. 2006). Moreover, there was no major compensatory changes in 
MOPr and DOPr in the brain of KOPr-deficient mice (Simonin et al. 1998).
I.3.5.3. DOPr knockout mice
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Two groups generated mice lacking DOPr (Zhu et al. 1999; Filliol et al. 2000). Gene 
targeting was used to delete exon 1 (Filliol et al. 2000) or exon 2 (Zhu et al. 1999) of 
mouse DOPr. A lack of binding of DOPr-selective radiolabelled compounds to the DOPr 
was observed in DOPr KO mice, confirming genetic ablation of DOPr (Zhu et al. 1999; 
Filliol et al. 2000). In addition, binding of [^HjDPDPE (ôi), [^H]deltrophin I or II (8%) and 
[^H]naltrindole (8 i and 82) was absent from DOPr KO mice suggesting DOP-l encodes 
both 81 and 82 subtypes if they exist (Zhu et al. 1999; Filliol et al. 2000). Genetic 
disruption of DOP-l did not influence the expression of MOPr ([^HjDAMGO) and KOPr 
([^H]U-69,593 or [^H]CI-977) demonstrating no obvious compensatory modification in 
the expression of other opioid receptor sites (Zhu et al. 1999; Filliol et al. 2000).
I.3.5.4. NOPr knockout mice
The generation of mice deficient in NOPr was reported by two groups (Nishi et al. 1997; 
Clarke et al. 2001). Homologous recombination lead to deletion of the first protein-coding 
sequence (Nishi et al. 1997) or exons 2 and 3 of mouse of NOPr (Clarke et al. 2001). 
There was a complete absence of NOPr binding ([^H]/ewcy/-nociceptin) (Clarke et al. 
2001) and mRNA (Nishi et al. 1997) in homozygous brains indicating deletion of the 
NOPr was successful and any putative subtypes of this receptor must arise from the single 
gene. The expression levels of nociceptin precursor mRNA was comparable in the brains 
of NOPr KO and WT mice (Nishi et al. 1997). Although there are no major 
compensatory changes in the expression of MOPr ([^HjDAMGO), DOPr ([^HJdeltorphin 
I) or KOPr ([^H]CI-977) there were a few region specific alterations in receptor binding 
which may reflect an interaction between opioid and NOPr systems (Clarke et al. 2001).
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1.4. Behavioural phenotypes in response to drugs of abuse in opioid peptide 
knockout mice
1.4.1. Psychostimulants
I.4.I.I. Preprodynorphin knockout mice
No significant differences were detected between WT and ppDYN KO mice in basal 
locomotor activity (Table 1.2.) (Chefer and Shippenberg 2006; Bailey et al. 2007). Acute 
cocaine administration increased locomotor activity in WT and ppDYN KO mice, 
however this effect was significantly lower in ppDYN KO mice compared with its WT 
controls (Chefer and Shippenberg 2006). In contrast to these results, Bailey et al. (2007) 
showed that there was no difference in acute cocaine-induced locomotor activity in 
ppDYN KO mice compared with WT mice. The different results from these two studies 
could be due to the different experimental protocols used in the two studies or to the 
different derivation of the ppDYN deletion. Chronic ‘binge’ cocaine administration for 
14 days induced behavioural sensitisation in WT and ppDYN KO mice. The cocaine- 
induced behavioural sensitisation of the KO mice was significantly higher than WT mice, 
indicating an enhanced cocaine-induced behavioural sensitisation in ppDYN KO mice 
after a chronic ‘binge’ cocaine administration suggesting the chronic ‘binge’ cocaine- 
induced activation of the KOPr system opposes the behavioural responses to cocaine that 
develops after repeated use, possibly by inhibiting DA release (Bailey et al. 2007). In this 
treatment, both WT and ppDYN KO mice exhibited lacking sensitisation effect of cocaine 
on stereotypy behaviour (Bailey et al. 2007). Disruption of ppDYN in mice reduced
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social defeat stress-induced potentiation of cocaine-induced CPP (McLaughlin et al. 
2006b). Overall, this evidence suggests that ppDYN system plays an important role in the 
modulation of the sensitization and stress-induced rewarding effects of cocaine.
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I.4.I.2. Preproenkephalin knockout mice
Nicotine decreased both horizontal and vertical locomotor activity in ppENK KO mice 
and WT littermates and no significant difference was found in locomotor activity between 
the genotypes (Table 1.2.) (Berrendero et al. 2005). A significant rewarding effect of 
nicotine was observed in a CPP paradigm in WT mice, whereas this effect was not 
observed in ppENK KO mice (Berrendero et al. 2005). Mecamylamine, a nicotinic 
receptor antagonist, administration in chronic nicotine-treated WT and ppENK KO mice 
induced a nicotine withdrawal syndrome. However, the intensity of the nicotine 
withdrawal syndrome was decreased in mice lacking ppENK compared with its WT mice 
(Berrendero et al. 2005). These results demonstrate that ppENK play an important role in 
the modulation of reward and withdrawal symptoms rather than locomotor effects of 
nicotine.
1.4.2. Opioids
I.4.2.I. Preprodynorphin knockout mice
Basal horizontal and vertical locomotor activities were similar in ppDYN KO and WT 
mice indicating that dynorphin is not essential for normal motor functions (Table 1.2.) 
(Zimmer et al. 2001). Morphine administration increased horizontal locomotor activity in 
both genotypes. There was no significant difference in horizontal locomotor activity
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between the genotypes suggesting that the endogenous opioid peptide dynorphin does not 
play a crucial role in movements in response to acute morphine (Zimmer et al. 2001). The 
rewarding effect of morphine was evaluated using the CPP paradigm in mice lacking 
ppDYN and WT control mice (Zimmer et al. 2001). Both ppDYN KO and WT mice 
exhibited a similar place preference for the morphine paired side indicating that the 
rewarding effect of morphine is not mediated by the endogenous opioid peptide 
dynorphin. Morphine withdrawal signs were observed in chronic morphine treated 
ppDYN KO and WT mice after administration of naloxone and the symptoms were 
similar between the genotypes suggesting dynophin is not involved in the expression of 
morphine dependence (Zimmer et al. 2001).
1.4.2.2. Preproenkephalin knockout mice
Naloxone produced a significant place aversion in WT mice but had no effect in ppENK 
KO mice suggesting that endogenous ppENK-derived peptides play an important role in 
mediating a ‘basal hedonic tone’ in mice (Table 1.2.) (Skoubis et al. 2005). No 
significant genotype effects was found in morphine-induced CPP between WT and 
ppENK KO mice indicating that endogenous release of these peptides is not essential for 
the rewarding effect of morphine (Skoubis et al. 2005). Continuous administration of 
morphine (pellet) in ppENK KO mice displayed an enhanced signs of naltrexone- 
precipitated withdrawal compared with WT mice suggesting endogenous ppENK-derived 
peptides are involved in physical dependence to morphine (Nitsche et al. 2002).
I.4.2.3. P-endorphin knockout mice
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Both morphine-dependent WT and morphine-dependent p-endorphin KO mice exhibited 
naloxone-induced conditioned place aversion (CPA) (Table 1.2.) (Skoubis et al. 2005). 
However, an enhanced aversive effect of naloxone was observed in the p-endorphin KO 
mice compared with their WT counterparts. The persistence of naloxone-induced CPA in 
P-endorphin KO mice indicates that endorphins may not be the main mediator of a ‘basal 
hedonic tone’ in mice (Skoubis et al. 2005). Morphine produced a significant place 
preference in WT and P-endorphin KO mice but the morphine-induced CPP was greater 
in P-endorphin KO mice suggesting subtle modulatory roles for endogenous release of p- 
endorphin in the rewarding effect of morphine (Skoubis et al. 2005). However, the 
persistence of morphine-induced CPP in p-endorphin KO mice indicates that p-endorphin 
is not essential in the rewarding effect of morphine (Skoubis et al. 2005).
I.4.2.4. Nociceptin knockout mice
Naloxone precipitated withdrawal symptoms were observed in both morphine-dependent 
nociceptin KO and morphine-dependent WT mice (Table 1.2.) (Chung et al. 2006). The 
withdrawal symptoms were no different between nociceptin KO and WT mice when 
receiving repeated low doses of morphine. In contrast, WT mice displayed an increase in 
morphine withdrawal jumping behaviours when an escalating doses of morphine was used 
(Chung et al. 2006). In contrast to the latter observation, morphine-pellet implanted 
nociceptin KO mice displayed greater naloxone-precipitated jumping than WT controls 
(Kest et al. 2001). These results suggest that endogenous nociceptin peptide differently 
contribute to the expression of physical dependence depending on the morphine treatment 
protocols.
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No significant differences in basal locomotor activity were detected between WT and 
nociceptin KO mice (Table 1.2.) (Murphy et al. 2002). Heroin produced dose-dependent 
increases in locomotor activity in both WT and nociceptin KO mice (Murphy et al. 2002). 
No significant difference in heroin-induced hyperlocomotion was found between the 
genotypes suggesting nociceptin may not be involved in the modulation of heroin-induced 
locomotor activity.
1.4.3. Other addictive substances
I.4.3.I. Preprodynorphin knockout mice
In a two-bottle choice paradigm, female ppDYN KO mice had lower preference for 
ethanol than female WT mice (Table 1.2.) (Blednov et al. 2006). However the total fluid 
intake was increased in female ppDYN KO mice compared to female WT mice. In male 
mice, both genotypes displayed preference for ethanol and no significant difference was 
detected between the genotypes. Moreover, there were no significant differences between 
the genotypes in acute ethanol withdrawal and ethanol-induced CPP. These results 
suggest that constitutive deletion of ppDYN gene produces a reduction of alcohol 
drinking in female mice.
A-9-Tetrahydrocannabinol (THC)-induced hypoactivity was not affected by the deletion 
of dynorphin (Table 1.2.) (Zimmer et al. 2001). No significant genotype effects were 
found in cannabinoid receptor antagonist N-(piperidin-l-yl)-5-(4-chlorophenyl)-l-(2,4- 
dichlorophenyl)-4-methyl-1 H-pyrazole-3 -carboxamide hydrochloride (SRI 41716 A)-
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precipiated withdrawal signs in chronic THC-treated WT and ppDYN KO mice, 
suggesting dynorphin deficiency does not substantially influence adaptive neuronal 
changes after chronic THC treatment (Zimmer et al. 2001). THC-induced CPA was 
completely suppressed in ppDYN KO mice suggesting the dynorphin gene is crucial for 
the aversive effects of THC (Zimmer et al. 2001).
1.4.3.2. Preproenkephalin knockout mice
Ethanol-induced CPP in WT mice was similar in magnitude to that observed in ppENK 
KO mice (Table 1.2.) (Koenig and Olive 2002). Moreover, ethanol intake or preference 
was no different between ppENK KO and WT mice in a two bottle choice paradigm 
(Koenig and Olive 2002). For ethanol self-administration, there was no significant 
difference between ppENK KO and WT mice (Hayward et al. 2004). These results 
indicate that the rewarding effects of ethanol are not mediated by endogenous ppENK- 
derived peptides.
Horizontal and vertical movements induced by acute THC were decreased in both ppENK 
KO and WT mice (Table 1.2.) (Valverde et al. 2000). Similarly, chronic THC treatment 
also decreased the movements in both genotypes. There was no significant tolerance to 
the hypolocomotion or the effect of chronic THC in ppENK KO and WT mice (Valverde 
et al. 2000). The cannabinoid withdrawal syndrome was observed in both genotypes but 
the intensity of THC withdrawal was significantly decreased in ppENK KO mice 
compared to WT mice (Valverde et al. 2000). These results demonstrate that an
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activation of the endogenous enkephalinergic system is required for the expression of 
cannabinoid dependence but not for the cannabinoid-induced hypolocomotion.
1.4.3.3. P-endorphin knockout mice
There was a modest correlation between the dose of ethanol and locomotion in p- 
endorphin KO mice, whereas no correlation was found in WT mice. These correlations 
appear to indicate that, for p-endorphin KO mice, self-administration of ethanol increases 
locomotor activity (Table 1.2.) (Grahame et al. 1998). p-endorphin KO mice were shown 
to have higher preference for ethanol than WT mice in a two-bottle choice paradigm 
(Grisel et al. 1999). Interestingly, p-endorphin KO mice acquired i.v. ethanol self- 
administration, whereas WT mice did not, indicating that acute P-endorphin release is not 
necessary for i.v. ethanol reward in these mice (Grahame et al. 1998). However, Hayward 
et al. (2004) showed that female P-endorphin KO mice had much higher responding for 
the lower ethanol concentrations compared to female WT mice under an FR2 schedule, 
but no significant difference was found between male P-endorphin KO and WT mice 
(Hayward et al. 2004). These results suggest that the role of the endogenous opioid 
peptide p-endorphin in the modulation of ethanol consuming behaviours is gender- 
dependent.
I.4.3.4. P-endorphin/enkephalin knockout mice
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No significant difference was found in ethanol self-administration in P- 
endorphin/enkephalin double KO compared to WT mice suggesting that deletion of both 
P-endorphin and enkephalin does not play a crucial role in the rewarding effects of 
ethanol (Table 1.2.) (Hayward et al. 2004).
1.5. Behavioural phenotypes in response to drugs of abuse in opioid receptor 
knockout mice
1.5.1. Psychostimulants
1.5.1.1. DOPr knockout mice
Filliol et al. (2000) showed that DOPr KO mice under a hybrid 129/Sv x C57BL/6 genetic 
background exhibited increased basal locomotor activity compared to WT mice. In 
agreement with these findings, DOPr KO mice maintained on a pure C57BL/6 
background (> NIO backcrossed to C57BL/6) exhibited higher basal locomotor activity 
compared to its WT mice (Table 1.3.) (Chefer et al. 2004). Interestingly, in another study, 
the same mice of pure C57BL/6 background exhibited no changes in basal locomotor 
activity between DOPr KO and WT control mice (Chefer et al. 2003).
Chefer et al. (2004) investigated the locomotor activity in response to acute cocaine in 
DOPr KO and WT mice maintained on a pure C57BL/6 background. Acute cocaine- 
induced hyper-locomotor activity was significantly increased in DOPr KO mice compared
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to WT mice (Table 1.3.) suggesting that the DOPr is involved in the acute psychomotor 
effect of cocaine (Chefer et al. 2004).
I.5.I.2. KOPr knockout mice
No significant differences in basal locomotor activity were detected between KOPr KO 
and WT mice maintained on either a mixed 129S6 x C57BL/6J background (Chefer et al. 
2005) or a mixed 129/Sv x C57BL/6J background (Filliol et al. 2000) (Table 1.3.). Acute 
cocaine administration enhanced locomotor activity in KOPr KO mice compared to WT 
mice (Chefer et al. 2005). Repeated treatment with cocaine in WT mice developed 
behavioural sensitization, whereas a sensitisation effect was not observed in KOPr KO 
mice indicating that the absence of KOPr in mice causes the development of a chronically 
sensitized state which results in an ineffective enhancement of locomotor response to 
repeated cocaine administration (Chefer et al. 2005).
In the CPP assay, the rewarding effects of cocaine in KOPr KO mice was equivalent to 
WT mice in the absence of stress (Table 1.3.) (McLaughlin et al. 2006b). Repeated swim- 
stress however potentiated the rewarding effects of cocaine in WT mice, whereas 
disruption of KOPr gene abolished the stress-induced potentiation of rewarding effects of 
cocaine, suggesting that an activation of KOPr is required for the potentiation of cocaine- 
induced CPP by forced swim-stress (McLaughlin et al. 2006b).
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I.5.I.3. MOPr knockout mice
The involvement of the MOPr in the rewarding properties of amphetamine was studied by 
using the CP? paradigm (Marquez et al. 2007). MOPr KO mice displayed a similar 
amphetamine-induced CPP compared to WT mice, indicating that an activation of the 
MOPr may not be required for the rewarding effects of amphetamine (Table 1.3.) 
(Marquez et al. 2007).
The rewarding and reinforcing effects of cocaine have been investigated in mice lacking 
MOPr generated by different laboratories. The first report by Becker et al. (2002) showed 
that MOPr KO mice maintained on a mixed 129/Ola x C57BL/6 background exhibited 
reduced cocaine-induced CPP compared to its WT mice at a dose of 5 mg/kg whereas 
administration of 10 mg/kg of cocaine only induced CPP in MOPr KO mice indicating a 
shift in the dose-response curve to the right (Table 1.3.). Interestingly, MOPr KO mice 
maintained on a mixed 129/SvxC57BL/6 background exhibited similar place preference 
for 10 mg/kg of cocaine compared to WT mice (Contarino et al. 2002) whereas cocaine- 
induced CPP was decreased in C57BL/6 congenic MOPr KO mice compared to WT 
controls at the same dose (Hall et al. 2004) suggesting that the rewarding effects of 
cocaine in MOPr KO mice may be influenced by genetic background. In addition to the 
cocaine-induced CPP test, Mathon et al. (2005) studied an involvement of MOPr in 
cocaine reinforcement using a cocaine self-administration paradigm. Disruption of MOPr 
gene reduced cocaine self-administration suggesting that the MOPr is involved in the 
modulation of cocaine reinforcement (Mathon et al. 2005).
71
Several laboratories have studied locomotor stimulating effects of cocaine in mice lacking 
the MOPr. A decrease (Yoo et al. 2003; Chefer et al. 2004) or no change (Becker et al. 
2002, Contarino et al. 2002; Hall et al. 2004; Mathon et al. 2005) of locomotor activity 
following acute cocaine administration was observed in mice lacking the MOPr compared 
to WT mice (Table 1.3.). Repeated cocaine administration induced an enhancement of 
locomotor activity which is a phenomenon known as behavioural sensitization or reverse 
tolerance that is thought to be due to neuroadaptation of the dopaminergic system, 
rendering it increasingly, and perhaps permanently, hypersensitive to the drug (Pierce and 
Kalivas 1997). Attenuation (Yoo et al. 2003) or no change (Hall et al. 2004; Lesscher et 
al. 2005) of cocaine-induced behavioural sensitisation was observed in mice lacking the 
MOPr compared to WT mice. These inconsistencies in the results are probably due to 
differences in genetic background and/or different administration protocols for cocaine. 
Recently, Hummel et al. (2004) studied the locomotor stimulating effects of cocaine on 
different genetic background strains of MOPr KO mice. An increase in acute cocaine- 
induced locomotor activity was observerd in congenic C57BL/6J MOPr KO mice 
compared to WT whereas no changes occurred in mixed 129S6xC57BL/6J, FI hybrid 
129S6 X C57BL/6J or isogenic 129S6 MOPr KO mice compared with their WT controls. 
In addition, MOPr KO mice of different genetic backgrounds displayed dissimilar 
cocaine-induced behavioural sensitisation effects. More significantly it was shown that 
cocaine-induced behavioural sensitisation was decreased in mixed 129S6xC57BL/6J, 
increased in congenic C57BL/6J or did not change in FI hybrid 129S6 x C57BL/6J and 
isogenic 129S6 background of MOPr KO mice compared with their respective WT 
controls, indicating strain does interact with MOPr deletion which may influence the 
sensitization and locomotor effects of cocaine in MOPr KO mice (Hummel et al. 2004).
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MDMA (3,4 methylenedioxymethamphetamine; ecstasy) is a synthetic, psychoactive drug 
chemically similar to the stimulant methamphetamine. A significant rewarding effect of 
MDMA as measured with a CPP paradigm was observed in both WT and MOPr KO mice. 
Deletion of MOPr gene does not influence the rewarding effects of MDMA (Table 1.3.) 
(Robledo et al. 2004).
The possible involvement of the MOPr in several behavioural responses to nicotine has 
been studied using MOPr KO mice. No significant difference in the locomotor activity in 
response to acute low or high doses of nicotine was observed in both MOPr KO and WT 
mice (Table 1.3.) (Berrendero et al. 2002; Yoo et al. 2004). Repeated low dose nicotine 
treatment induced behavioural sensitisation in WT mice but not in MOPr KO mice (Yoo 
et al. 2004). Chronic high doses of nicotine decreased horizontal and vertical locomotion 
in both MOPr KO and WT mice with no significant genotype effect (Galeote et al. 2006). 
A significant rewarding effect of nicotine was observed in the CPP paradigm in WT mice 
but not in MOPr KO mice. Nicotine abstinence was precipitated by mecamylamine in 
chronic nicotine-treated WT and MOPr KO mice. Chronic nicotine-treated MOPr KO 
mice exhibited a lower intensity of nicotine withdrawal signs (Berrendero et al. 2 0 0 2 ) 
suggesting that both nicotine-induced rewarding and dependence are mediated by MOPr.
1.5.2. Opioids
15.2.1. DOPr knockout mice
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Acute morphine dose-dependently increased locomotor activity in WT and DOPr KO 
mice (Table 1.3.) (Chefer et al. 2003). However, no significant genotype effects were 
detected (Chefer et al. 2003). Physical dependence to morphine was assessed by 
naltrexone-precipitated withdrawal in WT and DOPr KO mice implanted with morphine 
pellets (Nitsche et al. 2002). Physical dependence to morphine was observed in both WT 
and DOPr KO mice with no significant differences in withdrawal intensity. These results 
indicate that the DOPr does not play a role in locomotor activity and physical dependence 
to morphine.
I.5.2.2. KOPr knockout mice
Basal locomotor activity was evaluated under non-stressful conditions in locomotor 
activity boxes or under stressful conditions in the open-field test in both WT and KOPr 
KG mice (Simonin et al. 1998). Both groups of mice showed a similar pattern of 
habituation to a novel environment under non-stressful or stressful conditions. Rewarding 
properties of morphine were accessed in WT and KOPr KO mice using a CPP paradigm 
in order to investigate whether the KOPr contributed to the rewarding properties of 
morphine (Table 1.3.) (Simonin et al. 1998). Morphine administration produced CPP in 
both WT and KOPr KO mice but no genotype effect was observed. Naloxone- 
precipitated withdrawal syndrome was observed in both morphine-dependent WT and 
KOPr KO mice (Simonin et al. 1998) but the severity of morphine withdrawal syndrome 
was significantly decreased in KOPr KO mice compared with WT mice. These results 
indicate that the KOPr partially mediates the expression of withdrawal symptoms, but not 
the rewarding action of morphine.
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15.2.3. MOPr knockout mice
Disruption of MOPr gene completely attenuated morphine CPP (Matthes et al. 1996; Sora 
et al. 2001; Hall et al. 2003) and self-administration (Becker et al. 2000; Sora et al. 2001) 
suggesting MOPr are a primarily involved in the addictive properties of morphine (Table
1.3.). Sora et al. (2001) also examined the rewarding effects of morphine in MOPr KO
mice maintained on a mixed 129/SvEv x C57BL/6J or congenic C57BL/6J strain.
Morphine-induced increased CPP in both mixed and congenic WT mice, whereas this
preference was eliminated in MOPr KO mice, whether of mixed 129/SvEv x C57BL/6J or
congenic C57BL/6J strain. Interestingly, heterozygous MOPr KO mice on the 129/SvEv
X C57BL/6J mixed background displayed almost double the preference for the morphine-
paired compartment compared to WT mice (Sora et al. 2001). However, heterozygous
MOPr KO mice maintained on congenic C57BL/6J background exhibited slmOgr
preference to morphine when compared to WT mice. These results suggest that using
heterozygous mice with half of WT MOPr densities provide a useful tool to investigate
whether the different levels of MOPr expression could influence opioid addiction in 
humans.
Basal horizontal locomotor activity was greatly reduced (Tian et al. 1997) or not changed 
(Sora et al. 2001) in MOPr KO mice compared with WT controls (Table 1.3.). No 
significant genotype effects were observed in basal vertical activity of WT compared to 
MOPr KO mice (Tian et al. 1997). MOPr KO mice maintained on congenic C57BL/6 
backgoumd exhibited less locomotion at the beginning of the test session when compared 
to WT mice (Hall et al. 2003). These results indicate that motor activity in mice lacking 
MOPr is influenced by strain. Morphine increased horizontal activity in WT mice.
75
whereas this hyperlocomotion was not observed in MOPr KO mice (Tian et al. 1997; 
Becker et al. 2000; Sora et al. 2001; Chefer et al. 2003; Hall et al. 2003; Yoo et al. 2003). 
Vertical activity in WT mice was significantly reduced after acute morphine injection, 
whereas morphine did not change the level of vertical activity in MOPr KO mice (Tian et 
al. 1997). Repeated morphine treatment induced locomotor sensitization in WT mice but 
not in MOPr KO mice (Yoo et al. 2003). Chronic morphine treated WT mice exhibited 
classical withdrawal signs induced by naloxone (Matthes et al. 1996). In MOPr KO mice, 
naloxone failed to induce any morphine withdrawal signs suggesting MOPr are a 
mandatory component of morphine dependence (Matthes et al. 1996; Lichtman et al.
2001). Overall, these results strongly suggest that locomotor stimulating and rewarding 
effects of morphine are primarily mediated by MOPr.
Buprenorphine, a mixed opioid receptor agonist-antagonist, is used clinically for the 
treatment of opioid addicts and also as an analgesic. Acute buprenorphine increased 
locomotor activity in WT mice but failed to increase locomotor activity in MOPr KO 
mice (Table 1.3.) (Marquez et al. 2007). Moreover, the locomotor stimulating effect of 
buprenorphine was enhanced upon repeated treatment in WT mice whereas this locomotor 
sensitization effect of buprenorphine was not observed in MOPr KO mice (Marquez et al. 
2007). Buprenophine induced CPP in both WT and MOPr KO mice with MOPr KO mice 
exhibiting lower place preference than WT mice (Ide et al. 2004). Interestingly, a recent 
study showed that buprenophine induced CPP in WT which was completely abolished in 
MOPr KO mice (Marquez et al. 2007). These discrepancies could be due to different 
experimental conditions, i.e. differences between test doses (1 mg/kg and 3 mg/kg) and/or 
due to genetic background (hybrid 129Sv x C57BL/6 and congenic C57BL/6).
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Heroin increased locomotor activity in WT mice but not in MOPr KO mice (Table 1.3.) 
(Contarino et al. 2002). Moreover, WT but not MOPr KO mice exhibited strong 
preference for heroin (Contarino et al. 2002). In addition, Straub tail was detected in WT 
mice but not in MOPr KO mice following treatment with 2 or 3 mg/kg heroin. These 
results indicate that the MOPr plays an important role in the rewarding and locomotor 
stimulating properties of heroin.
I.5.2.4. NOPr knockout mice
The role of the NOPr in morphine dependence has been evaluated in NOPr KO and WT 
mice (Mamiya et al. 2001). Naloxone administered to chronic morphine treated WT and 
NOPr KO mice induced a significant morphine withdrawal syndrome (Table 1.3.) 
(Mamiya et al. 2001). However, there were no significant genotype differences in 
naloxone-precipitated withdrawal signs. Naloxone benzoylhydrazone, a putative 
nociceptin receptor antagonist, induced significant withdrawal jumping behaviour in 
morphine-dependent WT mice, whereas this behaviour was significantly reduced in 
morphine-dependent NOPr KO mice (Mamiya et al. 2001). However, no significant 
genotype effect was observed in the level of naloxone benzoylhydrazone-induced forepaw 
tremor and rearing behaviour. These results suggest that the NOPr is only partly involved 
in morphine dependence.
1.5.3. Other addictive substances
77
I.5.3.I. DOPr knockout mice
DOPr KO mice showed no preference for ethanol in the two bottle choice test (Table 1.3.) 
(Roberts et al. 2001). However, DOPr KO mice self-administered more ethanol than WT 
mice in operant self-administration tests (Roberts et al. 2001). In addition, DOPr KO mice 
consumed more ethanol than WT mice in a two bottle choice test after operant self­
administration of ethanol. These results indicate that the DOPr might have a protective 
role in ethanol consuming behaviours.
Acute administration of a high dose of THC (20 mg/kg) induced hypolocomotion in WT 
and DOPr KO mice (Table 1.3.) (Ghozland et al. 2002). However, no significant 
genotype effects were observed. In addition, tolerance to the locomotor effect of repeated 
THC administration developed similarly in DOPr KO and WT mice. These results 
showed that deletion of the DOPr does not influence THC-induced locomotor activity.
Low doses of THC (1 mg/kg) induced CPP whereas high dose of THC (5 mg/kg) induced 
CPA in both WT and DOPr KO mice (Table 1.3.) (Ghozland et al. 2002). However, there 
was no significant genotype effect. Chronically THC-treated WT mice exhibited 
withdrawal symptoms induced by the cannabinoid antagonist SRI 41716A. Expression of 
these symptoms in DOPr KO mice was comparable to their WT mice (Ghozland et al. 
2002). These results suggest the DOPr is not primarily involved in the motivational 
responses to THC.
15.3.2. KOPr knockout mice
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Acute administration of a high dose of THC (20 mg/kg) induced hypolocomotion in WT 
and KOPr KO mice (Table 1.3.) (Ghozland et al. 2002). However, there was no 
significant genotype effect in acute THC-induced hyperlocomotion (20 mg/kg) between 
WT and KOPr KO mice. A progressive decrease in locomotor activity was observed in 
WT and KOPr KO mice in response to repeated THC administration (Ghozland et al.
2002). However, a significantly lower THC-induced hypolocomotor effect was observed 
in KOPr KO mice compared to WT mice after repeated THC treatment suggesting that the 
KOPr could contribute the development of adaptive responses to chronic THC (Ghozland 
et al. 2 0 0 2 ).
THC-induced CPP was observed in both WT and KOPr KO mice with priming exposure 
(Table 1.3.) (Ghozland et al. 2002). There was no significant genotype effect in the THC- 
induced CPP test under these conditions. Interestingly, KOPr KO mice showed a 
significant place preference to THC, whereas this place preference was not observed in 
WT mice without priming exposure, suggesting KOPr activity hinders the rewarding 
properties of THC in WT mice (Ghozland et al. 2002).
Administration of a high dose of THC (5 mg/kg) induced CPA in WT mice whereas this 
place aversion was diminished in KOPr KO mice indicating that KOPr may play an 
important role in the dysphoric aspect of THC activity (Table 1.3.) (Ghozland et al. 2002). 
Administration of the cannabinoid antagonist SR141716A in chronically THC-treated WT 
and KOPr KO mice exhibited similar withdrawal signs (Ghozland et al. 2002). These 
results suggest that the KOPr is involved in the motivational effect but not in the 
withdrawal effect of THC.
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I.5.3.3. MOPr knockout mice
No significant genotype effects were found in the rewarding effects of ethanol between 
male MOPr KO and male WT mice (Table 1.3.) (Hall et al. 2001; Becker et al. 2002). 
However, ethanol-induced CPP was observed in female WT mice but abolished in female 
MOPr KO mice suggesting that the involvement of MOPr in the rewarding properties of 
ethanol is dependent upon gender (Hall et al. 2001). In two bottle choice tests, MOPr KO 
mice consumed less ethanol than WT mice (Roberts et al. 2000; Becker et al. 2002). 
Similarily the involvement of MOPr on ethanol consumption seems to be influenced by 
gender because female MOPr KO mice consumed less ethanol than female WT mice, 
whereas this difference was not observed between male MOPr KO and male WT mice in 
the two bottle choice test (Hall et al. 2001). MOPr KO mice showed less ethanol self­
administration in both nose-poke responding and lever pressing paradigms than WT mice 
(Roberts et al. 2000). These results suggest that the MOPr is involved in the rewarding 
and that reinforcing properties of ethanol may be dependent on gender.
No significant genotype effect was dectected in baseline locomotor activity between male 
WT and male MOPr KO mice (Table 1.3.) (Hall et al. 2001). However, in the same study, 
female MOPr KO mice exhibited higher basal locomotor activity than female WT mice at 
the beginning of the locomotor testing sessions but no significant genotype effects were 
observed at the end of the test sessions (Hall et al. 2001). Ethanol (1.25 and 1.75 g/kg) 
produced a significant hyperlocomotion in both WT and MOPr KO mice. However, 
MOPr KO mice displayed significantly less ethanol-induced hyperlocomotion compared 
to WT mice at a dose of 1.75 g/kg (Ghozland et al. 2005). However, a 2 g/kg dose of 
ethanol modestly increased locomotor activity in both WT and MOPr KO mice. A trend
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toward greater ethanol-induced locomotor activity was observed in WT mice than in 
MOPr KO mice (Hall et al. 2001). These results suggest that the MOPr plays a role in 
mediating the locomotor effects of ethanol which is dependent upon dose.
Acute high dose of THC administration (20 mg/kg) produced hypolocomotion in both 
WT and MOPr KO mice that did not differ between the two genotypes (Table 1.3.) 
(Ghozland et al. 2002). In a chronic study, both WT and MOPr KO mice developed 
tolerance to the locomotor response to THC after high doses of THC administration (20 
mg/kg), but no significant genotype effect was observed suggesting that deletion of the 
MOPr may not play a crucial role in either the acute or chronic THC-induced 
hyperlocomotion (Ghozland et al. 2 0 0 2 ).
Place preference following priming exposure at a dose of 1 mg/kg of THC was observed 
in WT mice but was abolished in MOPr KO mice (Table 1.3.) (Ghozland et al. 2002). 5 
mg/kg of THC induced CPA in WT mice whereas this place aversion was diminished in 
MOPr KO mice (Ghozland et al. 2002). These results provide evidence for an important 
role of MOPr in THC motivational responses.
The administration of the CBl receptor antagonist SR141716A induced a significant 
expression of somatic signs of withdrawal in chronic THC administered WT and MOPr 
KO mice maintained on a mixed 129/SV x C57BL/6 background (Table 1.3.) (Ghozland 
et al. 2002). However no significant genotype effects were observed. In contrast, 
Lichtman et al. (2 0 0 1 ) showed that SR141716A-precipitated cannabinoid withdrawal 
signs were significantly attenuated in MOPr KO mice compared to WT mice maintained 
on a mixed 129/Ola x C57BL/6 background. These conflicting results again indicate that
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strain background influences addictive behaviour and that MOPr involvement in 
cannabinoid withdrawal syndrom is strain-dependent.
I.5.3.4. MOPr/DOPr double knockout mice
Acute high-dose of THC (20 mg/kg) induces hyperlocomotion in WT and MOPr/DOPr 
double KO mice (Table 1.3.) (Castane et al. 2003). However, no significant genotype 
effects were observed. In addition, the same degree of tolerance for locomotion to 
repeated high dose of THC administration was observed in both WT and MOPr/DOPr 
double KO mice (Castane et al. 2003) indicating the deletion of both MOPr and DOPr 
does not influence either the acute or chronic THC-induced hyperlocomotion.
SRI 41716A-precipitated THC withdrawal signs were observed in both WT and 
MOPr/DOPr double KO mice (Table 1.3.) (Castane et al. 2003). However, these 
responses were signiflcantly reduced in double MOPr/DOPr KO mice compared with its 
WT control suggesting that MOPr and DOPr cooperate in mediating the somatic 
expression of the THC withdrawal syndrome (Castane et al. 2003).
In addition, the rewarding properties of THC were examined using a CPP paradigm in 
WT and MOPr/DOPr double KO mice (Castane et al. 2003). THC administration 
produced strong CPP in WT mice but not in MOPr/DOPr double KO mice suggesting 
MOPr and DOPr co-operate in mediating the rewarding properties of THC (Table 1.3.).
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1.6. Neurochemical effects of drugs of abuse in opioid peptide and receptor knockout
mice
1.6.1. Psychostimulants
I.6.I.I. Preprodynorphin knockout mice
Basal accumbal DA levels were decreased in ppDYN KO mice compared to WT mice, 
whereas basal DA uptake was unchanged in ppDYN KO mice compared with WT mice 
(Table 1.2.) (Chefer and Shippenberg 2006). Interestingly, basal DA levels in Acb were 
higher in KOPr KO mice compared to WT mice (Chefer et al. 2005) (See 1.6.1.4.). The 
discrepancy between ppDYN KO and KOPr KO mice may be partly explained by the 
compensatory up-regulation of KOPr in the Acb of ppDYN KO mice (Clarke et al. 2003a). 
Chefer and Shippenberg (2006) suggested that constitutive deletion of ppDYN leads to a 
compensatory increase in KOPr number (Clarke et al. 2003a) and that, in the absence of 
DYN, endogenous met-enkephalin and/or P-endorphin activate KOPr which results in the 
reduction of DA levels in ppDYN KO mice. Accumbal dialysate DA levels were 
significantly increased in WT mice in response to acute cocaine, whereas deletion of 
ppDYN gene reduced this cocaine-induced effect (Chefer and Shippenberg 2006). These 
results indicate that the deletion of ppDYN gene leads to diminished basal DA release and 
a reduction in cocaine-induced DA levels in the nucleus accumbens (Acb) suggesting a 
protective role of dynorphins against cocaine-induced DA release.
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No change in D2 binding in WT mice but lower overall D2 receptor binding was observed 
in chronic ‘binge’ cocaine-treated ppDYN KO mice compared to saline-treated ppDYN 
KO mice (See Chapter two in this thesis) (Table 1.2.) (Bailey et al. 2007). Moreover, a 
significantly lower D2 receptor binding was observed in the mediolateral part of the 
caudate putamen (CPu) of chronic ‘binge’ cocaine-treated ppDYN KO mice compared 
with saline-treated ppDYN KO mice. In contrast to D2 receptor binding, there was no 
significant difference in D1 ([^H]SCH23390) and dopamine transporter ([^HJmazindol, 
DAT) binding between ppDYN KO and its WT mice (See Chapter two in this thesis) 
(Bailey et al. 2007).
MOPr-stimulated [^^S]GTPyS binding was increased in chronic “binge” cocaine treated 
WT mice whereas this upregulation was not observed in ppDYN KO mice suggesting that 
ppDYN may mediate chronic ‘binge’ cocaine-induced alterations in MOPr activity (Table
1.2.) (Bailey et al. 2007). In addition, ppDYN may mediate cocaine-induced stimulation 
of the HP A axis as cocaine enhanced corticosterone levels in WT mice whereas in 
ppDYN KO animals this activation was blunted. These results suggest that ppDYN may 
play a centrol role not only in mediating the effects of cocaine on the D2 dopaminergic 
and the MOPr system but also in mediating the effects of cocaine on the hypothalamic- 
pituitary-adrenal axis, providing further evidence the ppDYN system functions as an 
endogenous antagonist of cocaine.
1.6.1.2. Preproenkephalin knockout mice
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Basal accumbal DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA) levels of ppENK KO mice were similar to its WT littermates (Table 1.2.) 
(Berrendero et al. 2005). Nicotine induced an enhancement of accumbal DA levels in WT 
mice but not in ppENK KO mice indicating a lack of nicotine effects on the extracellular 
DA levels by deletion of ppENK gene (Berrendero et al. 2005). Nicotine induced a 
significant enhancement of accumbal DOPAC levels in both genotypes (Berrendero et al. 
2005). However, no significant genotype difference was observed. These results suggest 
that ppENK-derived peptides participate in the effects of nicotine on extracellular levels 
of DA but not of DOPAC and HVA in the Acb.
I.6.I.3. DOPr knockout mice
Basal dialysate DA levels in the Acb did not differ between WT and DOPr KO mice 
(Table 1.3.) (Chefer et al. 2003, 2004). Acute cocaine increased DA levels in the Acb of 
WT mice, whereas in DOPr KO mice cocaine has less effect in enhancing DA levels in 
the Acb than in WT mice (Chefer et al. 2004). There results suggest that DOPr may 
modulate accumbal DA release in response to acute cocaine administration.
I.6.I.4. KOPr knockout mice
Chefer et al. (2005) investigated the influence of constitutive deletion of KOPr using two 
strains of mice of different genetic background, congenic C57BL/6J and mixed 129S6 x 
C57BL/6J strains, on cocaine-induced DA dynamics in the Acb. Basal DAT expression 
in the Acb did not differ between WT and KOPr KO mice in both mixed and congenic
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background. In KOPr KO mice maintained on a mixed background basal DA uptake and 
release were shown to be increased in the Acb of KOPr KO mice compared to WT (Table
1.3.) (Chefer et al. 2005). Basal dialysate DA levels in Acb were higher in KOPr KO 
mice compared to WT mice maintained on a pure C57BL/6J or a mixed 129S6 x 
C57BL/6J background indicating background strain does not influence the effects of 
KOPr gene deletion on accumbal dialysate DA levels (Chefer et al. 2005). However, in 
contrast to these results, there was no significant difference in basal dialysate DA levels in 
the Acb between WT and KOPr KO mice maintained on a mixed 129S6 x C57BL/6J 
background (F7) (Zapata and Shippenberg 2006). As a result, it is still not clear whether 
deletion of KOPr can modulate basal extracellular DA levels in the Acb.
Acute cocaine produced a significant dose-dependent increase in accumbal DA levels in 
WT and KOPr KO mice maintained on a mixed 129S6 x C57BL/6J background (Table
1.3.) (Chefer et al. 2005). However, the increase in cocaine-induced DA levels in the Acb 
was significantly higher in KOPr KO mice compared to WT mice suggesting the presence 
of the KOPr may have an inhibitory role of accumbal DA modulation in response to acute 
cocaine challenge.
Basal levels of immediate early genes (lEGs) expression such as c-jun, junB, junD, c-fos, 
fbs B, ffa-1, and fra-2 were assessed in KOPr KO and WT mice (Table 1.3.) (Chefer et al. 
2005). No significant genotype effects were found in the basal expression levels of lEGs. 
Cocaine-evoked lEGs induction was also assessed in KOPr KO and WT mice (Chefer et 
al. 2005). Both c-fos and jun B were significantly increased in both KOPr KO and WT 
mice after cocaine injection, but the induction was significantly less robust in KOPr KO
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compared to WT mice. These findings provide further evidence that KOPr are involved 
in cocaine-induced lEGs expression.
I.6.I.5. MOPr knockout mice
No significant genotype difference was dectected in either basal or acute cocaine-induced 
accumbal dialysate DA levels between MOPr KO and WT mice suggesting MOPr does 
not play an important role in modulation of DA release or in mediating acute cocaine- 
induced DA release in the Acb (Table 1.3.) (Chefer et al. 2004).
The expression of neuronal nitric oxide synthase (nNOS) in the dentate gyrus (DG) of the 
hippocampus but not in the cortex or striatum was significantly increased in both chronic 
cocaine-treated WT and MOPr KO mice compared to saline controls (Table 1.3.) (Yoo et 
al. 2006). However, chronic cocaine-induced upregulation of the expression of nNOS in 
the DG of hippocampus was significantly decreased in MOPr KO mice compared to WT 
suggesting that the MOPr is involved in the cocaine-induced modulation of the expression 
of nNOS in the DG of hippocampus.
Higher numbers of nNOS-positive cells were observed in the striatum of repeated 
nicotine-treated WT mice compared to saline-treated WT mice (Table 1.3.) (Yoo et al. 
2005). However, significantly lower nicotine-induced nNOS expression was observed in 
the striatum of MOPr KO versus WT mice suggesting that the deletion of MOPr can 
cause a significant reduction of nNOS expression in the striatum in response to repeated 
nicotine treatment (Yoo et al. 2005).
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Basal concentrations of extracellular DOPAC, HVA, and 5 -hydroxyindoleacetic acid (5- 
HIAA) in the striatum of MOPr KO mice were not significantly different from WT mice 
(Table 1.3.) (Lan et al. 2007). Acute or chronic injection of methamphetamine produced a 
progressive and time-dependent reduction in the extracellular levels of striatal DOPAC 
and HVA in both WT and MOPr KO mice and this effect was significantly reduced in 
MOPr KO mice compared to WT mice (Lan et al. 2007). In acute methamphetamine 
treatment, no significant genotype effects were found in striatal 5-HIAA levels between 
WT and MOPr KO mice. However, chronic methamphetamine treated MOPr KO mice 
had higher levels of 5-HIAA in striatum compared to WT mice. These results indicate 
that the MOPr modulates extracellular concentrations of striatal DOPAC, HVA, and 5- 
HIAA induced by chronic methampheatmine administration.
No significant genotype effect was observed in basal expression of striatal ppENK mRNA 
between WT and MOPr KO mice (Table 1.3.) (Tien et al. 2007). Repeated 
methamphetamine administration enhanced preproenkephalin mRNA expression in the 
CPu and Acb of WT mice, whereas this treatment did not induce any changes in 
methamphetamine-treated MOPr KO mice suggesting MOPr are involved in the 
regulation of methamphetamine-induced changes in ppENK mRNA expression (Tien et al. 
2007).
In saline-treated control groups, the density of D1 receptors assessed by [^H]SCH23390 
binding in the CPu and Acb of MOPr KO mice was higher than in WT mice (Table 1.3.) 
(Tien et al. 2007). Repeated methamphetamine treatment caused a significant decrease in 
D1 receptor binding in MOPr KO mice but not in the WT mice although no significant
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genotype difference was observed in D1 receptor binding suggesting that the MOPr 
mediates methamphetamine-induced modulation of D1 receptors (Tien et al. 2007).
In saline-treated control groups, D2 receptors, assessed by [^H] spiperone binding, were 
increased in the CPu but not in the Acb of MOPr KO mice compared to WT mice (Table
1.3.) (Tien et al. 2007). Repeated treatment with methamphetamine caused increases in 
D2 receptors in the CPu and Acb of MOPr KO and WT mice. However, higher levels of 
D2 binding were observed in the CPu of MOPr KO mice compared to WT, whereas lower 
levels of D2 binding were observed in the Acb of MOPr KO mice compared to WT mice 
(Tien et al. 2007) suggesting MOPrs are differentially involved in repeated 
methamphetamine-induced changes in the expression of D2 receptors depending on the 
region.
The binding levels of the MOPr ligand ([^HJDAMGO) in the CPu were significantly 
decreased in chronic methamphetamine-treated WT mice whereas no [^HJDAMGO 
binding was observed in any of the brains regions examined in MOPr KO mice 
confirming the result of no functional MOPr expression in the brains of MOPr KO mice 
(Table 1.3.) (Tien et al. 2007).
Lower DOPr ligand binding ([^HJDPDPE) was detected in the CPu and Acb of chronic 
saline-treated MOPr KO mice compared with WT controls suggesting a compensatory 
down-regulation of DOPr binding in brains of MOPr KO mice (Table 1.3.) (Tien et al. 
2007). Repeated treatment with methamphetamine caused a significant increase in 
[^H]DPDPE binding in the CPu and Acb of MOPr KO but not in WT mice. However, no 
significant genotype difference was detected.
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1.6.2. Opioids
I.6.2.I. DOPr knockout mice
Basal extracellular or dialysate DA levels in the Acb did not differ between WT and 
DOPr KO mice (Table 1.3.) (Chefer et al. 2003, 2004). However, basal DA uptake was 
decreased in the Acb of DOPr KO mice compared with WT controls (Chefer et al. 2003). 
No significant genotype effect was detected in acute morphine-induced changes in 
accumbal dialysate DA levels between DOPr KO and WT mice (Chefer et al. 2003). 
These results suggest that the DOPr may be involved in basal DA uptake but not involved 
in the modulation of the dialysate DA levels in response to acute morphine administration.
I.6.2.2. MOPr knockout mice
Saturation binding with the MOPr-selective ligand [^H]DAMGO showed total loss in the 
brains of MOPr KO mice (Table 1.3.) (Matthes et al. 1996). Autradiographic mapping of 
MOPr labelled with [^HJDAMGO confirms the gene targeting strategy led to a complete 
loss of MOPr (Matthes et al. 1996; Kitchen et al. 1997). The expression of other opioid 
receptors (pHJdeltorphin I to DOPr or [^H]CI-977 and [^HJbremazocine to KOPr) or the 
transcription of endogenous opioid peptide genes (proenkephalin, prodynorphin or 
proopiomelanocortin) was not affected by deletion of MOPr suggesting disruption of the 
MOPr gene in mice does not markedly alter expression of the opioid system (Matthes et al. 
1996; Kitchen et al. 1997). Chronic morphine treatment followed by a single naloxone 
injection upregulated adenylyl cyclase activity in the striatum of WT mice, whereas this
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upregulation was absent in mice lacking MOPr suggesting that the MOPr plays an 
important role in inhibition of naloxone-precipitated morphine withdrawal (Matthes et al. 
1996).
Basal dialysate DA levels in the Acb of MOPr KO mice did not differ from WT mice 
(Table 1.3.) (Chefer et al. 2003). Acute morphine administration increased DA levels in 
the Acb of MOPr KO and WT mice compared to saline controls (Chefer et al. 2003). 
However, MOPr KO mice had significantly lower DA levels in the Acb than WT mice 
suggesting MOPrs modulate accumbal DA release in response to acute morphine 
administration (Chefer et al. 2003).
Higher numbers of nNOS-positive cells in the DG of the hippocampus but not in cortex 
nor in striatum were observed in WT and MOPr KO mice treated with repeated morphine 
compared with saline controls (Table 1.3.) (Yoo et al. 2006). Repeated morphine 
treatment enhanced the expression of nNOS-positive cells in the DG of hippocampus in 
MOPr KO mice compared with WT mice suggesting that nNOS can modulate repeated 
morphine-induced expression of nNOS via MOPr in the DG of hippocampus.
I.6.2.3. NOPr knockout mice
There was no significant difference in Kd and Bmax values for MOPr binding 
([^H]DAMGO) between naïve NOPr KO and its WT mice (Table 1.3.) (Mamiya et al. 
2001). Repeated morphine treatment had no effect on MOPr binding in either WT or
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NOPr KO mice suggesting NOPr does not play an important role in the modulation of 
MOPr expression in response to chronic morphine treatment (Mamiya et al. 2001).
Acute administration of naloxone induced elevation of 3'-5'-cyclic adenosine 
monophosphate (cAMP) levels in the thalamus of chronic morphine-treated WT and 
NOPr KO mice compared to saline-administered WT and NOPr KO mice providing 
further evidence that morphine withdrawal syndorome is accompanied by the elevation of 
cAMP levels in the brain (Table 1.3.) (Mamiya et al. 2001). However, there was no 
significant genotype difference in the cAMP levels suggesting that deletion of NOPr does 
not affect induction of signal transduction of the naloxone-precipitated morphine 
withdrawal (Mamiya et al. 2001). Naloxone benzoylhydrazone-precipitated mophine 
withdrawal syndrome induced higher cAMP levels in the thalamus of chronic morphine- 
treated WT mice, but had no effects on cAMP levels in the thalamus of chronic morphine- 
treated NOPr KO mice suggesting the elevation of cAMP may not be essential for 
morphine withdrawal induced by naloxone benzoylhydrazone, except for withdrawal 
jumping behaviours (Mamiya et al. 2001).
1.6.3. Other addictive substances
1.6.3.x. P-endorphin knockout mice
Blood ethanol concentration following 12 % ethanol se lf administration in P-endorphin 
KO mice was similar to WT mice (Table 1.3.) (Hayward et al. 2004). No significant
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gender or genotype effect was observed in the blood ethanol concentration suggesting the 
deletion of P-endorphin may not play a crucial role in the regulation of blood ethanol 
concentration in ethanol self-administration.
I.6.3.2. Preproenkephalin knockout mice
ppENK KO mice following self-administration to 12 % ethanol had significantly lower 
blood ethanol concentration compared to WT controls only under a fixed ratio interval of 
2  but not under a fixed ratio interval of 8 nor under a progressive ratio interval of 2  
suggesting that enkephalins may play a role in modulating ethanol self-administration 
only under specific conditions (Table 1.3.) (Hayward et al. 2004).
I.6.3.3. P-endorphin/enkephalin double knockout mice
Female p-endorphin/enkephalin double KO mice had significantly lower blood ethanol 
concentrations than female WT mice following 12 % ethanol self-administration under a 
fixed ratio interval of 2  but not under a fixed ratio interval of 8 nor under a progressive 
ratio interval of 2 (Table 1.3.) (Hayward et al. 2004). However, there were no significant 
differences in blood ethanol conentration between male p-endorphin/enkephalin double 
KO and male WT mice. These results provide further evidence on the differences in 
operant self-administration of ethanol between female and male mice. Moreover, it may 
also indicate that p-endorphin interacting with enkephalin could partly contribute to the
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modulation of blood ethanol concentration under specific conditions and this is gender- 
dependent.
I.6.3.4. DOPr knockout mice
Following operant self-administration DOPr KO mice had significantly higher blood 
ethanol levels than WT mice suggesting that a reduction in DOPr activity may be 
associated with the increased blood ethanol levels (Table 1.3.) (Roberts et al. 2001). 
Ethanol-induced modulation of GABAa (y-aminobutyric acid A) receptor function in 
DOPr KO mice was studied using whole-cell patch recordings of the central nucleus of 
amygdala (CeA) in brain slices (Kang-Park et al. 2007). No significant differences were 
found between WT and DOPr KO mice in basal evoked inhibitory postsynaptic currents 
(elPSC) and miniature inhibitory postsynaptic currents (mIPSC) in CeA neurons (Kang- 
Park et al. 2007). Ethanol (40 mM) increased GABAa receptor-mediated elPSC, 
frequency of mIPSC and mIPSC amplitudes in CeA neurons of DOPr KO mice compared 
with its WT mice, suggesting that the increased ethanol effect on inhibitory postsynaptic 
currents in CeA of DOPr KO mice could be due to the absence of DOPr-mediated 
inhibition of GAB A (y-aminobutyric acid) release (Kang-Park et al. 2007).
I.6.3.5. KOPr knockout mice
Acute administration of ethanol significantly increased DA levels in the Acb of WT and 
KOPr KO mice and this effect was significantly higher in KOPr KO mice compared to 
WT mice, suggesting that endogenous KOPr may have a protective role against an
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enhancement of ethanol-evoked dialysate DA levels in the Acb (Table 1.3.) (Zapata and 
Shippenberg 2006).
1.6.3.6. MOPr knockout mice
Job et al. (2007) investigated whether MOPr receptors are involved in the modulation of 
acute ethanol-stimulated DA release using MOPr KO mice maintained on two different 
genetic backgrounds (C57BL/6J x 129/SvEv and congenic C57BL/6J). Basal DA levels 
were influenced by the deletion of MOPr in female but not in male mice maintained on 
the mixed background. Female MOPr KO mice had lower basal DA concentrations in 
Acb compared to male MOPr KO mice maintained on the mixed background (Table 1.3.) 
(Job et al. 2007). However, basal accumbal DA concentrations were not affected by the 
deletion of the MOPr in the congenic C57BL/6J strain in either males or females 
suggesting the alteration of accumbal DA concentration is influenced not only by the 
deletion of MOPr but also by gender as well as by background strain (Job et al. 2007). 
Acute ethanol administration caused an increased DA concentration not only in the Acb 
of male and female WT mice but also in male MOPr KO mice maintained on a mixed 
background. However, ethanol did not stimulate DA release in the Acb of female MOPr 
KO mice maintained on the mixed background suggesting that the ethanol-induced 
increase in accumbal DA concentration is influenced by gender (Job et al. 2007). 
Interestingly, both male and female WT mice that were backcrossed onto the C57BL/6J 
strain showed enhanced ethanol-induced accumbal DA levels induced. However, deletion 
of the MOPr inhibited acute ethanol-stimulated DA release in the Acb of either male or 
female mice of the congenic C57BL/6J strain (Job et al. 2007). These results
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demonstrated that the requirement for MOPr involvement in the ethanol-stimulated DA 
release is dependent upon both gender and strain.
Blood ethanol concentrations were determined immediately after the final operant self- 
administration of 10 % ethanol in MOPr KO and WT mice after a saccharin-fading 
procedure (Roberts et al. 2000). MOPr KO mice had lower blood ethanol concentrations 
than WT mice (Table 1.3.) (Roberts et al. 2000). Blood ethanol concentrations were also 
determined at different stages of ethanol withdrawal (three different withdrawal phases) 
(Ghozland et al. 2005). No significant differences were detected in blood ethanol 
concentrations between MOPr KO and WT mice although WT mice appeared to have 
higher levels of blood ethanol concentrations than MOPr KO mice during the second and 
third withdrawal stages (Ghozland et al. 2005). Neither sex nor genotype affected 
dialysate ethanol concentrations in the ventral striatum after intraperitoneal administration 
of ethanol in MOPr KO mice maintained on mixed C57BL/6J x 129/SvEv or congenic 
C57BL/6J background (Job et al. 2007). These results may indicate that ethanol 
concentration could be influenced by an absence of the MOPr depending upon 
experimental protocols.
1.7. Dopaminergic pathways
The dopaminergic system plays an important role in the control of many functions such as 
movement, emotion and addiction in the central nervous system (fore review, see Berke 
and Hyman, 2000). DA is synthesised from the amino acid tyrosine in the dopaminergic 
terminal neurons (Figure 1.3.). Two steps are involved in the synthesis of DA. Firstly, 
tyrosine is converted to L-dihydroxyphenylalanine by the enzyme tyrosine hydroxylase
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Figure 1.3. Cycling of dopamine in dopaminergic
neurons
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Legend to Figure 1.3.
Dopamine is synthesised from the amino acid tyrosine in the dopaminergic terminal 
neurons. Cocaine binds to the Na^^ binding sites, which leads to conformational changes 
of dopamine transporter which result in blocking uptake of dopamine from the synaptic 
cleft. Abbreviations: AAAD, Aromatic L-amino acid decarboxylase; ATP, Adenosine 
triphosphate; cAMP, 3'-5'-Cyclic adenosine monophosphate; COMT, Catechol-0- 
methyltransferase; DAT, Dopamine transporter; DOPAC, 3,4-Dihydroxyphenylacetic 
acid; GAP, GTPase-activating proteins; GDP, Guanylyl diphosphate; GTP, Guanylyl 
triphosphate; HVA, 3 -Methoxy-4-hydroxyphenylacetic acid; L-DOPA, L- 
Dihydroxyphenylalanine; MAO, Monoamine oxidase; 3-MT, 3-Methoxytyramine; Pi, 
Phospate; TH, Tyrosine hydroxylase; VMAT2, Vesicular monoamine transporter
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that in the presynaptic area of the dopaminergic neurons. Secondly, L- 
dihydroxyphenylalanine is converted to DA by aromatic L-amino acid decarboxylase. 
DA is transported to the vesicle by vesicular monoamine transporter in the presynaptic 
area. DA is converted to metabolites by the enzyme monoamine oxidase. Monoamine 
oxidase produces two metabolites DOPAC and HVA. Catechol-O-methyltransferase 
catalyses DA to metabolite 3 -methoxytyramine.
The main dopaminergic cell bodies are localized in both the ventral tegmental area and 
substantia nigra that project to the different target neurons in the dorsal and ventral 
striatum as well as frontal cortex (Figure 1.4.). There are at least three major 
dopaminergic pathways in the central nervous system. Firstly, the mesolimbic pathway 
which originates from the dopaminergic neurons of the ventral tegmental area that 
projects to the ventral striatum. Secondly, the mesocortical pathway which consist of 
projections of dopaminergic neurons from the ventral tegmental area to the frontal cortex. 
The mesolimbic and mesocortical pathway have been the main focus of the drug abuse 
field (for review, see Nestler, 2001). Thirdly, the nigrostriatal pathway which originates 
from the dopaminergic neurons of the substantia nigra that project to the striatum. This 
pathway is well studied in relation to Parkinson’s disease which is characterised by a 
destruction of the dopaminergic neurons of the substantia nigra.
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1.8. Dopaminergic system in drug addiction
Diagnostic and statistical manual (DSM-IV), which is the most influential system for 
diagnosis of mental disorders, uses the term “substance dependence” instead of 
“addiction” and DSM-IV defines substance dependence as a cluster of cognitive, 
behavioural, and physiological symptoms indicating that the individual continues use of 
the substance despite significant substance-related problems such as tolerance, 
withdrawal, and compulsive drug-taking behaviour (DSM-VI 1994). In addition to 
substance dependence, the system defines substance abuse as “a maladaptive pattern of 
substance use manifested by recurrent and significant adverse consequences related to 
the repeated use of substances” but it does not include tolerance, withdrawal, or a 
pattern of compulsive use and instead includes only the harmful consequences of 
repeated use (DSM-VI 1994).
DA transmission is thought to play an important role in the reinforcing and rewarding 
effects of psychostimulants and opioids (for review, see Pierce and Kumaresan, 2006). 
Genetic and pharmacological evidence suggest that DA receptors and DAT mediate 
cocaine- and morphine-induced behavioural and neurochemical changes (Spanagel et al. 
1992; Unterwald et al. 1994; Reith et al. 1997; Zhou et al. 2002; Hummel et al. 2004). 
Cocaine acts on the central nervous system by blocking the reuptake of DA by the DAT 
(for review, see Elliott and Beveridge, 2005) (Figure 1.3.). In addition to DAT, DA 
receptors are also implicated in the modulation of cocaine-induced locomotion, reward
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and stereotypy (Tsukada et al. 1996; Pierce and Kalivas 1997; Schlussman et al. 2003; 
Anderson and Pierce 2005).
1.9. Dopamine receptors
There are five known types of DA receptors (Dl, D2, D3, D4 and D5). These DA 
receptors are divided into Dl-like (Dl and D5) and D2-like (D2, D3 and D4) that are 
categorised by the ability of each DA receptor to stimulate adenylyl cyclase (AC) (for 
review, see Jaber et al, 1997). DA Dl-like receptors are coupled to G/Goif and thus 
stimulate AC to produce the intracellular second messenger, cAMP, while DA D2-like 
receptors are coupled to G/Goand thus inhibit AC (Figure 1.3.) (for review, see Missale 
et al., 1998). Both the DA Dl and D2 receptors are composed of 7 membrane spanning 
domains. Both receptors have a portion of domain in the C-terminus where G-proteins 
can bind to the domain. The G-proteins are composed of three subunits (a, P and y). 
When the a  subunit has guanylyl diphosphate (GDP) bound, the G protein is inactive. 
The activation of DA Dl receptors induces a separation of the G« and Gpy subunits by 
exchanging guanylyl triphosphate (GTP) with GDP in the G«. The separated G« 
stimulates AC, leading to increase in the production of cAMP (3'-5'-cyclic adenosine 
monophosphate). The GTPase-activating protein (GAP) stimulates hydrolyse the GTP 
to the GDP in the Ga, then it re-associates to the Py complex in order to reorganize the 
inactive G protein. In contrast to DA Dl receptors, activation of the postsynaptic DA 
D2 receptors inhibits AC, which leads to a decrease in the production of cAMP. The 
presynaptic DA D2 receptor functions as an autoreceptor. Stimulation of the
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presynaptic DA D2 receptors inhibits the release of DA from the presynaptic neurons. 
The structure of DAT is predicted to have 12 membrane spanning domains with the N- 
and C-termini being located intracellularly from the analysis of the primary amino acid 
sequence (Volz and Schenk 2005). DA transport from the synaptic cleft into the 
presynaptic membranes is carried out via DAT which is a Na^ "^ - and Cl'-dependent 
process. Cocaine binds to the Na^^ binding sites, which leads to conformational 
changes of DAT which result in blocking uptake of DA from the synaptic cleft.
1.10. Interaction between the opioid and the dopaminergic system
A large body of evidence suggests that the endogenous opioid system directly or 
indirectly regulates dopaminergic tone in the central nervous system (Spanagel et al. 
1992). MOP receptor agonists activate DA neurons by inhibiting GABA-mediated 
synaptic input to the DA cells in the ventral tegmental area of rats (Johnson and North 
1992). In contrast to MOP receptor agonists, the KOP receptor agonist U-50,488H 
inhibits DA release in the substantia nigra and neostriatum (You et al. 1999). Cocaine 
treatment increased ppDYN mRNA levels in the striatum of rats (Yuferov et al. 2001; 
Schlussman et al. 2005). It has been suggested that dynorphin has a protective role 
against cocaine-induced reward through inhibiting the DA release in the striatum of 
mice (Zhang et al. 2004). All of this evidence suggests that the dynorphin system is 
implicated in the neurochemical mechanism of cocaine addiction. Recently, Chefer et 
al. (2006) demonstrated that constitutive deletion of prodynorphin is associated with a
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reduction of extracellular DA levels in Acb and a decreased responsiveness to acute 
cocaine.
The functional interactions between the opioid and the dopaminergic systems have been 
described. For instance, co-localisation of opioid and DA receptors have been observed 
in brains of rats (Gerfen et al. 1990; Svingos et al. 2001; Ambrose et al. 2004; Ambrose 
et al. 2006). In addition, decrease in DAT has been observed in the striatum of 
morphine-tolerant rats (Gudehithlu and Bhargava 1996). However, the deletion of the 
MOPr genes results in only moderate changes in the DA Dl and D2 receptors (Lena et 
al. 2004).
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1.11. Aims of the Thesis
1. To investigate whether dynorphin mediated neurochemical changes in the 
dopaminergic system caused by cocaine, quantitative receptor autoradiograpy of D l, D2 
and DAT binding was carried out in brains of mice lacking dynorphins treated with 
chronic ‘binge’ cocaine.
2. To determine the effect of genetic background on neurochemical changes of the 
dopaminergic system in triple opioid receptor knockout mice, quantitative receptor 
autoradiography of D l, D2 and DAT binding was carried out in brains of triple opioid 
receptor knockout mice maintained on different genetic backgrounds.
3. To determine whether the MOPr is a major target of oxycodone, newly synthesized 
tritiated oxycodone was used in autoradiographic studies in brains of single MOPr, 
KOPr and DOPr KG mice as well as all three classical opioid receptor KG mice.
4. To develop a method using combinatorial KG mice to determine the presence of 
heterodimers in brain tissue and to validate the model using [^HJbremazocine and 
[^HJnor- binaltorphimine.
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Chapter 2. Quantitative D l, D2 receptor and 
dopamine transporter antoradiography in 
chronic “binge” cocaine treated preprodynorphin 
knockout and wild-type mice
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2.1. Introduction
Cocaine, one of the most commonly used psychostimulants, induces the elevation of 
extracellular dopamine (DA) in the striatum (Carboni et al. 1989; Maisonneuve et al. 
1995; Wise 1996) by blocking the dopamine transporter (DAT) (Heikkila et al. 1975). 
There is increasing evidence that K-opioid receptor (KOPr) agonists are able to 
modulate the neurochemical and behavioural effects of cocaine. KOPr agonists were 
shown to significantly decrease cocaine self-administration in rodents (Kuzmin et al. 
1997; Glickstein and Schmauss 2001), to decrease cocaine-induced locomotor activity 
(Crawford et al. 1995; Zhang et al. 2004), stereotypy (Heidbreder et al. 1993; 
Heidbreder et al. 1995), conditioned place preference (CPP) (Crawford et al. 1995; 
Zhang et al. 2004) and the development of locomotor sensitization to cocaine 
(Shippenberg et al. 1996).
There is a large body of evidence indicating that the K-opioid system is affected by 
chronic cocaine treatment (Heidbreder et al. 1993; Turchan et al. 1998; Yuferov et al. 
2001; Kreek et al. 2002; Schlussman et al. 2005). An increase in preprodynorphin 
(ppDYN) mRNA has been repeatedly observed in the caudate putamen of rodents after 
cocaine administration (Spangler et al. 1993; Turchan et al. 1998; Werme et al. 2000). 
Together, these results suggest that cocaine induces endogenous K-opioid activity, 
which is a homeostatic mechanism that opposes alterations in behaviour and 
neurochemistry resulting from repeated cocaine use.
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There is also evidence for an interaction of the K-opioid system with the dopaminergic 
systems. In microdialysis studies, Chefer et al. (2006) showed that acute cocaine 
treatment in ppDYN knockout (KO) mice results in a reduction of the extracellular DA 
level in nucleus accumbens compared to wild-type (WT) mice suggesting the presence 
of ppDYN genes in mice may contribute to the release of DA induced by acute cocaine 
treatment. In binding studies, chronic repeated administration of selective KOPr 
agonists were shown to decrease DAT (Thompson et al. 2000; Collins et al. 2001) as 
well as D2 receptor density (Izenwasser et al. 1998) and function (Izenwasser et al. 
1998; Acri et al. 2001) in the striatum of rats. Given that chronic cocaine administration 
also decreases D2 receptor density (Volkow et al. 1990; Voikow et al. 1993) and DAT 
(Sharpe et al. 1991; Pilotte et al. 1994; Pilotte et al. 1996) in human and animal models, 
it was hypothesized that the neuroadaptive changes in the dopaminergic systems 
occurring after chronic cocaine administration might be mediated by ppDYN.
Behavioural studies were carried out by Dr. Bailey (University of Surrey, UK) and 
published with the receptor binding in these animals (Bailey et al. 2007). The 
behavioural results obtained in the study show an enhanced cocaine-induced locomotor 
sensitisation in ppDYN KO mice after a chronic ‘binge’ administration protocol. In 
order to investigate whether neuroadaptive changes in the dopaminergic systems 
occurring after chronic coaine administration might be mediated by ppDYN, 
quantitative autoradiography of D l, D2 receptor and DAT binding was carried out in 
the brains of ppDYN KO and WT mice treated with the chronic “binge” cocaine 
administration protocol.
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2.2. Materials and Methods
2.2.1. Animals
The development of mice with a deletion of the ppDYN has been described previously 
(Zimmer et al. 2001) and mice were provided for this study by Professor Zimmer’s 
labolatory (University of Bonn, Germany). All animals were crossed for at least 10 
generations to C57BL/6J mice and were therefore congenic for this genetic background. 
ppDYN KO and WT mice from the same litters were bred from heterozygous mice and 
genotyped by PCR at weaning. Male mice aged between 9 and 16 weeks were used in 
this study. Mice were individually housed in a temperature and humidity controlled 
room with a 12h light/dark schedule for at least 2 weeks before experiments. Food and 
water were available ad libitum. All experiments were carried out in accordance vdth 
the German Animal Protection Law (issued in 1998).
2.2.2. Drug treatment
Three daily equal intraperitoneal injections of either saline or cocaine (15 
mg/kg/injection giving a total of 45 mg/kg/day) were administered to ppDYN KO and 
WT mice in a steady dose “binge” paradigm to mimic a common pattern of self­
administration in human cocaine abusers (Tsukada et al. 1996). The injections were 
given at 1 h intervals commencing 60 min following the daily light cycle. All animals
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received a total of 14 days of “binge” pattern injection. Animals were killed 30 min 
following the last injection of saline or cocaine on day 14 of the study.
2.2.3. Materials
[^H]SCH23390 (85 Ci/mmol), [^Hjraclopride (60.1 Ci/mmol) and [^HJmazindol (20.6 
Ci/mmol) were purchased from PerkinElmer Life Sciences (PerkinElmer House, 
Cambridge, UK). Mianserin, cis-flupenthixol, sulpiride, desipramine and mazindol 
were purchased from Sigma-Aldrich (Sigma-Aldrich Company Ltd., Dorset, UK).
2.2.4. Autoradiography
2.2.4.I. Preparation of knockout mice tissue for sectioning
Animals were killed and the brains were immediately removed and were then quickly 
frozen at -20 °C in isopentane for 30 sec. Brains were stored at -80 °C for a maximum 
period of one month before sectioning.
2.2.4.2. Subbing microscope slides
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Slides were soaked in warm dilute detergent overnight. The slides were rinsed under 
hot running water for 15 min followed by distilled water for 15 min. Slides were then 
removed and soaked in 90 % ethanol/ 10 % hydrochloric acid mix for 20 min before a 
further wash for 5 min in running distilled water. Five grams of gelatine (BDH 
chemicals, UK) was dissolved in 500 ml of water to which 0.35 g of chromium 
potassium sulphate (Sigma-Aldrich, UK) was added. The solution was warmed until 
hot but not boiling before being filtered (Whatmann GF/B grade) onto the prepared 
slides. Each rack of slides was left for 2 min before being removed and left to dry 
overnight. Subbed slides were kept in labelled boxes until required.
2.2.4.3. Tissue sectioning
Frozen brains were removed from storage in a -80 °C freezer and were placed into a 
Cryostat (Zeiss Microm HM505E, Germany), and equilibrated at -20 °C. 20 pm
coronal sections were then cut (300 pm apart) and thaw-mounted onto gelatine coated 
ice-cold slides to assess levels of binding from fore- to hind-brain regions. Consecutive 
sections were taken for determination of total and non-specific binding. Slides were 
transferred into sealed plastic containers containing anhydrous calcium sulphate 
(Drierite, BDH, UK) for dehydration purposes. The containers were stored at 4 °C for 
two hours then transferred to a freezer (- 20 °C) for a minimum period of one and a 
maximum of four weeks prior to autoradiographic binding.
2.2.4.4. Dopamine D l, D2 receptor and dopamine transporter autoradiography
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Quantitative autoradiography was performed as detailed previously for Dl , D2 receptor 
binding (Lena et al. 2004) and DAT binding (Javitch et al. 1985) using the general 
procedures of Kitchen et al. (1997). The brief description of protocols is in the Table
2.1. Frozen sections were removed from storage at -20 °C and warmed to room 
temperature over 30 min.
For the Dl receptor binding, all of the slides were pre-washed for 20 min in 50 mM 
Tris-HCl buffer, pH 7.4, containing 120 mM NaCl, 5 mM KCl, 2 mM CaCli and 1 mM 
MgCb at room temperature. The slides were then incubated in the same buffer at room 
temperature in the presence of 4 nM [^H]SCH23390 and 1 pM mianserin which blocks 
binding of [^H]SCH23390 to 5-HTi and 5-HTic receptors for 90 min. Non-specific 
binding was determined an adjacent sections in the presence of 10 pM of cis- 
flupenthixol.
For the D2 receptor binding, all of the slides were pre-incubated in Tris-HCl buffer as 
described for Dl binding. Incubation was carried out in the presence of 4 nM 
[^Hjraclopride for 60 min. Non-specific binding was determined in adjacent sections in 
the presence 10 pM of sulpiride.
For DAT binding, all of the slides were pre-incubated for 5 min at 4 °C in 50 mM Tris- 
HCl buffer, pH 7.9, containing 300 mM NaCl and 5 mM KCl. These slides were then 
incubated for 45 min at 4 °C in the same buffer containing 4 nM [^HJmazindol and 0.3 
pM desipramine which blocks potential binding to noradrenaline uptake sites. Non­
specific binding was determined in the presence of 10 pM mazindol.
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Incubations were terminated by rapid rinses ( 6 x 1  min) in ice-cold 50 mM Tris-HCl 
buffer, pH 7.4, for Dl and D2 receptors or by rapid rinses ( 2 x 1  min) in ice-cold 50 
mM Tris-HCl buffer, pH 7.9, for the DAT followed by a dip into ice-cold distilled water. 
Slides were then dried for two hours under a cold air stream, before being placed in a 
sealed plastic container with Drierite (for further dehydration) for a minimum of 5 days.
2.2.5. Autoradiographic film preparation
Autoradiograms were generated by apposing the labelled tissues to Kodak BioMax MR 
films (Eastman Kodak Co., Rochester, NY, USA). Cassettes were sealed using opaque 
tape to prevent light entry and stored in a dark place for a period of 4 weeks 
([^H]SCH23390 and [^H]mazindol) or 5 weeks ([^H]raclopride) in X-ray film cassettes 
along with Amersham tritiated polymer microscale standards at room temperature.
2.2.6. Autoradiographic film development
Kodak BioMax MR films were developed in 50 % Kodak D19 developer solution for 1 
min. The film was then placed in a stop solution (distilled water with a few drops of 
glacial acetic acid) for 30 sec before transferring to Kodak rapid fixer for a further 3 min. 
The films were rinsed in running distilled water for 20 min and left to dry overnight. 
Sections from WT and KO animals were processed together to ensure a paired protocol 
for binding, film apposition and image analysis.
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2.2.7. Autoradiographic image analysis
All films were analysed by video-based computerized densitometry using an MCID 
image analyser (Imaging Research, Canada) as previously described (Kitchen et al. 
1997). Films were placed onto a light box (Kaiser Pro-lite, Germany) and calibration 
took place using the exposed images of the tritium microscale standards. An appropriate 
adjustment was made to allow for radioactive decay of both the standards and 
radioligands.
Brain regions were analysed in duplicate for each brain using left and right hemispheres. 
The cortical structures and the olfactory tubercle were analysed by sampling 5-20 times 
with a box tool (10 x 10 mm). All other regions were analysed by freehand drawing 
tools. Structures were identified by reference to the mouse atlas of Franklin & Paxinos 
(2001). Specific binding was calculated by subtracting the level of non-specific binding 
from the total binding level.
2.2.8. Data analysis
The mean and standard error of ligand binding (fmol/mg) was calculated in each region 
for each genotype. A P value of 0.05 was used as the threshold for significance in all 
cases. Three-way ANOVA (for factors genotype, treatment and region) was used for 
comparison of quantitative measures of D l, D2 receptors and DAT binding in chronic
115
“binge” saline and cocaine treated ppDYN KO and WT brains followed by a LSD post 
hoc test to determine significant difference in individual regions.
2.3. Results
DA D l, D2 receptors and DAT binding were analysed from coronal brain sections of 
“binge” cocaine and saline treated ppDYN KO and WT mice. The overall qualitative 
and quantitative distribution of D l, D2 receptor and DAT labelled with [^HJSCH- 
23390 (4 nM), [^HJraclopride (4 nM) and mazindol (4 nM) in coronal sections of 
brains of chronic “binge” saline treated mice was similar to measurements made in 
previous studies (Javitch et al. 1985; Puschban et al. 1999; Lena et al. 2004).
2.3.1. The effects of chronic “binge” cocaine treatment on D l receptor binding in 
the brain of ppDYN knockout and wild-type mice
Figure 2.1. shows the distribution of [^H]SCH23390 binding in the brains of “binge” 
cocaine and saline treated ppDYN KO and WT mice. Three-way ANOVA showed no 
significant effect of treatment, genotype or any treatment x genotype interaction in Dl 
receptor binding. No significant differences in [^H]SCH23390 binding were detected 
between “binge” cocaine and saline treated ppDYN KO and WT mice (Figure 2.2.).
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2.3.2. The effects of chronic “binge” cocaine treatment on D2 receptor binding in 
the brain of ppDYN knockout and wild-type mice
Figure 2.3. shows the distribution of [^HJraclopride binding in the brains of “binge” 
cocaine and saline treated ppDYN KO and WT mice. Three-way ANOVA showed a 
significant main effect of genotype (F(ijo) = 4.45, P < 0.05), region (F(4j 2) = 15.31, 
P < 0.001) and genotype x treatment interaction {F^ a,iq) = 8.85, P < 0.01) but no 
significant effect of treatment (F(i jo) = 2.76, P = 0.10). Lower overall D2 receptor 
binding (18-27%) was observed in chronic “binge” cocaine-treated KO mice compared 
with KO saline control (P < 0.01, LSD post hoc test) and compared with “binge” 
cocaine-treated WT (P < 0.01, LSD post hoc test). A significant decrease in D2 
receptor binding was observed in the mediolateral part of the caudate putamen of 
chronic “binge” cocaine treated KO mice compared to KO saline controls (P < 0.01, 
LSD post hoc test) (Figure 2.4.). However, post hoc analysis did not show significant 
changes in D2 receptor binding in other regions of chronic cocaine treated KO mice 
compared to cocaine treated WT (P > 0.05).
2.3.3. The effects of chronic “binge” cocaine treatment on dopamine transporter 
binding in the brain of ppDYN knockout and wild-type mice
Figure 2.5. shows the distribution of [^HJmazindol binding in the brains of “binge” 
cocaine and saline treated ppDYN KO and WT mice. Three-way ANOVA showed no
121
significant effect of treatment, genotype or treatment x genotype interactions in Dl 
receptor binding. No significant differences in [^HJmazindol binding were observed 
between “binge” cocaine and saline treated ppDYN KO and WT mice (Figure 2.6.).
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2.4. Discussion
The D2 dopaminergic system was not shown to be altered following chronic “binge” 
cocaine treatment in WT animals. The lack of significant decrease in D2 receptor binding 
observed in the brains of chronic “binge” cocaine treated WT animals compared to saline 
is in contrast with the consistent report of a decrease in D2 receptor binding and 
availability following chronic cocaine exposure in rodents, primates and abstinent humans 
(Goeders and Kuhar 1987; Peris et al. 1990; Voikow et al. 1990; Farfel et al. 1992; 
Alburges et al. 1993; Volkow et al. 1993; Tsukada et al. 1996; Maggos et al. 1998). 
However, the present study is in agreement with a study performed by Unterwald et al., 
(1994) who showed a lack of alteration in D2 receptor binding in rats treated with cocaine 
under the same experimental protocol that we used. Thus, one has to consider the 
discrepancy in experimental paradigms as well as ligands used between studies. In 
contrast to WT animals, there was a significant decrease in overall D2 receptor binding in 
the brains of chronic cocaine treated ppDYN KO mice compared to KG controls and 
compared to cocaine treated WT animals. This finding further endorses studies showing 
strong interactions between the KOPr system and the D2 dopaminergic system. The 
inhibitory action of KOPr agonists on extracellular DA levels in the striatum (Di Chiara 
and Imperato 1988; Spanagel et al. 1992) suggests a close functional interaction between 
the KOPr system and the D2 receptor dopaminergic system.
The exact mechanism for the downregulation of D2 receptors in chronic cocaine treated 
ppDYN KO mice as well as the nature of the population of those receptors (i.e. pre- or 
post-synaptie) cannot be determined from this experiment. However, there is evidence 
that D2 autoreceptors are crucial in controlling extracellular DA induced by cocaine
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(Rosin et al. 1999). The alterations in D2 receptor binding in ppDYN KO mice might 
partially explain the enhancement of cocaine-induced sensitization in these animals 
(Bailey et al. 2007). Although the changes in D2 dopamine receptor binding are relatively 
small (18-27%) that does not rule out the possibility that they might be of behavioural 
significance. For instance, small changes in opioid receptor density (20-30%) in A2A 
adenosine receptor KO mice have been shown to result in marked changes in 
antinociceptive responses (Bailey et al. 2002). Behavioural sensitization to cocaine has 
been attributed previously to changes in presynaptic D2 receptor function (King et al. 
1994; Jones et al. 1996). Moreover, activation of presynaptic D2 receptors has been 
shown to decrease extracellular DA levels by means of inhibition of DA synthesis and 
release (Dwoskin and Zahniser 1986; Zetterstrom et al. 1986). Taken together, these 
results suggest that the enhancement of cocaine sensitization in chronic cocaine treated 
ppDYN KO mice (Bailey et al. 2007) might partly be due to the downregulation of 
presynaptic D2 receptor in these animals. Nevertheless, the present binding results suggest 
that chronic “binge” cocaine treatment decreases the D2 receptors in ppDYN KO mice 
but not in WT mice.
Although anatomical and neuroehemieal data suggest the existence of an interaction 
between the KOPr system and the Dl receptor as well as with the DAT (Izenwasser et al. 
1998; Thompson et al. 2000; Collins et al. 2001), no change in either Dl receptor or DAT 
binding was observed either in cocaine-treated animals or in mice lacking the ppDYN 
gene. There is literature that has shown a lack of change in Dl receptor number and 
affinity and in DA uptake in rats repeatedly treated with the KOPr agonist U-69593 
(Izenwasser et al. 1998). As for DAT binding, as assessed by radioligand binding, the 
number of DAT binding sites has been reported to increase (Alburges et al. 1993; Little et
132
al. 1993; Wilson et al. 1994; Hitri et al. 1996; Little et al. 1998; Little et al. 1999) or 
decrease (Sharpe et al. 1991; Farfel et al. 1992; Hurd and Herkenham 1993; Pilotte et al. 
1994), whereas in other studies the number of DAT sites remains unchanged (Allard et al. 
1990; Kula and Baldessarini 1991; Benmansour et al. 1992; Cass et al. 1993) in response 
to cocaine treatment. The lack of concordance in these results may arise from differences 
in treatment paradigms (varying dosage, schedule and route of administration), length of 
withdrawal and/or ligand used to quantify DAT. A study conducted by Maggos et al. 
(1997) in rats, who used an identical chronic “binge” cocaine administration protocol to 
study described in this thesis, failed to demonstrate an alteration in DAT mRNA in the 
cocaine group. However, that does not exclude the possibility that DAT function (e.g. 
increases or decreases in DA uptake or release) is altered in the brains of saline or 
chronically “binge” cocaine treated ppDYN KO mice.
Overall, the present study demonstrates that ppDYN can modulate D2 receptors rather 
than Dl receptors and DAT induced by chronic “binge” cocaine administration. 
Although additional studies are needed to elucidate further mechanisms underlying the 
effect of ppDYN modulation of D2 receptors, the present binding data suggest that 
ppDYN may play a role in mediating the effects of “binge” cocaine on the D2 
dopaminergic system.
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Chapter 3. Effect of genetic background on 
dopamine D l, D2 receptors or dopamine 
transporters in triple opioid receptor knockout
mice
134
3.1. Introduction
There is growing evidence from different strains of mutant mice with genetic ablation of 
the same gene(s) that shows the genetic background can influence the behaviour and 
neuroehemistry of mutant animals (Boehme and Ciaranello 1981; Cabib et al. 2002; 
D'Este et al. 2007). Although the utilization of transgenic or knockout (KO) mice has 
become a useful tool to investigate the role of receptors and neurotransmitter systems, it 
remains possible that alterations in behaviour or neuroehemistry observed in mutant mice 
may reflect not only the lack of function of the gene(s) but also the effect of genetic 
background and the interaction with the gene deleted. For instance, p-opioid receptor 
(MOPr) KO mice of eongenic C57BL/6 (B6) strain demonstrated a significantly higher 
level of baseline locomotor activity compared to its wild-type (WT) control, whereas 
MOPr KO mice bred on a mixed B6 and 129/SvEvTac (129S6) (B6 x 129S6) background 
from successive heterozygote matings of the original KO strain displayed a lower level of 
basal locomotion compared to its WT control (Hummel et al. 2004). Moreover, the effect 
of repeated cocaine administration is differentially modulated in different strains of mice 
lacking MOPr, suggesting that genetic background could influence the effects of cocaine 
on mice with MOPr gene manipulations (Hummel et al. 2004). Furthermore, genetic 
background has also been shown to influence individual threshold responses to both the 
locomotor and rewarding effects of cocaine in dopamine transporter (DAT) KO mice of 
three different strains (C57BL/6JOrl, DBA/2J0rl, and hybrid C57BL/6JOrl x DBA/2J0rl) 
suggesting that the behavioural phenotypes of mice lacking the DAT is dependent on 
strain (Morice et al. 2004).
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Strain differences in the dopaminergic system have been shown to exist between inbred 
strains of mice (Puglisi-Allegra and Cabib 1997; He and Shippenberg 2000; Janowsky et 
al. 2001). For instance, lower basal dopamine (DA) uptake was observed in 129/Sv-ter 
miee compared to B6, DBA/2J and Swiss-Webster miee (He and Shippenberg 2000). 
Although acute amphetamine treatment increased DA efflux both in B6 and 129S2/SvHsd 
strains of mice, lower levels of amphetamine-induced DA efflux were detected in the 
striatum of 129S2/SvHsd mice compared to the B6 strain of miee suggesting the existence 
of strain differences in the dopaminergic system of these miee (Chen et al. 2007). 
Moreover, quantitative trait loci studies also found significant strain differences in the 
binding of [^^^]RTI-55 to DAT in the neostriatum of B6, DBA/2J and B6 x DBA/2J 
recombinant inbred mouse strains; the DBA/2J allele has shown to be associated with 
higher Bmax values relative to the B6 allele (Janowsky et al. 2001). In summary, the 
evidence points to profound differences in the dopaminergic system of different strains of 
mice which could account for some of their distinct behavioural phenotypes.
A number of studies have shown the existence of interactions between opioidergic and 
dopaminergic neurons with the use of genetically modified mice (Spielewoy et al. 2000; 
Becker et al. 2001; Tien et al. 2003; Chefer et al. 2004; Lena et al. 2004). Moderate 
overall up-regulation of both Dl and D2 receptors have been shown in the brains of 
MOPr KG miee of a mixed B6 x 129S2 background (Lena et al. 2004). In addition, acute 
treatment with apomorphine, a mixed Dl and D2 receptor agonist, enhanced locomotor 
activity in MOPr KO mice of B6 x 129/Ola genetic background compared to its WT 
control (Tien et al. 2003). Moreover, loss of Dl receptors in the Drdla^ "^ ^^ ^® strain or D2 
receptors in B6 x 129/SwEv strain has been shown to lead to an increase in the analgesic 
effects of morphine suggesting an involvement of Dl and D2 receptors in morphine-
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induced analgesia as determined in both hot plate and tail flick tests (Becker et al. 2001; 
King et al. 2001). With respect to DA neurotransmission, higher DA levels were detected 
in the nucleus accumbens of eongenic B6 ô-opioid receptor (DOPr) KO mice after acute 
cocaine administration compared to its WT control (Chefer et al. 2004). Moreover, 
cocaine-induced increases in extracellular DA levels were shown to be attenuated in the 
nucleus accumbens of eongenic B6 MOPr KO mice (Mathon et al. 2006). Furthermore, 
an enhancement of cocaine-induced DA levels was observed in the nucleus accumbens of 
K-opioid receptor (KOPr) KO mice compared to their WT controls (Chefer et al. 2005). 
This behavioural and neuroehemieal evidence in KO miee suggests that there is a clear 
interaction between the opioidergic systems and the dopaminergic systems.
Although previous studies have shown that there are significant differences in DA related 
behaviours and neuroehemistry among different inbred strains of mice, no studies have 
investigated the effects of genetic background on DA D l, D2 receptor and DAT binding 
in miee lacking all three classical opioid receptors. This would give further insight on 
how genetic background interacts with opioid receptors and influences the dopaminergic 
system. The first aim of this study is to investigate whether there are strain differences in 
D l, D2 receptor and DAT binding in brain regions of B6 and 129S6 mice. Moreover, in 
order to investigate whether D l, D2 and DAT binding is altered in mice lacking all three 
classical opioid receptors and whether these possible alterations are strain-dependent, 
quantitative receptor autoradiography was carried out in the brains of triple opioid 
receptor KO and WT miee generated from pure B6 or 129S6 genetic background.
3.2. Materials and Methods
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3.2.1. Animals
Triple opioid receptor KO and WT mice brains from eongenic (backcrossed to at least 
F10) C57BL/6 and coisogenic 129S6 miee were obtained from Prof. John E. Pintar 
(Department of Neuroscience, University of Medicine and Dentistry of New Jersey, New 
Jersey, USA). Mice deficient in the genes coding for MOPr, DOPr and KOPr were 
generated by cross-breeding KO eongenic C57BL/6 or coisogenie 129S6 miee produced 
by standard homologous recombination techniques (Schuller et al. 1999; Zhu et al. 1999; 
Ansonoff et al. 2006). Figure 3.1. presents the strategy used to produce eongenic 
C57BL/6 triple opioid receptor KO mice. To produce triple opioid receptor KO and WT 
mice on a pure 129S6 line, the chimeric male miee from MOPr, DOPr or KOPr KO were 
mated with 129S6 females to produce coisogenic 129S6 miee containing the mutation. 
Coisogenie MORr/DORr double KO mice on the 129S6 line were generated from mating 
between coisogenic MORr and DORr KO mice on the 129S6 line. Once the double KO 
was available it was mated to KORr KO mice to generate coisogenic triple opioid 
heterozygous on the 129S6 line. These triple heterozyous mice were then mated to 
generate the coisogenic 129S6 triple opioid receptor knockout mice. Mice were genotyped 
by PGR at weaning. All male animals used were between 9 and 11 weeks old. All 
experiments were carried out in accordance with the National Institutes of Health guide 
for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978).
3.2.2. Materials
See section 2.2.3.
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3.2.3. Autoradiography
Preparation of knockout tissue for sectioning and radioligand binding, drying and storage was 
carried out as detailed in section 2.2.4.
3.2.4. Autoradiographic film preparation and development
See section 2.2.5 and 2.2.6 for autoradiographic film preparation and development, 
respectively.
3.2.5. Autoradiographic image analysis
See section 2.2.7.
3.2.6. Data analysis
Three-way ANOVA (for the factors genotype, strain and region) was used for comparison of 
quantitative measures of D l, D2 receptors and DAT binding in WT and triple opioid receptor 
KO mice of two different genetic background (maintained on pure C57BL/6 and 129S6 
background) followed by a Bonferroni post hoe test.
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3.3. Results
3.3.1. D l binding in the brains of wild-type and triple opioid receptor knockout mice of 
B6 and 129S6 genetic backgrounds
Three-way ANOVA showed a significant region (F(i4,288)“  448.52, P < 0.001) effect with no 
genotype, strain, genotype x strain interaction, strain x region interaction or genotype x strain 
X region interaction effect in the expression of the Dl receptor in WT and triple opioid 
receptor KO mice in any of the two different genetic backgrounds (Figures 3.2. and 3.3.). No 
significant difference in Dl receptor binding was observed in any of the regions of the WT 
and triple opioid receptor KO mice in either of the two different genetic backgrounds 
(Bonferroni post hoc test).
3.3.2. D2 binding in the brains of wild-type and triple opioid receptor knockout mice of 
B6 and 129S6 genetic backgrounds
Three-way ANOVA showed a significant region (F(3,n6) = 19.42, P < 0.001) effects with no 
genotype, strain, genotype x strain interaction, strain x region interaction or genotype x strain 
X region interaction effect in levels of D2 receptor binding in WT and triple opioid receptor 
KO mice in any of the two different genetic backgrounds (Figures 3.4. and 3.5.). No 
significant difference in D2 receptor binding was observed in any of the regions of the WT
142
and triple opioid receptor KO miee in either of the two different genetie backgrounds 
(Bonferroni post hoe test).
3.3.3. DAT binding in tbe brains of wild-type and triple opioid receptor knockout mice 
of B6 and 129S6 genetic backgrounds
Three-way ANOVA showed a significant region (F(6,i30)=  8.53, P < 0.001) effects with no 
genotype, strain, genotype x strain interaction, strain x region interaction or genotype x strain 
X region interaction difference in WT and triple opioid receptor KO mice in any of the two 
different genetie backgrounds (Figures 3.6. and 3.7.). No significant difference in DAT 
binding was observed in any of the regions of WT and triple opioid receptor KO miee in 
either of the two different genetie backgrounds (Bonferroni post hoe test).
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3.4. Discussion
The effect of genetic background on D l, D2 receptor and DAT binding was investigated 
in WT and triple opioid receptor KO mice of two different genetic backgrounds. The 
receptor binding results obtained in this study demonstrate that ablation of the three 
classical opioid receptor genes does not influence D l, D2 or DAT binding in any brain 
regions of mice of 129S6 or B6  background.
In the present study, a null mutation of all three classical opioid receptors in mice of 
129S6 genetic background displayed no significant difference in D l, D2 or DAT 
regulation compared to B6  genetic background. These results suggest that D l, D2 or 
DAT expression is not influenced by ablation of all three classical opioid receptors that is 
also not dependent on genetic background. Our findings might provide an explanation for 
previous studies which investigated whether strain interacts with deletion of MOPr genes 
in morphine-induced antinociception, locomotion and reward tests. It has been reported 
that MOPr KO mice of hybrid B6  x 129/SvEv or congenic B6  background displayed 
similar behavioural responses to morphine and concluded that strain does not influence 
morphine-induced behavioural changes in MOPr KO mice (Sora et al. 1997; Hall et al. 
2003). In contrast to these results, another study showed strain differences in basal 
locomotion and cocaine-induced locomotor sensitization between mice lacking MOPr 
with B6 , 129, B6  x 129S6 or FI B6  x 129S6 genetic background (Hummel et al. 2004). 
Specifically, lower basal locomotor activity was observed in MOPr KO mice of B6  x 
129S6 background compared to its WT control, whereas MOPr KO mice of congenic B6
156
background were shown to have higher basal locomotion compared to their WT controls. 
No significant changes were observed in basal locomotor activity between the MOPr KO 
and WT of FI hybrid B6  x 129S6 and of isogenic 129S6 backgrounds. Moreover, MOPr 
KO mice of different genetic backgrounds have been shown to have different behavioral 
sensitisation effects in response to repeated cocaine administration which is in accordance 
with results observed from basal locomotion studies in these strain of mice suggesting that 
strain does interact with deletion of MOPr gene to affect behaviour (Hummel et al. 2004). 
Nevertheless, our binding study suggests that the regulation of D l, D2 or DAT binding in 
the absence of all three classical opioid receptors is not strain-dependent.
The lack of significant strain difference in Dl binding in any brain regions between the 
two WT strains is in accordance with Schlussman et al. (2003) who found no differences 
in Dl receptor binding between B6  and 129P3 (formerly 129/J) (Schlussman et al. 2003). 
In addition to Dl binding, there were no significant differences in D2 binding in any brain 
regions of WT and KO of B6  background compared to WT and KO of 129S6 background. 
As far as the strain effect on D2 binding is concerned, this is the first report comparing D2 
binding between B6  and 129 strains. Previous studies showed Dl and D2 receptors are 
involved in the control of motor activity (Clark and White 1987; Jackson and Westlind- 
Danielsson 1994; Jaber et al. 1997; Missale et al. 1998). For instance, activation of Dl 
receptors in the striatum was shown to promote motor activity (Missale et al. 1998). 
Moreover, activation of post-synaptic D2 receptors was also shown to increase motor 
action, while stimulation of the pre-synaptic D2 autoreceptors has been shown to decrease 
the level of motor action (Jackson and Westlind-Danielsson 1994). Recent studies showed 
no significant strain difference between B6  and 129S2/SvHsd in baseline locomotor
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activity studies when measured in the homecage (Chen et al. 2007). In addition, in studies 
that used the prepulse inhibition test, which is believed to be modulated by DA and by 
D l- (SKF82958) or D2-like (quinpirole) agonists showed similar trends in either B6  or 
129S6 mice (Ralph-Williams et al. 2003). The lack of significant difference in those DA- 
related behavioural changes between B6  and 129S2/SvHsd accords with the lack of 
significant difference in both Dl and D2 binding observed between B6  WT and 129S6 
WT strain. Moreover, the lack of strain effects in DAT binding in regions of WT and KO 
mice of B6  compared to WT and KO mice of 129 background is also consistent with the 
findings of the lack of significant differences in the surface expression of DAT, DAT 
activity as well as the DA concentrations in the striatum of B6  compared to 129S2/SvHsd 
mice (Chen et al. 2007).
The lack of significant difference in Dl binding in the brains of triple opioid receptor KO 
mice compared to its WT is in line with previous studies showing no significant changes 
in Dl and D2 binding in any of brain regions analysed in MOPr KO mice of B6  x 129S2 
background relative to its WT control (Lena et al. 2004). In contrast to these findings, 
pharmacological blockade of opioid receptors has been shown to modulate Dl receptors. 
For instance, acute administration of the opioid receptor antagonist nalmefene produced 
an increase in Dl binding ([^^C]SCH23390) in the striatum of rats with no changes in D2 
binding ([^^C]N-methylspiperone) as measured by positron emission tomography 
potentials (Unterwald et al. 1997) suggesting that pharmacological blockade of opioid 
receptors could modulate DA Dl receptors without modification of D2 receptors. 
Moreover, repeated intermittent treatment with the opioid receptor antagonist naloxone 
was shown to decrease both B^axand Kj values of DA Dl ([^H]SCH23390) receptors in 
specific regions of rats (Elwan and Soliman 1995). In addition to this evidence, in situ
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hybridization studies have shown that enkephalin mRNA expression is significantly 
higher in the striatum of Dl KO mice compared to WT controls, whereas dynorphin 
mRNA expression is significantly lower in the striatum of Dl KO mice compared to their 
WT controls (Wong et al. 2003), suggesting an involvement of DA Dl receptors in the 
modulation of endogenous opioid peptide mRNA expression in the striatum. The lack of 
significant difference in DAT binding in the brains of triple opioid receptor KO mice 
compared to their WT is also in contrast to previous findings observed with 
pharmacological antagonism of opioid receptors. Chronic blockade of opioid receptors by 
naltrexone was shown to result in down-regulation of DAT density but not Kd (Bhargava 
and Gudehithlu 1996). However, blockade of endogenous opioid tone by opioid 
antagonists may differ from genetic ablation of all three opioid receptor genes with 
respect to modulation of endogenous opioid peptide levels. Therefore, it would be of 
interest to investigate whether compensatory changes of endogenous opioid tone occur in 
the absence of all three opioid receptor genes. Depite differences in pharmacological 
blockade of opioid receptors, D l, D2 and DAT binding levels remained unchanged in any 
of the brain regions analysed in both WT and KO mice of B6  and 129 genetic 
backgrounds suggesting a lack of interaction of D l, D2 and DAT with opioid receptors.
The interaction between opioidergic and dopaminergic systems has been studied in single 
opioid receptor KO mice using several different behavioural and neurochemical 
techniques. For instance, acute Dl and D2 agonist apomorphine treatment increased 
locomotor activity in MOPr KO mice compared to WT control suggesting MOPr may 
negatively regulate locomotor activity in response to a DA agonist (Tien et al. 2003). 
Previous studies using single opioid KO mice showed that mesoaccumbal DA 
neurotransmission is differentially modulated by different opioid receptor subtypes. For
159
instance, DA uptake and release were increased in the nucleus accumbens of KOPr KO 
compared to its WT control (Chefer et al. 2005), whereas DA uptake and release was 
decreased in the nucleus accumbens of MOPr and DOPr KO mice suggesting that KOPr 
may have opposite roles in mediating DA neurotransmission compared to both the MOPr 
and DOPr (Chefer et al. 2003, 2004). It is possible that an absence of all three classical 
opioid receptors may lead to balance of DA neurotransmission through tonic inhibition 
and/or activation of MOPr, DOPr and KOPr which may result in the no compensatory 
changes of D l, D2 and DAT binding in the triple opioid receptor KO mice compared to 
its WT control.
In summary, the present studies demonstrate that the absence of all three classical opioid 
genes does not affect D l, D2 or DAT binding. Moreover, the lack of alteration in D l, D2 
or DAT binding in both C57BL/6 and 129S6 background demonstrating there is no effect 
of the strain on the dopaminergic system in mice lacking all three classical opioid 
receptors. However, the possibility of alterations in behaviour and neurochemistry would 
need to be assessed in experiments with the use of pure single strains of WT and triple 
opioid receptor KO mice.
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CHAPTER 4. Quantitative receptor 
autoradiography of [^ H] oxycodone binding in the 
brains of single and triple opioid receptor
knockont mice
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4.1. Introduction
Oxycodone (14-hydroxy-7,8-dihydrocodienone), a semi-synthetic opioid derived from the 
alkaloid thebaine, is well known as one of the most powerful medications for the relief of 
pain that can be taken orally (Beaver et al. 1978; Leow et al. 1992; Heiskanen and Kalso 
1997; Cicero et al. 2005) (Figure 4.1.). Oxycodone has been used in patients with 
moderate to severe pain via intravenous, intramuscular, intranasal, subcutaneous, rectal, 
epidural or controlled-release tablets for the treatment of postoperative and cancer pain 
since it was introduced into clinical practice in Germany in 1917 (for review, see Kalso, 
2005).
Intravenous oxycodone appeared to be equipotent to intravenous morphine in post­
operative analgesia (Silvasti et al. 1998). Rectal oxycodone provides longer analgesic 
effects ( 8 - 1 2  hours) than intravenous administration of oxycodone (4 hours) in adult 
patients with cancer pain whereas intravenous oxycodone is more effective in establishing 
a rapid onset of pain relief ( 5 - 8  min) compared to rectal administration (0.5 to 1.0 hour) 
(Leow et al. 1995). The analgesic effects of oxycodone is comparable to morphine but it 
has higher oral bioavailability ratios (> 60 %) compared to morphine (30 %) in cancer 
patients (Kalso and Vainio 1990). Oxycodone has a faster and longer analgesic action 
compared to morphine when given intravenously to patients who have gone through 
abdominal surgery (Kalso et al. 1991). The mean elimination half-life of oxycodone (3.7 
hours) was longer than morphine (1.9 hours) after intravenous injection in adults which 
may account for the longer analgesic action in oxycodone (Hoskin et al. 1989; Poyhia et 
al. 1991).
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Two major metabolic pathways of oxycodone have been characterised in humans. 
Liver enzyme P4503A-mediated A-demethylation is involved in the conversion of 
oxycodone to noroxycodone whereas cytochrome P4502D6-mediated O- 
demethylation is involved in the conversion of oxycodone to oxymorphone (Lalovic 
et al. 2006). Eight to 14 % of the total dose of oxycodone is excreted in urine as 
unconjugated and conjugated oxycodone over 24 hours; noroxycodone is excreted 
mostly unconjugated and oxymorphone mainly in conjugated form (Poyhia et al. 
1992).
According to a recent survey, the abuse of oxycodone containing analgesics has 
increased among street and recreational drug users (for review, see Cicero et al., 
2005). There are a number of commonly prescribed oxycodone containing analgesic 
medications. These drugs contain oxycodone in small amounts and they are 
combined with other active ingredients such as aspirin (Percodan®) or paracetamol 
(Percocet®) for treating moderate and severe pain. OxyContin® (Purdue Pharma, 
Stamford, CT, USA) is formulated as a sustained release of oxycodone hydrochloride 
over a period of 12 hours which was approved by the US Food and Drug 
Administration (FDA) in 1995. Recent studies showed that OxyContin® is being 
increasingly abused and spreading throughout the United States because of its easy 
accessibility in places such as schools, compared to other drugs such as heroin and 
cocaine (for review, see Cicero et al., 2005). OxyContin® abusers often remove the 
drug’s waxy time-release coating then either chew, snort or dissolve the power for 
injection (FDA consumer 2001). Frequent and high doses of oxycodone can achieve 
“highs” which can easily lead to drug dependence (for review, see Hays, 2004). The 
prevalence of lifetime non-medical uses of oxycodone increased from 1 1 .8  million in
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2002 to 13.7 million in 2003 (US Department of Health and Human Services 2005). 
Oxycodone may have been involved in multiple drug abuse deaths in which there was 
at least one other plausible contributory drug in addition to oxycodone such as 
benzodiazepines, alcohol, cocaine, other narcotics, marijuana, or antidepressants 
(Cone et al. 2003). Although clinical studies showed oxycodone containing products 
are highly abused, few studies have been published illustrating the mechanism of the 
action of oxycodone.
The pharmacological profile of oxycodone has become an issue of debate in the 
literature (Kalso 2007; Smith et al. 2007). When the selective ji-opioid receptor 
(MOPr) antagonist P-funaltrexamine (p-FNA), the K-opioid receptor (KOPr) 
antagonist nor-binaltorphimine (nor-BNI) or the 5-opioid receptor (DOPr) antagonist 
naltrindole were co-administered with oxycodone and tested in the tail-flick assay in 
mice, only the MOPr antagonist, P-FNA, was effective in attenuating oxycodone’s 
effects (Beardsley et al. 2004). These results suggest that the antinociceptive and 
abuse liability profile of oxycodone is solely via the MOPr. Moreover, oxycodone 
effectively relieved the withdrawal syndrome in morphine-dependent rhesus monkeys 
and its abuse liability is similar to morphine in humans (James and Sandra 2003; 
Beardsley et al. 2004). The adverse effects of controlled-release formulations of 
oxycodone were similar to those of morphine although morphine-treated patients 
experienced more vomiting, whereas constipation was more common with oxycodone 
(Heiskanen and Kalso 1997). In addition to behavioral studies, competition binding 
studies also showed that oxycodone has higher relative affinity for the MOPr binding 
sites (Ki = 18 nM) rather than DOPr (K; = 958 nM) or KOPr (Ki = 677 nM) (Monory 
et al. 1999). These results clearly indicate that oxycodone is a MOPr agonist.
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However, other studies suggested that oxycodone’s analgesic effects were principally 
mediated by the KOPr rather than the MOPr or DOPr (Ross and Smith 1997; Ross et 
al. 2000). This hypothesis was based on the findings that oxycodone’s 
antinociceptive effect was attenuated by the KOPr antagonist nor-BNI but not by the 
MOPr antagonist naloxonazine or by the DOPr antagonist naltrindole in rats (Ross 
and Smith 1997).
Previous binding studies suggest that a putative K2 receptor may be subdived into K2a 
and K2b receptors (Rothman et al. 1992b; Rothman et al. 1993). Recent observations 
from in vitro competitive binding studies by Nielsen and co-workers showed that a 
putative K2b-opioid ligand, leu-enkephalin, prevented oxycodone’s displacement of 
[^HJbremazocine, a putative K2-opioid ligand, in rat brain membranes depleted of their 
MOPr and DOPr, suggesting that oxycodone appears to be a putative K2b-opioid 
ligand (Nielsen et al. 2007). In order to clarify the exact nature of the subtype of 
opioid receptor which mediates the pharmacological effects of oxycodone in the brain, 
quantitative autoradiographic binding of [^H]oxycodone was carried out in brains of 
mice lacking either MOPr, KOPr or DOPr as well as in mice lacking all three classical 
opioid receptors. This is the first study that attempts to visualize the localization of 
oxycodone binding sites with the use of [^H]oxycodone.
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4.2. Materials and Methods
4.2.1. Animals
4.2.I.I. Single MOPr, DOPr and KOPr knockout mice
Mice lacking MOPr (Matthes et al. 1996), DOPr (Filliol et al. 2000) and KOPr 
(Simonin et al. 1998) were generated from Prof Brigitte L. Kieffer’s laboratory 
(CNRS, University of Louis Pasteur, France). Congenic C57BL/6 MOPr, DOPr and 
KOPr KO mice were derived following at least 10 generations of successive 
backcrossing of 129/SV x C57BL/6 heterozygotes to C57BL/6 mice. The congenic 
KO animals used in this study were between 8 and 24 weeks old adult male and 
female mice and genotyped by PGR at weaning. All experiments were carried out in 
accordance with the the European Communities Council Directive of 24 November 
1986.
4.2.I.2. Triple opioid receptor knockout mice
As described previously by Simonin et al. (2001), triple mutant mice lacking MOPr, 
DOPr and KOPr genes were generated by interbreeding of single MOPr (Matthes et al. 
1996), DOPr (Filliol et al. 2000), and KOPr (Simonin et al. 1998) KO mice. In brief, 
double MOPr/DOPr KO mice (50% C57BL/6 and 50% 129S2) were mated with 
double MOPr/KOPr KO mice (50% C57BL/6 and 50% 129S2) to generate triple
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opioid receptor KO mice maintained on a mixed background (50% C57BL6/J and 
50% 129S2). Both the triple opioid receptor KO and WT mice are on a mixed 
C57BL/6J and 129Sv background. Animals used in this study were between 21 and 
23 weeks old adult male and female mice and genotyped by PCR at weaning. All 
experiments were carried out in accordance with the the European Communities 
Council Directive of 24 November 1986.
4.2.2. Materials
Oxycodone (53.49 Ci/mmol) was synthesised by Dr. Géza Toth and Dr. Anna 
Borsodi at the Hungarian Academy of Sciences, Szeged and produced as a gift. 
Naloxone was purchased from Sigma-Aldrich (Sigma-Aldrich Company Ltd., Dorset, 
UK).
4.2.3. Autoradiography
4.2.3.I. Preparation of knockout tissue for sectioning
See section 2.2.4.1
4.2.3.2. Subbing microscope slides and tissue sectioning
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See section 2.2.4.2 for subbing microscope slides and section 2.2.4.S. for tissue 
sectioning.
4.2.3.3. [^ H] Oxycodone autoradiography
Prior to preparing tissue for receptor autoradiography, saturation experiments were 
performed in whole mouse brain membranes to determine its Kd value. According to 
the saturation binding studies, the affinity of [^H] oxycodone at multiple opioid 
receptor sites (MOPr, DOPr and KOPr) is 16 nM when 10 pM of naloxone was used 
for non-specific binding (personal communication. Dr. Anna Borsodi at the 
Hungarian Academy of Sciences, Szeged).
All slides were preincubated in 50 mM Tris-HCl, pH 7.4, plus 0.9 % NaCl for 30 min, 
to remove endogenous opioids (Kitchen et al. 1997). For a screening test to find an 
adequate concentration of the [^H] oxycodone binding, three different concentrations 
of [^H]oxycodone (2 nM, 50 nM and 100 nM) were used in MOPr KO mice as 
[^H] oxycodone yielded a low level of specific binding in the saturation binding 
studies (personal communication. Dr. Anna Borsodi at the Hungarian Academy of 
Sciences, Szeged). Quantitative autoradiographic binding of [^H]oxycodone was 
carried out at the concentration 50 nM, which was based on the preliminary binding 
study, in 50 mM Tris-HCl, pH 7.4, at room temperature for 60 min in brains of WT 
and mice lacking either MOPr, KOPr or DOPr as well as in mice lacking all three 
classical opioid receptors. Non-specific binding was determined by adding 10 pM
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naloxone. Slides were washed 3 times with ice-cold Tris-HCl buffer, pH 7.4, for 5 
min and rapidly cool-air dried.
4.2.4. Autoradiographic film preparation
Autoradiograms were generated by apposing the labelled tissues to Kodak BioMax 
MR films (Eastman Kodak Co., Rochester, NY, USA). Cassettes were sealed using 
opaque tape to prevent light entry and stored in a dark place for a period of 9  weeks in 
X-ray film cassettes along with Amersham tritiated polymer standards at room 
temperature.
4.2.5. Autoradiographic film development and image analysis
See section 2.2.6. for film development and section 2.2.7 for image analysis.
4.2.6. Data analysis
Comparison of specific binding of [^HJoxycodone in single MOPr, KOPr and DOPr 
KO as well as WT mice was carried out using two-way ANOVA with genotype and 
region as factors. Newman-Keuls test was used for post hoc comparisons of changes 
in each individual brain region.
4.3. Results
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4.3.1. 2 nM oxycodone binding in MOPr knockout and wild-type mice
No specific binding was detected in either WT or MOPr KO mice when 2 nM of 
[^H]oxycodone was used (data not shown).
4.3.2. 50 nM [^ H] oxycodone binding in wild-type, MOPr, KOPr and DOPr 
knockout mice
High levels of [^H]oxycodone binding were found in the nucleus accumbens, 
olfactory tubercle, dorsal endopiriform nucleus, ventral tegmental area and superficial 
gray layer of the superior colliculus and interpeduncular nucleus of WT mice (Figure
4.2. and Table 4.1.). The pattern of [^H]oxycodone was similar to MOPr binding in 
WT mice (Figures 4.2.). Two-way ANOVA revealed a significant genotype (^(3,425) = 
31.11, P  < 0.001) and region (P(i6,425)=  4.46, P < 0.001) effects but no significant 
genotype x region effect (F(48,425)= 1.29, P = 0.09).
Newman-Keuls post hoc test revealed no significant genotype differences in any of 
the regions analysed. However, there were significantly lower levels of 
[^H]oxycodone binding in MOPr KO compared to WT mice (overall mean of 49 % 
lower than that observed in WT animal; P < 0.001, Figure 4.2. and Table 4.1.). In 
contrast there was an overall increase in [^H]oxycodone binding across all regions 
examined of 61 % and 47 % in KOPr KO mice {P < 0.001) and in DOPr KO mice {P 
< 0.01), respectively, relative to WT mice (Figure 4.2. and Table 4.1.).
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4.3.3.100 nM [^H]oxycodone binding in MOPr knockout and wild-type mice
Quantitative analysis of 100 nM oxycodone binding, two-way ANOVA revealed
a significant genotype effect (F(i 6^8)= 81.64, P < 0.001), region effect (F(i6,68)= 180, 
P < 0.05) and genotype x region effect (F(i6,68) = 2.41, P  < 0.01). An overall 
significant 6 8  % loss of oxycodone binding was observed in MOPr KO mice 
compared to WT mice across all regions analysed (P < 0.001, Figures 4.3. and Table
4.2.). A significant decrease in oxycodone binding was observed in the nucleus
accumbens (P < 0.01) and superficial gray layer of the superior colliculus (P < 0.01) 
of MOPr KO compared to WT mice (Table 4.2.).
4.3.4. 50 uM [ H] oxycodone binding in triple opioid receptor knockout mice
Triple opioid receptor KO mice were used to determine whether the ligand bound to a 
non-opioid binding component. No [^H] oxycodone binding was detected in mice 
lacking all three classical opioid receptor indicating that the ligand only can bind to all 
three classical opioid receptors (Figure 4.4.).
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4.4. Discussion
There has been considerable debate on whether MOPr or KOPr or both are involved in the 
analgesic effects of oxycodone (Smith et al. 2007). Quantitative analysis of the 
distribution of [^H]oxycodone was carried out in mice lacking MOPr, KOPr and DOPr as 
well as in mice lacking all three classical opioid receptors in order to detect the nature of 
the ligand among three classical opioid receptors.
The distribution of [^H]oxycodone binding was found to be similar to MOPr binding as 
described for [^HJDAMGO binding (Kitchen et al. 1997) in WT mice. In line with this 
observation, the present results showed that the [^H]oxycodone binding levels were 
significantly decreased in the brains of MOPr KO whereas increases in [^H]oxycodone 
binding was observed in the brains of KOPr and DOPr KO giving further evidence that 
the MOPr is the prime target for the ligand in mouse brain tissues. In support of this 
evidence, oxycodone has been shown to have pure MOPr agonist properties in in vitro 
binding studies (Monory et al. 1999). In the present study, [^H]oxycodone binding was 
carried out in the absence of Na"^  during incubation so that MOPr affinity would be 
increased relative to KOPr and DOPr. Therefore, the increased [^H]oxycodone binding 
levels in the brains of KOPr and DOPr KO mice could be due to the high affinity of 
[^H]oxycodone binding sites to MOPr. In competition binding studies, oxycodone 
showed higher selectivity for MOPr ([^HJDAMGO, K; = 17.8 to 18.0 nM) rather than 
DOPr ([^H]DPDPE, Ki = 1721 nM; [^HJnaltrindole, K, = 958 nM) or KOPr ([^H]U69,593, 
Ki = 677 to 3490 nM) suggesting oxycodone is a MOPr selective ligand (Yobum et al. 
1995; Monory et al. 1999). In behavioural studies, oxycodone effectively relieved 
naltrexone withdrawal syndrome in morphine-dependent rhesus monkeys and was shown
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to have abuse liability similar to morphine in humans (James and Sandra 2003; Beardsley 
et al. 2004). Moreover, Beardsley et al. (2004) showed that P-FNA, but not nor-BNI or 
naltrindole, was able to block the antinociceptive effects of oxycodone in mice in the tail- 
flick test, suggesting that the analgesic property of oxycodone is likely to be mediated by 
the MOPr rather than the KOPr or the DOPr (Beardsley et al. 2004).
In contrast to these results, Ross and Smith (1997) showed that intracerebroventricular 
administration of nor-BNI, 24 h prior to the intracerebroventricular administration of 
oxycodone, resulted in complete attenuation of the antinociceptive effects of oxycodone 
in the tail flick assay, whereas neither naloxonazine nor naltrindole blocked oxycodone’s 
analgesic effects suggesting that oxycodone interacts with KOPr rather than MOPr or 
DOPr to elicit antinociception when it is administered intracerebroventricularly in rat. 
This discrepancy suggests that the pharmacological profile of oxycodone could be 
explained by a concept which different from the traditional view of monomeric entities 
for opioid receptors. Recent studies suggested that opioid receptors may exist as 
heterodimers (Jordan and Devi 1999; Gomes et al. 2000; Gomes et al. 2004). Therefore, 
the observed up-regulation of [^H]oxycodone binding in the brains of KOPr KO mice 
(where both MOPr and DOPr are expressed) and DOPr KO mice (where both MOPr and 
KOPr are expressed) compared to WT controls may suggest [^H]oxycodone could bind to 
the heterodimer/hetero-oligomer conformations of the MOPr and DOPr (Gomes et al. 
2000; Gomes et al. 2004) and/or the MOPr and KOPr. A novel approach combining 
quantitative autoradiography of radiolabeled ligands with opioid receptor KO mice 
(termed Knockout .Subtraction ^Autoradiography, see Chapter 5) could be a useful tool to 
identify the MOPr and DOPr and/or the MOPr and KOPr heterodimers in in vitro and test 
binding properties of [^H]oxycodone to heterodimers.
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The midbrain periaqueductal gray region has been shown to be implicated in endogenous 
analgesia (pain suppression) by electrical stimulation of the midbrain in freely moving 
rats (Reynolds 1969) and is thought to be an important site for opioid analgesia (Basbaum 
and Fields 1984). The periaqueductal gray contains both MOPr and KOPr binding sites 
(Mansour et al. 1987; Kitchen et al. 1997). In the present study, lower levels of 
[^H]oxycodone binding were detected in the periaqueductal gray of MOPr KO mice 
compared with WT mice (- 73 %) suggesting that [^HJoxycodone may bind to KOPr 
opioid receptors in addition to MOPr sites as there are no DOPr binding sites in the 
periaqueductal gray (Kitchen et al. 1997; Goody et al. 2002). The debate on the nature of 
receptors (MOPr or KOPr) mediating the analgesic effect of oxycodone remains unclear 
although the present data support the hypothesis that MOPr is the prime mediator of the 
analgesic effect of oxycodone. For instance, oxycodone’s antinociceptive effect after 
intracerebroventricular administration was blocked by intracerebroventricular 
administration of the KOPr-selective opioid antagonist nor-BNI (Ross and Smith 1997) 
whereas oxycodone’s antinociceptive effect after subcutaneous administration was not 
blocked by subcutaneous administration of nor-BNI (Lemberg et al. 2006) suggesting that 
the receptors involved in mediating the analgesic effect of oxycodone depends on the 
route of administration of the drug (Leow and Smith 1994; Lemberg et al. 2006).
Binding of [^H]oxycodone was carried out in the mice lacking all three classical opioid 
receptor genes to investigate whether the ligand binds to any other opioid binding sites in 
addition to the three classical opioid receptors. No specific [^H]oxycodone binding was 
detected in the sagittal brain sections of mice lacking three classical opioid receptor genes 
suggesting the ligand can only bind to the three classical opioid receptors .
186
Overall, the distribution of [^H]oxycodone in the mouse brain was similar to that of MOPr 
binding sites. In addition the reduction in [^H]oxycodone binding in the brains of MOPr 
KO mice indicates that the prime binding site of the ligand is the MOPr. However, the 
up-regulation of [^H]oxycodone in the brain of KOPr and DOPr KO mice compared to 
WT mice suggests that [^H] oxycodone may bind to a different combination of opioid 
receptors (heterodimers) such as MOPr/DOPr and/or MOPr/KOPr. Further studies are 
needed to clarify this issue.
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Chapter 5. Knockout Subtraction Autoradiography: 
A novel method to identify KOPr/DOPr 
heterodimers in mouse brain tissue
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5.1. Introduction
The structural feature common to all known G-protein coupled receptors (GPCRs) is the 
presence of seven transmembrane helices linked by three alternating extracellular and 
intracellular loops, with an extracellular N-terminus and an intracellular C-terminus. 
Opioid receptors belong to the superfamily of GPCRs and have been believed to be 
present as monomeric entities (Figure 5.1.). However, recent studies suggested that these 
receptors may exist as heterodimers (Jordan and Devi 1999; Gomes et al. 2000; Gomes et 
al. 2004). In addition, Rogers and Henderson (1990) showed that MOPr and DOPr are 
located on the same presynaptic nerve terminals in the same neurons. Homodimerisation 
is defined as a physical association between identical proteins, whereas 
heterodimerisation is defined as the association between non-identical proteins (Rios et al. 
2001).
There are at least three possible candidate scenarios for the assembly of G-protein coupled 
receptor (GPCR) dimer/oligomer although it is not clear whether GPCRs exist at the cell 
surface as monomers, dimers, or oligomers (Rios et al. 2001) (Figure 5.2.). Firstly, 
GPCRs may be synthesized in the endoplasmic reticulum and transported to the cell 
surface as monomers. Agonists stimulate the monomers which may lead to assembly as 
dimers. Secondly, GPCRs could be assembled in an intracellular compartment such as 
the endoplasmic reticulum, Golgi apparatus, or secretory vesicles and are shuttled to the 
cell surface as dimers where they can be influenced by agonists. A third possibility is that 
oligomers assemble in an intracellular compartment and are transported to the cell surface. 
Agonist treatment might then affect GPCR dimers and/or oligomer assembly (Rios et al. 
2001).
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Figure 5.1. Diversity through oligomerization
A Old view
vYVvYVvI)/ Single gene Single gene
Single receptor 
product
Single receptor 
product
B New view
Single gene
j m i M
Single gene
Multiple receptor products
Legend to Figure 5.1.
The classical view of GPCR systems presumes that the functional receptor unit is the 
product of a single gene (A). The repertoire of functional receptor units may also include 
homo-oligomers of a single gene product and hetero-oligomers of multiple gene products 
(B). Adapted from Park and Palczewski, (2005).
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A number of studies have evaluated the existence of opioid heterodimers in vivo and 
in cell systems. In cell studies, co-expression of K-opioid receptors (KOPr)/5-opioid 
receptors (DOPr) (Jordan and Devi 1999) or p-opioid receptors (MOPr)/DOPr 
(Gomes et al. 2000; Gomes et al. 2004) heterodimers exhibited distinct ligand binding 
and signalling characteristic compared to individually expressing these receptors, 
suggesting heterodimerisation between the two different subtypes of opioid receptors 
could modulate receptor function differently from monomers. Recently, ligands 
which selectively target KOPr/DOPr heterodimers have been reported (Daniels et al. 
2005; Waldhoer et al. 2005; Xie et al. 2005). For example, KDN21, a bivalent ligand 
that contains KOPr and DOPr antagonist pharmacophores linked through a 21-atom 
spacer (Xie et al. 2005), or KDAN-18, a bivalent ligand containing KOPr agonist and 
DOPr antagonist pharmacophores linked through a 18-atom spacer (Daniels et al. 
2005), have been reported to target specifically the KOPr/DOPr heterodimer. 
Moreover, Waldhoer et al. (2005) showed that 6 '-guanidinonaltrindole, which 
selectively targets the KOPr/DOPr heterodimer, generates a unique signalling entity, 
giving further evidence for the existence of opioid heterodimers. As a result, it could 
be speculated that some opioid receptor agonists or antagonists are able to distinguish 
monomer and heterodimers in physiological systems, in vivo and in vitro.
Several methods have been developed including biochemical (co- 
immunoprecipitation and western blotting), biophysical (fluorescence resonance 
energy transfer, FRET and bioluminescence resonance energy transfer, BRET) and 
pharmacological (competitive ligand binding) methods in order to investigate 
oligomerization of GPCRs in vitro (Harrison and van der Graaf 2006). Jordan and 
Devi (1999) provided biochemical and pharmacological evidence for the existence of
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heterodimer forms of the KOPr and the DOPr in a cell culture study. Co- 
immunoprecipitation and ligand binding experiments of co-expressed KOPr and 
DOPr in HEK cells have demonstrated that these receptors heterodimerise. However, 
this has not been confirmed to occur in a physiological system.
In cell studies, (5a,7a,8p)-N-methyl-N-[7-(l-pyrrolidinyl)-l-oxaspiro[4,5]dec-8- 
yljbenzeneacetamide (U-69,593), a selective ligand for the KOPr and [o-Ala^,D- 
Leu^]enkephalin (DPDPE), a selective ligand for the DOPr, have been shown to be 
inactive at the heterodimer whereas [^Hjbremazocine (a putative ligand that is thought 
to bind to KOPr/DOPr heterodimer) has a 3-fold lower or a 6 -fold higher affinity for 
the KOPr/DOPr heterodimer than for the KOPr monomer or the DOPr monomer, 
respectively (Table 6.1.) (Jordan and Devi 1999). In the same study, the selective 
KOPr-selective antagonist nor-binaltorphimine (nor-BNI) had a 40 fold lower affinity 
for the KOPr/DOPr heterodimer than for the KOPr. As a result, it was hypothesised 
that quantitative receptor autoradiography with [^HJbremazocine and [^H]nor-BNI 
could be used to show binding to a monomeric and heterodimeric form of the KOPr 
and the DOPr by carrying out binding in single and combinatorial opioid receptor 
knockout (KO) mice. The model is based on the principle that ligands recognise the 
monomer/homo-oligomer and heterodimer/hetero-oligomer forms of the receptor with 
different affinities, and that mice lacking MOPr/DOPr or MOPr/KOPr will not be able 
to form heterodimers (Figure 5.3.). To test this hypothesis coronal brain sections 
were cut from single (MOPr) and double (MOPr/KOPr and MOPr/DOPr) KO mice 
and [^HJbremazocine and [^H]nor-BNI binding was measured at a single 
concentration. If binding of these ligands is to monomer/homo-oligomer forms of the 
KOPr and DOPr then binding from the equation MOPr KO -  MOPr/KOPr KO =
194
MOPr/DOPr KO should apply. However if binding of these ligands is to 
heterodimer/hetero-oligomer forms then MOPr KO -  MOPr/KOPr KO ^  MOPr/DOPr 
KO should apply. In addition, account was taken of any possible compensatory 
changes of DOPr and KOPr in single MOPr, double MOPr/DOPr and MOPr/KOPr 
KO mice (Figure 5.4.). Moreover, binding of [^HJbremazocine and [^H]nor-BNI was 
carried out in mice lacking all three classical opioid receptor genes to confirm both 
opioid ligands do not bind to any non-opioid sites.
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5.2. Materials and Methods
5.2.1. Animals
5.2.1.x. Single MOPr, double MOPr/DOPr and MOPr/KOPr knockout mice
Mice lacking MOPr (Matthes et al. 1996), DOPr (Filliol et al. 2000) and KOPr 
(Simonin et al. 1998) were generated from Prof Brigitte L. Kieffer’s laboratory 
(CNRS, University of Louis Pasteur, France). They were bom in the expected 
Mendelian proportion, indicating that there was no in utero or post-natal mortality. 
Breeding pairs of single MOPr and double homozygous (MOPr/DOPr and 
MOPr/KOPr) KO mice, maintained on a pure C57BL/6 genetic background, were 
obtained from hybrid mutant mice originally created on a mixed of C57BL/6J and 
129Sv background. Congenic C57BL/6 MOPr, MOPr/DOPr and MOPr/KOPr KO 
mice were derived following at least 10  generations of successive backcrossing of 
129Sv X C57BL/6 heterozygotes to C57BL/6 mice. Animals used in this study were 
between 32 and 45 weeks old adult male and female mice and genotyped by PCR at 
weaning.
5.2.1.2. Triple opioid receptor knockout mice
See section 4.2.1.2.
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5.2.2. Materials
[^H]Bremazocine (26.5 Ci/mmol) was purchased from New England Nuclear (Boston, 
MA, USA). [^H]nor-BNI (24.0 Ci/mmol) was synthesised by Dr. Géza Toth and Dr. 
Anna Borsodi at the Hungarian Academy of Sciences, Szeged and produced as a gift. 
Naloxone was purchased from Sigma-Aldrich (Sigma-Aldrich Company Ltd., Dorset, 
UK).
5.2.3. Autoradiography
5.2.3.I. Preparation of knockout tissue for sectioning
See section 2.2.4.1,
5.2.3.2. Subbing microscope slides and tissue sectioning
See section 2.2.4.2 for subbing microscope slides. Coronal sections (20 pm) were cut 
from single MOPr, double MOPr/DOPr and MOPr/KOPr according to the method in 
section 2.2.4.B. Sagittal sections (20 pm) were cut from triple opioid receptor KO and 
WT at an interval of 300 pm to assess the levels of binding in fore- through to 
hindbrain structures.
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S.2.3.3. [^H]Bremazocine autoradiography
The [^H]bremazocine binding protocol used was identical to that for [^H]oxycodone 
binding detailed in section 4.2.3.3. The concentration of the ligand (2 nM) was 
chosen from previous binding studies (Morris and Herz 1986; Kitchen et al. 1997; 
Jordan and Devi 1999).
S.2.3.4. [^H]nor-BNI autoradiography
The [^H]nor-BNI binding protocol used was identical to that for oxycodone 
binding detailed in section 4.2.3.3. The concentration of the ligand (2 nM) was 
chosen from previous binding studies (Jordan and Devi 1999; Xie et al. 2005).
5.2.4. Autoradiographic film preparation
Autoradiograms were generated by apposing the labelled tissues to Kodak BioMax 
MR films (Eastman Kodak Co., Rochester, NY, USA). Cassettes were sealed using 
opaque tape to prevent light entry and stored in a dark place for a period of 8 weeks in 
X-ray film cassettes along with Amersham tritiated polymer standards at room 
temperature. In the case of [^H]nor-BNI binding, slides were apposed to MR films for 
a period of 6  weeks at 4 °C.
5.2.5. Autoradiographic film development and image analysis
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See section 2.2.6. for film development and section 2.2.7. for image analysis.
5.2.6. Data analysis
Comparison of specific binding of either [^H]bremazocine or [^H]nor-BNI in MOPr, 
double MOPr/DOPr and MOPr/KOPr KO mice was made using the equations 
described in Figure 5.3. The variation from the theoretical value for the solution of 
the monomer/homo-oligomer equation can be obtained through the formula:
100-(A -B) /A  = C
where A is MOPr KO -  MOPr/KOPr KO (fmol/mg), B is MOPr/DOPr KO (fhiol/mg) 
and C is the variation (%). If the variation from the theoretical value for the solution 
of the monomer/homo-oligomer equation was < 2 0  %, then the binding was defined 
as fitting monomer/homo-oligomer labelling; “x” is used to indicate this model. If the 
variation was between 20 and 40 %, then the binding was defined as partially fitting 
heterodimer/hetero-oligomer labelling; “(^ )” is used to indicate this model. If the 
variation was > 40 %, then the binding was classified as a closest fit to 
heterodimer/hetero-oligomer labelling is used to indicate this model. The 
rationale for the choice of criteria for monomer/homo-oligomer fit was made as 2 0  % 
is a typical maximal SEM observed in ligand autoradiography. With regard to the 
partial fit heterodimer/hetero-oligomer criterion a doubling of the criterion used in the 
monomer/homo-oligomer fit was considered as a typical outlier of SEM observed in 
ligand autoradiography. Variation above this was considered highly unlikely to be an 
acceptable variation from the monomer/homo-oligomer binding and thus 
unequivocally indicative of a heterodimer/hetero-oligomer fit.
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5.3. Results
5.3.1. [^H]Bremazocine binding in wild-type, MOPr, MOPr/DOPr and 
MOPr/KOPr knockout mice
[^H]Bremazocine binding was higher in most brain regions of WT mice compared to 
single MOPr KG, double MOPr/DOPr and MOPr/KOPr KO mice (Figure 5.5.). The 
pattern of [^H]bremazocine binding in MOPr KO mice was similar to that observed in 
the brains of MOPr/DOPr KO animals (Figure 5.5.). In MOPr KO, high levels of 
binding were detected in regions such as olfactory bulb, claustrum, caudate putamen, 
nucleus accumbens and olfactory tubercle (Figure 5.6.). Interestingly, in the olfactory 
bulb, the level of [^HJbremazocine binding in WT mice was not appreciably different 
from those of MOPr, MOPr/KOPr and MOPr/DOPr KO mice. When quantitative 
subtraction (MOPr KO -  MOPr/KOPr KO) was applied to the [^HJbremazocine 
binding results obtained from single MOPr KO and double MOPr/KOPr KO mice 
(Figure 5.6.) the subtraction binding fitted best to the heterodimer/hetero-oligomer 
model (MOPr KO -  MOPr/KOPr KO ^ MOPr/DOPr KO) in most regions (Figure
5.6.). In contrast, the subtraction binding fitted best to the monomer/homo-oligomer 
model in the nucleus accumbens shell. The regions such as claustrum, hypothalamus, 
thalamus, periaqueductal gray and substantia nigra closes to fit the 
heterodimer/hetero-oligomer model (Figure 5.6.). A mean value of [^H]bremazocine 
binding computed from all regions analysed was shown to fit to the equation of the 
heterodimer/hetero-oligomer model (Figure 5.6. inset).
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5.3.2. Absolute and corrected values of [^H]bremazocine binding in single and 
double opioid receptor knockout mice
Compensatory changes in monomeric DOPr and KOPr in brain regions of single and 
double opioid receptor KO mice were evaluated using a specific ligand for DOPr 
([^HJdeltorphin I) and for KOPr ([^H]CI-977) (unpublished data from Kitchen et al.) 
(Figure 5.4.). No major compensatory changes of DOPr and KOPr were observed in 
the brains of single and double opioid receptor KO mice. Figure 5.7A. shows the 
levels of [^HJbremazocine binding in the same regions where the levels of the binding 
were over 50 fmol/mg in MOPr KO group and the corresponding regions in 
MOPr/DOPr KO and MOPr/KOPr KO mice which was taken in Figure 5.6. The 
choice of the higher level of binding was due to the sensitivity limitation of the 
technique. The compensatory changes in monomeric DOPr and KOPr in brain regions 
of single and double opioid receptor KO mice were applied to absolute values (Figure 
5.7A.) in order to obtain corrected values (Figure 5.7B.). The observed 
[^Hjbremazocine binding in single MOPr, double MOPr/DOPr and MOPr/KOPr KO 
mice are not likely to be influenced by compensatory changes occurring due to the 
deletion of genes for the receptors except for the nucleus accumbens core where the 
subtraction binding fitted best to the monomer/homo-oligomer model (Figure 5.7A. 
and B.).
210
OX)
a
a
oo
N
O
c/2
g
>
o  
o  
o
k
uo
u
c
CQ
c>
oc/ 2
X)<
I/)
o
g
OX)
(Biu/iouii) aujoozBuiajqlHp] (Bui/iOLUi) au!OOZBiuajq[Ho]
9 3 a-5
2 1 1
in
I
s
"O
I
i
S'
I
I
q-4O
I
ê
I
I
&
I
I
I
I
I
X
CN
i
<u
s
. 1X
2 X
. 1 ; # ' g
X ' GO
.B
4-> gCO
i
1 I
" S S )CO G
<U
T 3
CO \ pa G
1 ê 1o CO
4 3 g a
1 1
t 3 ' G 2p U G
e Ü "go p
U g G
c j 8
Ü . a O
a i Q
i G
I o
V O
(4-, «
o ' G
1O
W M G
( / ] • 1-H ' S
-H ' G
< U
1
i n coG
œ G<a G ü
V .
û û
X
5 . a
s t J û
<u G
a X ' Gcd (U O
CO G g
a
' ü
q G
cd N G
> 1 oÜA
v d ; g
i n . o o
o œ è
G a
. S P q - i G
. a
O
G
î G
G GSo • PM
Ü n 3
- a > Oa
o 1 1
O r G& co■g êo G O-5 +->4->.a O «4-* 4->
% i
o
§ 1 13G G
coo G
m >h !
> r GO in CO
i
U
I
I
I
i
a
Q
VO
ri
in
%I
I
1
I
I
I
I
I
Î
12
&
I
I
CO T3
O
?CO
ëQ
1
j
g
IÜ
Ü
I
i
1
i
a
I
IÜ
i
1
01I
f
HI
f
0
1
T)
&
è
212
5.3.3. [^H]nor-BNI binding in wild-type, single and double opioid receptor 
knockout mice
[^H]nor-BNI binding was higher in most brain regions of WT mice compared to 
single MOPr and double MOPr/KOPr KO mice (Figure 5.8). In MOPr KO and 
MOPr/KOPr KO mice, highest level of binding was localised to the claustrum (Figure
5.8. and 5.9.). In MOPr KO, high levels of binding were detected in regions such as 
olfactory tubercle, claustrum and cingulate cortex (Figure 5.9.). When quantitative 
subtraction (MOPr KO -  MOPr/KOPr KO) was applied to the [^H]nor-BNI binding 
results obtained from single MOPr KO and double MOPr/KOPr KO mice (Figure
5 .9 .) the subtraction binding fitted best to the heterodimer/hetero-oligomer model 
(MOPr KO -  MOPr/KOPr KO ^  MOPr/DOPr KO) in all regions. A mean value of 
[^H]nor-BNI binding computed from all regions analysed was shown to fit to the 
heterodimer/hetero-oligomer model (Figure 5.9. inset).
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5.3.4. Absolute and corrected values of [^H]nor-BNI binding in single and double 
opioid receptor knockout mice
Figure 5.10A. shows the levels of [^H]nor-BNI binding in the same regions where the 
levels of the binding are over 15 fmol/mg in MOPr KO group and its corresponding 
regions in MOPr/DOPr KO and MOPr/KOPr KO mice which was taken from Figure
5.9. The choice of the higher level of binding was due to the sensitivity limitation of 
the technique. The compensatory changes in monomeric DOPr and KOPr in brain 
regions of single and double opioid receptor KO mice were applied to absolute values 
(Figure 5.10A.) in order to obtain corrected values (Figure 5.10B.). The observed 
[^H]nor-BNI binding in single MOPr, double MOPr/DOPr and MOPr/KOPr KO mice 
are not likely to be influenced by compensatory changes occurring due to the deletion 
of genes for the receptors (Figure 5.10A. and B.).
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5.3.5. [^H]Bremazocine and pH]nor-BNI binding in triple opioid receptor
knockout mice
Triple opioid receptor KO mice were used to confirm whether the ligands bind to 
other receptors in addition to all three classical opioid receptors. No specific 
[^H]bremazocine or [^H]nor-BNI binding was detected in the sagittal brain sections of 
mice lacking the three classical opioid receptor genes suggesting the ligands can only 
bind to the three classical opioid receptors (Figure 5.11.).
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5.4. Discussion
In the present study, a novel approach combining quantitative autoradiography of 
[^HJbremazocine and [^H]nor-BNI with opioid receptor KO mice (termed Knockout 
iShbtraction /Autoradiography, KSA) was used in an attempt to give further evidence for 
the presence of DOPr/KOPr heterodimers in mouse brain tissue. [^HJBremazocine were 
chosen to the label monomer form and heterodimer forms of the DOPr and KOPr in 
mouse brain because of the distinctive pharmacological profiles of the ligand in cell 
studies (Table 5.1.) (Jordan and Devi 1999). In this study, higher levels of 
[^Hjbremazocine binding was observed in most brain regions of WT mice compared to 
single MOPr, double MOPr/KOPr or MOPr/DOPr KO mice confirming that 
[^HJbremazocine can bind to all three classical opioid receptor when no suppressors for 
DOPr and KOPr are present (Simonin et al. 2001). In addition, the sum of the mean of 
[^HJbremazocine binding across all regions in both double KO strains (MOPr/KOPr and 
MOPr/DOPr) was substantially higher than in the single KO brains (MOPr KO) where 
both DOPr and KOPr are expressed. In other words, the subtraction binding fitted best 
to the heterodimer/hetero-oligomer model (MOPr KO -  MOPr/KOPr KO ^  
MOPr/DOPr KO). This result does not fit the traditional view of monomeric entities for 
opioid receptors. One of the assumptions in this study was that there is a significant 
difference in the affinity of [^HJbremazocine for the monomer or the heterodimer 
conformations of the DOPr and KOPr. In support of this assumption, the observed 
similar levels of [^HJbremazocine binding between MOPr and MOPr/DOPr KO mice 
may be due to the different affinity for DOPr/KOPr heterodimer in MOPr KO mice and
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KOPr monomer in MOPr/DOPr KO mice. In line with this result, previous studies 
showed that [^HJbremazocine had a higher affinity for KOPr monomer (Kj = 0.4 nM) 
than for the DOPr/KOPr heterodimer (Ki = 1.2 nM) or DOPr monomer (Ki = 7.5 nM) in 
cell studies (Jordan and Devi 1999). Moreover, a higher affinity of [^HJbremazocine 
for KOPr binding sites (0.04 nM) compared to multiple opioid receptor sites (DOPr and 
MOPr, 0.22 nM) was shown in saturation binding studies using brain membranes of 
single MOPr KO and double MOPr/DOPr KO mice (Simonin et al. 2001). Overall, this 
study strongly suggests that [^HJbremazocine can distinguish DOPr/KOPr heterodimers 
from KOPr or DOPr monomers in mouse brain tissue in physiological systems.
The density of KOPr binding using [^H]nor-BNI is lower in rat brain membranes (Bmax 
= 36.3 fmol/mg) than guinea pig brain membranes (Bmax = 115.7 fmol/mg) although the 
Kd values to the KOPr are identical between the species (Kj = 0.1 OnM) demonstrating 
species differences in the number of KOPr (Marki et al. 2000). In the present study, a 
concentration of 20 times the Kd (0.1 nM) of [^H]nor-BNI was chosen because at that 
amount [^H]nor-BNI could label DOPr-KOPr heterodimers based on previous binding 
studies (Jordan and Devi 1999; Xie et al. 2005). In the present study, quantitative 
analysis of [ H]nor-BNI binding in WT brains showed high binding in regions where 
KOPr are highly expressed such as olfactory tubercle, claustrum, nucleus accumbens, 
and hypothalamus in mouse brain (Kitchen et al. 1997; Slowe et al. 1999; Goody et al. 
2002) confirming the distribution pattern of this ligand maps to the pattern of the KOPr 
(Gackenheimer et al. 2005). It is noteworthy that the overall levels of [^H]nor-BNI 
binding was higher in MOPr/DOPr KO brains than in MOPr KO or MOPr/KOPr KO 
brains. In agreement with these results, nor-BNI had 40 or 6  fold higher affinity at the
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KOPr monomer (Ki = 4.9 nM) than that for the DOPr-KOPr heterodimers (Ki = 126 
nM) or for the DOPr monomer (Ki = 31.8 nM) in cell systems (Jordan and Devi 1999) 
further suggesting this ligand could distinguish DOPr-KOPr heterodimers from their 
monomers in the physiological systems.
The heterodimer/hetero-oligomer model did fit in most regions (except the nucleus 
accumbens shell) in the [^HJbremazocine binding and in all regions in the [^H]nor-BNI 
binding. These result suggest that heterodimer/hetero-oligomer forms of the DOPr and 
KOPr may be present in mouse brain in specific regions. In support of this finding, 
Waldhoer et al., (2005) showed that 6 '-guanidinonaltrindole, which has been shown to 
selectively target the DOPr/KOPr heterodimer, induces analgesia only when it is 
administered in the spinal cord but not when administered in the brain suggesting the 
organisation of the heterodimer is tissue-specific (Waldhoer et al. 2005). The reason 
why the presence of heterodimer/hetero-oligomer forms of the DOPr and KOPr in 
mouse brain is region-specific is not clear. It could be due to the different abundance of 
MOPr, DOPr and KOPr in different mouse brain regions (Kitchen et al. 1997). For 
example, the olfactory bulb and olfactory tubercle of mouse brain contain higher levels 
of DOPr and KOPr than MOPr. Therefore, it is likely that the brain regions where both 
DOPr and KOPr have high abundance will have more chance to form DOPr/KOPr 
heterodimers/hetero-oligomers compared to other brain regions. Although further 
studies will be needed to prove the hypothesis with other ligands which could possibly 
distinguish the heterodimer/hetero-oligomer form of the DOPr and KOPr, this result 
provides the first direct evidence for the presence of the heterodimer/hetero-oligomer 
form of the DOPr and KOPr in specific regions of brain tissue.
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It is important to consider compensatory changes of other opioid receptors, which may 
occur due to the deletion of single or double opioid receptors. The compensatory 
changes of DOPr and KOPr were examined in single and double opioid receptor KO 
mice, and the results showed that only subtle compensatory changes of DOPr and KOPr 
were observed (unpublished data from Kitchen et al.). This result is consistent with the 
findings of no major compensatory changes of other opioid receptors in the brains of 
single MOPr (Kitchen et al. 1997), KOPr (Slowe et al. 1999) and DOPr (Goody et al. 
2002) KO mice. As a result, only subtle adjustments to the raw data were seen in single 
and double opioid receptor KO mice. Therefore, the observed [^HJbremazocine and 
[^H]nor-BNI binding in single MOPr, double MOPr/DOPr and MOPr/KOPr KO mice 
are not likely to be influenced by compensatory changes occurring due to the deletion of 
genes for the receptors. The use of a correction is prudent to reduce the chance of false 
positive results in the study.
Evidence from behavioural and pharmacological studies suggests that multiple subtypes 
of KOPr (ki, K2,ks) (Zukin et al. 1988; Clark et al. 1989) or DOPr (ôi, Ô2) (Jiang et al. 
1991; Sofuoglu et al. 1991a; Portoghese et al. 1992) exist although this is still 
controversial. In this study, the presence of DOPr/KOPr heterodimer/hetero-oligomer 
in some brain regions could be due to different affinity of [^HJbremazocine and [^HJnor- 
BNI to several different combinations between DOPr (61, 82) and KOPr (ki, K2, K3) if  it is 
the case for this study. Deletion of the KOPr gene causes complete loss of Ki binding 
sites for [^H]CI-977 throughout the brain suggesting ki receptors are encoded by a 
single gene (Slowe et al. 1999). On the other hand, [^Hjbremazocine binding revealed 
remaining residual binding (under conditions of MOPr, DOPr and ki, receptor blockade)
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in single MOPr, DOPr and KOPr KO mice, even in the presence of high concentrations 
of the cold suppressors for MOPr, DOPr and ki receptors suggesting that receptors 
are not encoded by a gene but indeed arise from a mixed population of receptor proteins 
produced by the three known opioid receptor genes (Simonin et al. 2001). 
[^HJBremazocine could label both ki and K2 receptors as the ligand has been used in the 
past to identify total KOPr binding sites (ki and K2) under conditions of MOPr and 
DOPr blockade or to identify K2 binding sites (under conditions of MOPr, DOPr and Ki^  
receptor blockade) (Morris and Herz 1986; Unterwald et al. 1991; Kitchen et al. 1997) 
because the ligand is well recognised to have affinity for all three classical opioid 
receptor subtypes (Simonin et al. 2001). Therefore, the observed residual binding of 
[^HJbremazocine in the claustrum of double MOPr/KOPr KO mice where KOPr are 
only expressed may be due to the presence of monomer/homo-oligomer or 
heterodimer/hetero-oligomer forms of DOPr (ôi, 62) and K2 receptors. Although Pan et 
al. (1995) have isolated the gene for a K3 receptor from a mouse genomic library and 
obtained a K3-related protein, it is not clear whether the protein is the K3 receptor itself, a 
splice variant, a nociceptin receptor or a K2 receptor (for review, see Connor and Kitchen, 
2006). Therefore both K2 and K3 receptors may arise from different combinations of 
multiple opioid receptors rather than a unique gene for each KOPr subtype. It is 
unlikely that there will be any DOPr (5i, 82) remaining in MOPr/DOPr KO mice as both 
81 and 82 receptors have been shown to arise from a single DOPr gene according to 
previous saturation binding studies in DOPr KO mice which showed the complete 
absence of DOPr (81, 82) binding sites in DOPr KO mice (Filliol et al. 2000). In the 
case of MOPr KO mice, combinations of heterodimer/hetero-oligomer forming between 
DOPr (81, 82) and KOPr (ki^  K2, K3) are likely. This concept is supported from the
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previous proposed conceptual model of organisational differences between DOPr (ôi, 
Ô2) and KOPr (ki, K2) (Daniels et al. 2005). For example, a bivalent ligand KDN-21 
containing DOPr antagonist and KOPr agonist pharmacophores interacts with allosteric 
DOPr/KOPr heterodimers whose properties are characteristic of 81 and K2 phenotypes in 
binding studies in human embryonic kidney cells that contain singly expressed or 
coexpressed DOPr and KOPr (Xie et al. 2005). Moreover, another bivalent ligand 
KDAN-18 containing DOPr and KOPr antagonist pharmacophores bridges 
neighbouring DOPr and KOPr homodimers that give rise to 82 and ki phenotypes in the 
mouse tail-flick assay upon intrathecal administration and binding studies in human 
embryonic kidney cells (Daniels et al. 2005). Taken together, these data support the idea 
that the putative multiple subtypes of DOPr and KOPr could induce different 
combinations of heterodimer/hetero-oligomer between DOPr and KOPr. Moreover, the 
different combination of DOPr and KOPr may reflect K2 and/or K3 receptor itself, which 
probably do not arise from different genes of the KOPr subtypes.
It is unlikely that both [^HJbremazocine and [^H]nor-BNI bind to additional non-opioid 
receptor binding sites at the concentration of each used in this study. [^HJBremazocine 
showed labelling in WT brains qualitatively similar to the labelling of all three classical 
opioid receptor types. This labelling was completely absent in animals deficient in the 
three classical opioid receptor genes in accordance with previous studies by Clarke et al., 
(2002). In addition, no [^H]nor-BNI binding was detected in mice lacking all three 
classical opioid receptors. These results indicate that the ligands can only bind to all 
three classical opioid receptors.
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There are two limitations of this study. The first thing to point out is the resolution of 
the autoradiographic method, which is not designed to analyse the interaction between 
two molecules at the single cell level, to detect heterodimers. This method cannot 
distinguish whether the two receptors are expressed at the surface of the same cell or if 
they physically interact with each other to form a functional heterodimer molecule. 
Although several methods such as FRET, BRET, competitive ligand binding, co- 
immunoprecipitation and Western blotting have been developed in order to investigate 
the existence of heterodimer/hetero-oligomer in vitro (Jordan and Devi 1999; Gomes et 
al. 2000; Gomes et al. 2004; Harrison and van der Graaf 2006), no suitable techniques 
are available to prove the existence of heterodimer/hetero-oligomer in physiological 
systems so far. Secondly, it is not known yet whether opioid receptors may exist as 
dimers, which may be present as homo- or heterodimers/oligomers in physiological 
systems (Cvejic and Devi 1997; Bouvier 2001; Rios et al. 2001; Gomes et al. 2004; 
Reggio 2006). This raises an important question whether radiolabeled ligands 
discriminate monomer, homodimer, homo-oligomer, heterodimer or hetero-oligomer 
forms of opioid receptors with different affinities. In the present study, the KSA 
method cannot provide molecular mechanisms of the DOPr/KOPr heterodimer/hetero­
oligomer but can infer the presence/absence of the heterodimer in a physiological 
system.
In conclusion, the data show that both bremazocine and nor-BNI are ligands that act at 
heterodimers in most brain regions. Moreover, the KSA method could be a useful tool 
to identify heterodimers in in vitro and test binding properties of pharmacological 
ligands to heterodimers. The potential of this technique for studying heterodimerisation
230
of all GPCRs has the potential to screen for heterodimer interactions of a large number 
of existing and new chemical entities.
NB. After submitting this thesis, I was informed by Prof Brigitte L. Kieffer who 
supplied the brains for this study that the double MOPr/DOPr KO mice were actually 
single MOPr KG mice.
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Chapter 6. General discussion
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6.1. General discussion
The role of individual opioid receptors and endogenous peptides in several biological 
functions has been studied utilising opioid receptor and/or opioid peptide knockout 
(KO) mice (for review, see Kieffer and Gaveriaux-Ruff, 2002). Gene KO models have 
provided important fundamental information on issues including interactions of opioid 
with other neurotransmitter systems and their physiological and pharmacological roles 
(for review, see Kieffer, 1999; Kieffer and Gaveriaux-Ruff, 2002). Moreover, receptor 
autoradiography in mutant mice have been used to visualise and to confirm the 
distribution of opioid receptors (Kitchen et al. 1997; Clarke et al. 2003b; Clarke et al. 
2003a; Cox et al. 2005; Gackenheimer et al. 2005). In this thesis, receptor 
autoradiography in opioid receptor and peptide KO mice was used in order to 
investigate the interactions of the opioidergic system with the dopaminergic system as 
well as the effects of genetic background on opioid-dopamine receptor interactions. In 
addition, this technique was also used to determine the receptor binding profile of 
oxycodone as well as the existence of heterodimer/hetero-oligomer forms of the 6 - 
opioid receptors (DOPr) and K-opioid receptors (KOPr) in brain tissue slices.
6.1.1. Role of preprodynorphin in cocaine-induced changes in dopamine D2 
receptors
T h e r e  i s  a  l a r g e  a m o u n t  o f  d a t a  d e m o n s t r a t i n g  a n  i n v o l v e m e n t  o f  t h e  K - o p io id  s y s t e m  i n  
t h e  m o d u l a t i o n  o f  c o c a i n e - i n d u c e d  b e h a v i o u r a l  a n d  n e u r o c h e m i c a l  c h a n g e s  i n  h u m a n
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cocaine users (Hurd and Herkenham 1993; Kreek et al. 1999; Yuferov et al. 2001) as 
well as in animal models (Zhang et al. 2004; Schlussman et al. 2005; Chefer and 
Shippenberg 2006; McLaughlin et al. 2006b; Bailey et al. 2007) suggesting that the k- 
opioid system may participate in the reinforcing and rewarding effects of cocaine. The 
behavioural results obtained in the same animals used in this study show an enhanced 
cocaine-induced locomotor sensitisation in preprodynorphin (ppDYN) KO mice after a 
chronic ‘binge’ administration protocol suggesting ppDYN may play a central role in 
mediating the behavioural sensitisation effects of cocaine (Bailey et al. 2007).
The autoradiographic binding studies in this thesis suggests that ppDYN may play a 
central role in mediating the neurochemical effect of cocaine on the D2 dopaminergic 
system, providing further evidence that the ppDYN system functions as an endogenous 
antagonist of cocaine. Although it has been previously reported that treatment with 
selective KOPr agonists cause psychotomimetic effects and dysphoria in clinical trials 
(for review, see Wadenberg, 2003), synthesis of novel KOPr agonists such as salvinorin 
A which lacks any aversive effects may be useful for the treatment of cocaine addiction. 
This study further suggests that dynorphin has a protective role in cocaine addiction by 
inhibiting dopamine release.
6.1.2. Genetic background does not influence the interactions between the 
dopaminergic system and opioid receptors
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Although the use of mutant animals in pharmacological studies has its advantage over 
the use of pharmacological tools (normally antagonists) mainly due to selectivity 
problems with conventional approaches, there are a number of potential limitations of 
using mutant mice which must be carefully considered. For example, compensatory 
changes and/or different genetic background of KO mice could influence the 
behavioural and neurochemical phenotype of the animal in a manner which could 
compromise the interpretation of biochemical and behavioural data (Crawley et al. 
1997; Pich and Epping-Jordan 1998; Balogh et al. 1999; Seong et al. 2004). The 
autoradiographic mapping in this thesis clearly shows that no compensatory changes in 
D l, D2 receptors and dopamine transporters occurred in mice lacking all three classical 
opioid receptors on either pure C57BL/6 or 129S6 genetic backgrounds suggesting that 
the endogenous opioid system may not modulate the dopaminergic system and this is 
also not dependent on the background strain of the KO mice.
6.1.3. The binding profile of [^ H] oxycodone is similar to p-opioid receptor
Oxycodone has been used clinically for patients in order to treat severe to moderate pain 
(Beaver et al. 1978; Leow et al. 1992; Heiskanen and Kalso 1997; Cicero et al. 2005). 
However, increasing number of reports show a high abuse potential (for review, see 
Cicero et al., 2005). There is a current debate on the pharmacological profile of this 
drug (Kalso 2007; Smith et al. 2007) as data from previous behavioural and binding 
studies in search of a primary target receptor for oxycodone have yielded inconsistent
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results (Ross and Smith 1997; Ross et al. 2000; James and Sandra 2003; Beardsley et al. 
2004; Kalso 2007; Smith et al. 2007).
The studies from this thesis clearly showed that the localisation of [^HJoxycodone 
binding is typical of the ja-opioid receptor (MOPr) distribution. However, small but 
significant residual binding of [^H]oxycodone was observed in some brain areas of 
MOPr KO mice suggesting that [^HJoxycodone may bind to other opioid receptor 
binding sites in addition to MOPr. Interestingly, [^H]oxycodone binding was increased 
in both KOPr and DOPr KO mice suggesting alterations in the binding profile of 
[^HJoxycodone in the absence of the MOPr. This evidence may suggest that the ligand 
may act on opioid heterodimer/hetero-oligomer forms of the MOPr and KOPr or the 
MOPr and DOPr.
6.1.4. Knockout Subtraction Autoradiography as a useful tool to identify of 
heterodimer/hetero-oligomer in physiological system
A new conceptual view of the composition of opioid receptors has been suggested from 
findings that heterodimerisation and/or oligomerisation of opioid receptors leads to 
altered opioid ligand properties and affects receptor trafficking in cell culture model 
systems (Jordan and Devi 1999; George et al. 2000; Gomes et al. 2000; Gomes et al. 
2002; Gomes et al. 2004). However, there has not been any direct evidence to support 
the existence of heterodimer/hetero-oligomer in physiological systems.
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The knockout subtraction autoradiography approach used in this study was developed as 
a novel way to investigate the potential existence of heterodimer/hetero-oligomer forms 
of the DOPr and KOPr in mouse brain tissue. The subtraction binding fitted best the 
heterodimer/hetero-oligomer model in most regions of the brain supporting the 
existence of the DOPr and KOPr heterodimer/hetero-oligomer in physiological system. 
The subtraction binding also fitted best to monomer/homo-oligomer model in other 
brain regions suggesting that the presence of heterodimer/hetero-oligomer form of the 
DOPr and KOPr is region-specific. As a result, this method could help identifying 
novel ligands that selectively target opioid receptor heterodimer/hetero-oligomer in 
physiological systems. Moreover, this could be potentially used in predicting the 
therapeutic potential of compounds directed at these systems, particularly the 
DOPr/KOPr heterodimer/hetero-oligomer which is not currently a therapeutic target in 
the pharmaceutical industry.
Multiple subtypes of the three classical opioid receptors have been postulated for many 
years (Pasternak and Wood 1986; Zukin et al. 1988; Clark et al. 1989; Jiang et al. 1991; 
Sofuoglu et al. 1991a; Portoghese et al. 1992; Cabib et al. 1998). Despite the 
pharmacological evidence supporting the existence of subtypes of the three classical 
opioid receptors only three genes has been discovered encoding for three classical 
opioid receptors (Evans et al. 1992; Kieffer et al. 1992; Chen et al. 1993b; Yasuda et al. 
1993). The data from this thesis suggest that heterodimerisation and/or hetero­
oligomerisation between opioid receptors may explain the presence of subtype of opioid 
receptors.
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6.1.5. Future work
It will be interesting to investigate whether the heterodimeric forms of the DOPr and 
KOPr in mouse brain are a functional receptor. Therefore, bremazocine-induced 
GTPyS binding in opioid receptor KO mice could be useful tool to provide functional 
properties of the heterodimer/hetero-oligomer forms of the DOPr and KOPr in mouse 
brain tissue.
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